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Ovarian cancer is the most fatal of all gynecological malignancies. Epithelial ovarian 
cancer (EOC) accounts for about 90% of malignant ovarian tumours and is thought 
to originate mostly from ovarian surface epithelium (OSE) cells. Epidemiological 
data suggest that hormone replacement treatment (HRT) users have a higher risk of 
ovarian cancer, which is related to the use of oestrogen-only HRT. In addition, EOC 
is oestrogen responsive. This thesis reveals the capacity for production and 
metabolism of oestrogen in normal OSE and malignant primary EOC cells, and 
describes the action of oestrogen in the development of EOC at three levels.  
Abstract 
 
First, the expression of the genes encoding oestrogen production and metabolism and 
oestrogen receptor (ER) was investigated in OSE and EOC cells at RNA and protein 
levels. Immunohistochemistry revealed that steroid sulphatase (STS), oestrogen 
sulfotransferase (EST), 17βhydroxysteroid dehydrogenase (17βHSD) 2 and 
17βHSD5 proteins were present in pre-menopausal, post-menopausal and inclusion 
cystic OSE as well as EOC cells. Taqman qRT-PCR revealed STS, EST, 17βHSD1, 
17βHSD2, 17βHSD5, ERα, ERβ and oestrone sulphate (E1S) transporters such as 
organic anion transporting polypeptide (OATP)-B, OATP-D and OATP-E mRNAs 
were expressed in pre-menopausal OSE and EOC at different levels. When basal 
mRNA levels were compared among untreated samples of pre-menopausal OSE and 
EOC, EST mRNA expression was significantly higher in the OSE compared to EOC 
cells (P<0.05) while OATP-B mRNA level was the opposite (P<0.05). Radiometric 
enzyme activity assays demonstrated different metabolism patterns of E1S and 
oestrone (E1) between normal and malignant cells, indicating overall activities of 
STS and 17βHSD1 or 17βHSD5 to be higher than the overall activities of EST and 
17βHSD2 in cancer cells while enzyme activities in OSE cells were opposite to this. 
Second, the impact of inflammation on oestrogen production, metabolism and action 
was compared in OSE and EOC cells by testing the response of target genes to a 
panel of pro-inflammatory cytokines. The data revealed that in OSE cells, EST 
(P<0.01) and 17βHSD2 (P<0.001) mRNAs were decreased while ERα mRNA 
(P<0.001) was increased by IL-1α. In addition, EST mRNA was inhibited by IL-4 
(P<0.05). In SKOV-3 (EOC cell line) cells, IL-1α stimulated STS mRNA (P<0.001) 
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and enzyme activity (P<0.05). Moreover, IL-4 inhibited (P<0.05) while IL-8 and IL-
10 enhanced (P<0.01) ERα mRNA levels. Finally, the effect of oestrogenic 
components of HRT medication (equilin and equilin-sulphate) on the expression of 
cancer-associated genes was compared to that of 17β-oestradiol (E2) in PEO-1 (an 
oestrogen-responsive EOC cell line) cells. Expression of the oestrogen-responsive 
genes FN1 and IGFBP3 mRNA expression was similarly inhibited by E2 and equilin 
(P<0.05) as well as E1S and sodium equilin-sulphate (P<0.05). 
 
In conclusion, this thesis presents evidence that intracrine oestrogen formation and 
metabolism differs between OSE and EOC cells, such that E2 formation is inhibited 
in normal OSE but is promoted in EOC. Inflammatory cytokines also influence the 
local production of E2 by regulating genes encoding oestrogen production and 
metabolism and receptors. Finally, local HRT metabolites can regulate cancer-
associated gene expression in EOC. Together, these data suggest a role for local 
oestrogen production and action in inflammation-associated development of EOC. 
Conversely, differential regulation of the same parameters in OSE cells from pre-
menopausal women minimizes oestrogen formation and ‘protects’ against the 
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The aim of this thesis is to demonstrate that the surface of the human ovary, the 
ovarian surface epithelium (OSE), contains the machinery to produce, activate and 
respond to hormonal oestrogens. The translational importance of this is that OSE is 
the site of development of potentially lethal, oestrogen-responsive disease in the 
form of epithelial ovarian cancer (EOC). Understanding factors controlling oestrogen 
metabolism in the OSE may therefore unlock new therapeutic options. This literature 
review presents a background to the experimental studies described in later sections 
of the thesis. 
 
1.1 The human ovary 
1.1.1 Ovarian histology 
The adult ovary is the source of oocytes and also responsible for much of the 
production and action of sex hormones. They are located in pairs in the abdominal 
cavity on either side of the uterus as part of the female reproductive tract. The adult 
ovary comprises three zones of stroma: the outer cortex, the inner medulla and the 
hilus, containing follicles at various stages of development, corpora lutea and corpora 
albicans. The tunica albuginea is a tough fibrous layer that surrounds the outer cortex. 
External to this is OSE, which is loosely attached to a thin basal lamina on the 















Figure 1.1: The human ovary. Follicles at various stages of development with corpus luteum and 
corpus albicans are located in cortical region. The medullary region contains arteries and veins. 
The OSE is separated from tunica albuginea by a basal lamina. Picture courtesy of Dr Chris 
Harlow. 
 
The OSE comprises a single layer of mesothelial squamous-to-cuboidal cells 
covering the entire surface of the ovary and continuous with the peritoneal 
mesothelium. Normal OSE is developmentally a mesothelium with both epithelial 
and mesenchymal characteristics. In response to stimuli that initiate a regenerative 
(repair) response, such as ovulatory rupture in vivo or explantation into culture, OSE 
cells assume phenotypic characteristics of stromal cells. Additionally, OSE acquires 
complex epithelial characteristics of the Mullerian duct-derived epithelia, when it 
undergoes metaplasia, benign tumour formation, and neoplastic progression 
(Auersperg, Wong et al. 2001). Normal OSE does not have known tissue-specific 
differentiation markers. However, it has classical epithelial features, which include 
desmosomes, tight junctions and keratin (van Niekerk, Boerman et al. 1991) but 
rarely expresses E-cadherin and cancer Antigen 125 (CA125) (Kabawat, Bast et al. 
1983). In situ, it expresses mucin and 17β hydroxysteroid dehydrogenases (17βHSDs) 
(Nicosia and Johnson 1984) and it lacks CA125, which distinguish it from extra-
ovarian mesothelium. OSE provides the external cellular barrier of the ovary, 
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transports materials to and from the peritoneal cavity and takes part in the cyclical 
ovulatory rupture and repair (Auersperg, Wong et al. 2001). In the last decade, many 
studies have implicated OSE as the main source of ovarian cancer, and interest in this 
compartment of the ovary has risen sharply. The role of OSE in the initiation and 
development of ovarian cancer will be discussed later. 
 
Although OSE is not thought to be a major site of steroid hormone synthesis, it 
expresses genes encoding steroid hormone biosynthesis and nuclear hormone 
receptors suggesting a role of these cells in ovarian function. An oligonucleotide 
microarray analysis revealed mRNA expression for key enzymes required to 
synthesis de novo steroids in the C21-pregnane and C19-androstane series and the 
expression of dehydrogenase, hydroxylase, conjugation and deconjugation enzymes. 
The presence of these enzymes suggested the possibility of intracrine steroid 
generation in the cultured OSE cells (Rae, Niven et al. 2004b). Notably, the Rae 
study showed the presence of transcripts for steroid sulphatase (STS) and 17βHSD1 
enzymes that are involved in oestrogen biosynthesis, highlighting the potential for 
production of biologically active oestrogen from inactive precursors in situ. 
Therefore, it is interesting that OSE cells can synthesize steroid precursors from 
cholesterol and also use precursors produced by extra-ovarian or adjacent ovarian 
cells to generate bioactive steroid. In addition, the expression of gonadotrophin-
releasing hormone receptor (GnRHR) (Kang, Cheng et al. 2000), follicle-stimulating 
hormone receptor (FSHR) (Choi, Kang et al. 2002) and luteinizing hormone receptor 
(LHR) (Kuroda, Mandai et al. 2001), androgen receptor (AR), progesterone receptor 
(PR), oestrogen receptor (ER) including both ERα and ERβ (Lau, Mok et al. 1999; 
Edmondson, Monaghan et al. 2002) and glucocorticoid receptor-α (GRα) (Rae, 
Niven et al. 2004a) in OSE indicates that OSE is a steroid target. Moreover, thyroid 
hormone receptor, retinoic acid receptor and peroxisome proliferation-activated 
receptor (PPAR) are also expressed in OSE cells (Rae, Niven et al. 2004b). Thus the 
OSE is a site of steroid production and a target of hormone action, consistent with 
the idea that hormone signalling in the OSE can critically influence the initiation and 
development of ovarian cancer.  
 
 5 
1.1.2 Ovulation and inflammation 
1.1.2.1 Ovulation process 
Ovulation is the release of a fertilizable oocyte from the adult ovary. This tightly 
controlled process occurs on a monthly basis and lasts as much as 30-36h in human. 
During folliculogenesis, by the late follicular phase of the menstrual cycle only one 
follicle becomes mature. The LH surge initiates the ovulatory process and the apex 
of the mature follicle protrudes progressively above the surface of the ovary, while 
the follicle wall gradually becomes thinner to form a stigma from where the follicle 
ruptures. Following proteolytic degradation of follicular cells and OSE layer at the 
apex of the ovulation site, the follicle wall bursts and the oocyte is released into the 
peritoneal cavity. Ovulation is complete when the egg-bearing cumulus mass is 
expelled from the ovary (Espey 1999).  
 
1.1.2.2 Ovulation and inflammation 
30 years ago, Espey first proposed the hypothesis that ovulation was comparable to 
an acute inflammatory reaction, based on similar physical and biochemical changes 
occurring during ovulation and acute inflammation (Espey 1980). The inflammatory 
reaction causes an increase in vasodilatation, hyperemia, exudation, oedema, 
collagenolysis, cell proliferation, tissue remodelling, and other common changes in 
inflamed tissue (Espey 1994). Like their role in other inflammatory events, 
leukocytes appear to be critical to ovulation. There is a marked increase in both 
neutrophil and macrophage density in the theca layer of the ovulatory follicles just 
prior to ovulation and leukocyte-derived inflammatory factors including 
prostaglandins (PGs), bradykinin, histamine, platelet activating factor and various 
cytokines are potential mediators of the ovulatory process (Espey 1994). For 
example, histamine released by mast cells is responsible for increased vascular 
permeability observed during ovulation (Abisogun, Daphna-Iken et al. 1988). 
Ovarian follicular wall collapse is mediated by proteolytic enzymes such as 
plasminogen activator (PA) and elastase that are mainly released by neutrophils and 




Following ovulation associated tissue damage at the site of oocyte expulsion, anti-
inflammatory repair and reorganization of the site is necessary to form a corpus 
luteum. During the repair process, nitric oxide (NO) released by invading leukocytes 
facilitates vasodilatation and secretion of interleukin (IL)-1 for tissue remodelling 
(Fleming, Beaugie et al. 2006). Epidermal growth factor (EGF) and platelet-derived 
growth factor (PDGF) are released from platelets, and pro-inflammatory cytokines 
and prostanoids stimulate OSE growth (Auersperg, Wong et al. 2001). Additionally, 
infiltrating macrophages produce tumour necrosis factor (TNF-α), which also 
facilitates proliferation of OSE (Auersperg, Wong et al. 2001).  
 
1.1.2.3 Cytokines involved in ovulation  
As mentioned above, ovulation is an acute inflammatory process involving 
leukocytic invasion and local production of pro-inflammatory cytokines. The 
ovulatory follicle becomes surrounded by cytokines such as IL-1 and TNF-α secreted 
by neutrophils, macrophages, and lymphocytes that have migrated to the site of 
rupture (Brannstrom and Norman 1993). Several cytokines such as IL-1, IL-2 (Wang 
and Norman 1992), TNF-α (Wang, Brannstrom et al. 1992) and granulocyte-
macrophage-colony-stimulating factor (GM-CSF) (Jasper, Brannstrom et al. 1996) 
have been demonstrated in human pre-ovulatory follicular fluid obtained during 
follicular aspiration at oocyte recovery for in vitro fertilization (IVF). IL-4 (Hashii, 
Fujiwara et al. 1998) and IL-8 (Zhao, Rong et al. 1995; Buscher, Chen et al. 1999) 
are also found in the follicular fluid of the peri-ovulatory follicle, supporting roles for 
each of these inflammatory mediators in ovulation as well.  
 
There is also experimental evidence that cytokines facilitate the process of ovulation. 
For example, IL-l and TNF-α promote ovulation in combination with LH in the 
perfused ovary (Brannstrom, Wang et al. 1993; Brannstrom, Bonello et al. 1995). In 
addition, they enhance the production of PGs in the intact isolated organ or from 
isolated follicles or ovarian cells (Brannstrom and Norman 1993). Cytokines also 
promote the post-ovulatory healing process. Thus, cytokines are important 
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determinants of ovarian function, including ovulation and formation of the corpus 
luteum. 
 
1.1.3 Ovulation, inflammation and ovarian cancer 
Given that ovulation resembles an inflammatory episode, involving secretion of 
immune mediators that impact the local cellular milieu, it is therefore of interest that 
epidemiological studies have identified ovulation and ovulation-associated hormones 
as risk factors in epithelial ovarian cancer (EOC). Thus if ovulation occurs relatively 
frequently, or at an artificially higher rate, or for longer periods during life (e.g. 
nulliparity, use of ovulation-inducing drugs, early age at menarche and late age at 
menopause) ovarian cancer risk increases (Franceschi, La Vecchia et al. 1991; 
Whittemore, Harris et al. 1992). Conversely, there is a decreased risk of developing 
EOC with pregnancy or oral contraceptive pill use; conditions which decrease 
ovulation (Whittemore, Harris et al. 1992; Adami, Hsieh et al. 1994; Risch, Marrett 
et al. 1994; Modan, Hartge et al. 2001; Titus-Ernstoff, Perez et al. 2001; Riman, 
Dickman et al. 2002; Riman, Nilsson et al. 2004). When the total lifetime ovulation 
number is calculated for women who have EOC and for those that do not, there is a 
significant correlation between high total ovulation number and the occurrence of 
ovarian cancer (Purdie, Bain et al. 2003). On the other hand, there have been many 
epidemiological studies demonstrating exposure to inflammatory factors such as talc 
or asbestos particles are associated with higher EOC risk (Purdie, Green et al. 1995; 
Ness and Cottreau 1999). Furthermore, endometriosis and pelvic inflammatory 
disease (PID), which cause local pelvic inflammation, are also EOC risk factors (Shu, 
Brinton et al. 1989; Brinton, Gridley et al. 1997). Conversely, hysterectomy and 
tubal ligation, which may decrease the likelihood that OSE will be exposed to 
environmental inflammatory stimuli, act as protective factors. Additionally, the risk 
of EOC in women who use low dose aspirin, acetaminophen or non-steroidal anti-
inflammatory agents consistently for at least 6 months is reduced (Akhmedkhanov, 
Toniolo et al. 2001; Altinoz and Korkmaz 2004). Thus taken in combination, this 
evidence supports the idea that inflammatory events triggered either by ovulation or 
by extra-ovarian factors may impact upon OSE integrity, thereby initiating or 




The role of inflammation in the development of cancer was first hypothesized in 
1863 by Rudolf Virchow who recognized the infiltration of leukocytes into tumour 
tissues, suggesting initiation of tumour progression at sites of chronic inflammation 
(Balkwill and Mantovani 2001). A series of studies have been performed to 
investigate the mechanisms through which inflammation can promote the 
development of EOC. Firstly, ovulation may trigger cellular events that result in 
carcinogenesis. Repeated damage caused by ovulation and OSE proliferation to 
repair the wound, places a strain on the OSE, increasing the chance of errors 
occurring during DNA replication (Fathalla 1971). In women, mutations of the p53 
tumour suppressor gene that are thought to result from spontaneous errors of 
deoxyribonucleic acid (DNA) synthesis during cell proliferation were associated with 
an increased number of lifetime ovulations (Schiffenbauer, Abramovitch et al. 1997). 
Moreover, inclusion cysts are formed as OSE become entrapped in the ovarian 
wound created during ovulation. OSE cells lining inclusion cysts are less plastic than 
the relatively pluripotent normal OSE, and more likely to proceed to ovarian 
carcinogenesis (Auersperg, Maines-Bandiera et al. 1997). Furthermore, inflammation 
produces toxic oxidants that can give rise to direct damage to DNA and proteins and 
may play a direct role in carcinogenesis (Dreher and Junod 1996). Also, chronic 
inflammation is associated with increased cell division, which can cause the potential 
for replication errors following DNA repair; aberrant DNA repair, especially at main 
regulatory sites, may increase the risk of mutagenesis (Ames, Gold et al. 1995). 
Moreover, cytokines, growth factors and prostaglandins involved in the 
inflammatory process may play an important role in ovarian mutagenesis and 
development. For example, the pro-inflammatory cytokine TNF-α, which has a role 
in the natural ovulation process, promotes EOC (Murdoch, Colgin et al. 1997). Its 
possible involvement in OSE neoplastic transformation is through regulating genes 
participating in membrane degradation, such as urokinase plasminogen activator 
(uPA) and matrix metalloproteinase (MMP)-9, prior to and after ovulation (Murdoch 
and Lund 1999; Yang, Godwin et al. 2004). More evidence for the positive link 
between inflammation and EOC comes from studies with IL-1α, which will be 




In conclusion, inflammation-associated events affect the functionality of ovarian 
cells prior to and after ovulation, and inflammation is intimately involved with 
tumour initiation, progression and invasion. Taken together, this suggests a need to 
understand the physiological mechanisms of inflammatory and anti-inflammatory 
processes in the ovarian cell surface, as well as in ovarian cancer as a basis for 
developing novel molecular markers for diagnosing and treating ovarian cancer (Rae 
and Hillier 2005).  
 
1.1.4 Interleukin system 
1.1.4.1 IL-1 system 
In humans, the IL-1 gene is located on chromosome 2 and its encoded protein 
consists of two bioactive ligands, IL-1α and IL-1β, with two cell surface receptors, 
the IL-1 type 1 (IL-1R1) and type 2 (IL-1R2) receptors and a natural receptor 
antagonist, IL-1RA (Webb, Collins et al. 1986). IL-1α and IL-1β share 26% and 45% 
homologies of amino acid and nucleotide sequence respectively and have 
comparable biological effect, playing an essential role in the inflammatory process 
and the immune response (Dower, Kronheim et al. 1986). IL-1RA is a secreted 
glycosylated protein of 22 kDa (Hannum, Wilcox et al. 1990), which can bind to IL-
1Rs with the same affinity as IL-1 but without initiating downstream signalling 
(Arend and Guthridge 2000). The main function of IL-1RA is to regulate the effects 
of IL-1 by blocking receptor signalling. IL-1α, IL-1β and IL-1RA bind to membrane 
receptors localized on target cells. IL-1R1, an 80kDa glycoprotein and IL-1R2, a 
60kDa protein belong to the immunoglobulin family. Although the homology of the 
two receptors is only 28%, they can both bind the two agonist and antagonist ligands 
with high affinity, because their extracellular domains share high similarity 
(McMahan, Slack et al. 1991). However, IL-1α, IL-1β and IL-1RA responses are 
exclusively mediated through IL-1R1, because IL-1R2 is a decoy receptor, unable to 




Several publications demonstrate that IL-1 can be produced in the ovary. The 
biological activity of IL-1 was measured for the first time in human follicular fluid 
by Khan (Khan, Schmidt et al. 1988). This result has been subsequently confirmed 
(Barak, Mordel et al. 1992; Wang and Norman 1992), and indicates local IL-1 
production by granulosa and/or theca cells. Also, IL-1α is secreted by OSE (Ziltener, 
Maines-Bandiera et al. 1993). Moreover, cumulus cells were demonstrated to express 
IL-1α and IL-1β mRNAs in women undergoing IVF (de los Santos, Anderson et al. 
1998).  
 
IL-1 plays a major role throughout the ovarian cycle, in particular in the ovulatory 
process, during which it can regulate the synthesis of proteolytic enzymes, 
production of PGs and NO as well as steroidogenesis. As reviewed in the previous 
section, ovulation is a risk factor for ovarian cancer. Therefore, the pro-inflammatory 
effect of IL-1 in ovulation is proposed to be causal in the initiation and promotion of 
ovarian cancer. Since OSE is suggested to be the main origin of EOC, there have 
been many studies on the effect of IL-1 on OSE. IL-1α potentially promotes PG 
secretion and leads to follicular rupture that is associated with cell damage and 
genotoxicity by increasing cyclooxygenase (COX)-2 mRNA expression in OSE (Rae, 
Niven et al. 2004a). In addition, IL-1α up regulates IL-6 and IL-8 mRNAs; both 
encoded proteins being secreted as pro-inflammatory ovulation-associated factors. 
Also, lysyl oxidase (LOX) mRNA that is associated with tissue post-ovulatory repair 
as well as stimulation of nuclear factor-kappa B (NF-Κb) inflammatory pathway 
molecules is enhanced by IL-1α (Rae, Niven et al. 2004b). IL-1α depresses GnRH 
receptor mRNA expression (Rae, Niven et al. 2004b), through which GnRH 
regulates its anti-proliferative effects. Furthermore, IL-1α induces 11βHSD1 mRNA 
and enzyme activity, which converts inactive cortisone to cortisol, demonstrating a 
potential role of locally generated active glucocorticoid in the OSE to reduce tissue 
damage and promote post-ovulatory wound healing (Yong, Harlow et al. 2002; Rae, 
Niven et al. 2004a). By contrast, 11βHSD2 that is responsible for inactivation of 
cortisol by converting it to cortisone, is undetectable in primary OSE cells while its 
levels are significantly higher in ovarian cancer cell lines (Gubbay, Guo et al. 2004). 
Moreover, 11βHSD1 expression in cancer cell lines is not responsive to IL-1α. These 
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data imply that 11βHSD2 expression and lack of 11βHSD1 response to IL-1α 
stimulus might be features of ovarian neoplastic transformation (Gubbay, Guo et al. 
2005).  
 
There is evidence that IL-1α produced by EOC cells is involved in the development 
of EOC. The IL-1α level is elevated in the serum of patients with EOC (Zeisler, 
Tempfer et al. 1998; Kondera-Anasz, Mielczarek-Palacz et al. 2003) and IL-1α is 
detectable in ascites from ovarian cancer patients (Moradi, Carson et al. 1993). The 
levels of both IL-1α and IL-1β detected by immunohistochemical staining and their 
bioactivities are markedly higher in cancerous than in normal ovarian tissues. In 
addition IL-1α and IL-1β are secreted mainly by epithelial cancer cells (Huleihel, 
Maymon et al. 1997). Furthermore, IL-1α has been reported to stimulate growth of 
ovarian cancer cells in an autocrine manner (Marth, Zeimet et al. 1996; Kawakami, 
Nagai et al. 1997).  
 
1.1.4.2 IL-4 
IL-4 is a T lymphocyte-associated cytokine produced mainly by T helper 2 (Th-2) 
cells. It exerts its effect by binding to the IL-4 receptor (IL-4R), which belongs to the 
family of type I cytokine receptor and contains two polypeptide chains, the IL-4Rα 
chain and common γ chain (Nelms, Keegan et al. 1999). IL-4 participates in several 
cell immune responses with a central role in mediating the differentiation of antigen-
stimulated naive T cells. IL-4 also plays an important role in tissue adhesion and 
inflammation as well as regulating inflammation-associated diseases such as cancer 
by decreasing Th-1 responses (Nelms, Keegan et al. 1999). 
 
OSE cells seem unable to secrete IL-4 although IL-4R mRNA has been detected 
(Ziltener, Maines-Bandiera et al. 1993; Burke, Relf et al. 1996). IL-4 in the pre-
menopausal ovary is mainly secreted by the peripheral blood mononuclear cells that 
infiltrate the peri-ovulatory follicle and later the corpus luteum. The IL-4 level 
appears to be progesterone responsive and may have a role in post-ovulatory ovarian 
repair during the luteal phase of the menstrual cycle and in the corpus luteum of 




IL-4 has been shown to have a role in EOC. In one study, about 60% of 21 ovarian 
cancer tissue samples expressed high levels of IL-4R, while seven normal ovarian 
tissues tested express no or low levels of IL-4R. In addition, IL-4 cytotoxin prolongs 
survival of tumour-bearing mice, suggesting that IL-4R-targeted cytotoxin may be a 
potent agent for the treatment of EOC patients (Kioi, Takahashi et al. 2005). In 
another study in which a cytokine antibody array was used, the level of IL-4 was 
shown to be two times higher in the culture supernatants of EOC cell lines compared 
to those of OSE cells, indicating EOC can produce  more IL-4 (Chen, Ye et al. 2009). 
 
1.1.4.3 IL-6  
IL-6, a pleiotropic inflammatory cytokine, is encoded by the IL6 gene located on 
chromosome 7. The action of IL-6 is mediated through binding to the IL-6 receptor 
(IL-6R), which is a type I cytokine receptor and consists of a heterodimeric complex 
made up of a IL-6R subunit and signal transducer, Glycoprotein 130. IL-6 regulates 
the differentiation of lymphocytes, cell proliferation, cell survival and apoptotic 
signals (Hodge, Hurt et al. 2005). In addition, it plays a role in general system 
metabolism, endocrine functions, and other tissues and organ systems (Hodge, Hurt 
et al. 2005). Depending on the cell type, IL-6 can act via several classic protein 
kinase cascades such as mitogen activated protein kinase (MAPK) and phosphatidyl-
inositol-3 kinase (PI-3K) (Yang, Wang et al. 2003).  
 
IL-6 is present in the normal ovary, where it may act in follicle development by 
reducing the FSH binding capacity of granulosa cells. It is suggested that intra-
ovarian IL-6 may be secreted by lymphocytes (Machelon, Nome et al. 1994). There 
is evidence that IL-6 is secreted by OSE cells (Ziltener, Maines-Bandiera et al. 1993). 
IL-6 mRNA expression is also detected in OSE cells and this expression can be 
enhanced by IL-1α treatment (Rae, Niven et al. 2004b).  
 
IL-6 is one of the most widely studied cytokines in ovarian cancer. There are 
increased levels of IL-6 in ascites of EOC patients in comparison to plasma (Giuntoli, 
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Webb et al. 2009). Serum IL-6 levels are significantly higher in ovarian cancer than 
in endometriosis or benign tumours (Darai, Detchev et al. 2003). Women with 
advanced cancer have remarkably higher serum IL-6 levels than women with early 
stages or benign tumours. The concentrations of IL-6 are higher in ascites of cancer 
patients than in ascites of women with benign tumours (Nowak, Glowacka et al.). 
Two proposed major cellular tumour-associated sites of IL-6 production are 
peritoneal mesothelial cells and cancer cells (Offner, Obrist et al. 1995). Also, a 
correlation was found between enhanced levels of IL-6 in the cystic fluids of ovarian 
cancer patients and inhibited haemoglobin levels, which is another poor prognostic 
factor for EOC (van der Zee, de Cuyper et al. 1995). However, IL-6 appears not to 
stimulate tumour growth directly, because anti-IL-6 antibody fails to affect tumour 
cell proliferation in vitro (Watson, Sensintaffar et al. 1990). In contrast, IL-6 is 
demonstrated to enhance the invasiveness of ovarian cancer cells significantly by 
increasing their attachment and migration (Obata, Tamakoshi et al. 1997).  
 
1.1.4.4 IL-8 
 IL-8, also known as CXCL8, is a proinflammatory chemokine. Transcription of the 
IL- 8 gene encodes for either a 72 amino acid protein in monocytes and macrophages 
or a 77 amino acid form in nonimmune cells. Expression of IL-8 is principally 
mediated by activator protein and/or nuclear factor-κB-mediated transcriptional 
activity (Xie 2001). Additionally, IL-8 is regulated by other factors including 
inflammatory signals, chemotherapy agents and hypoxia, as well as steroid hormones 
such as androgens and oestrogens (Xie 2001). IL-8 is a ligand for two cell-surface G 
protein–coupled receptors, CXCR1 and CXCR2 (Holmes, Lee et al. 1991). As a 
member of the CXC chemokine family, IL-8 plays an important role as an activator 
and chemoattractant for neutrophils. IL-8 is mainly produced by 
monocytes/macrophages, but also by other cells. Its expression occurs in many 
human cancers, including breast, colon, cervix, lung, ovary, prostate and renal cell 
carcinoma (Xie 2001). 
 
There is evidence that IL-8 plays an important role in ovulation. In one study high 
concentrations of IL-8 were detected in follicular fluid of women hyperstimulated 
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during gonadotrophin-induced follicle growth (Runesson, Bostrom et al. 1996) and 
also in ovulatory follicles collected from the natural human menstrual cycle 
(Runesson, Ivarsson et al. 2000). Moreover, IL-8 is secreted from theca and 
granulosa cells isolated from preovulatory follicles, with significantly higher 
secretion from the theca cells (Runesson, Ivarsson et al. 2000). Finally, IL-8 mRNA 
expression is detected in OSE and its expression is up-regulated by IL-1α treatment 
(Rae, Niven et al. 2004b). 
 
There are also several lines of evidence to suggest the involvement of IL-8 in the 
progression of EOC. Firstly, enhanced levels of IL-8 are detected in ascites of 
ovarian cancer patients compared to plasma (Giuntoli, Webb et al. 2009). Secondly, 
the levels of IL-8 are markedly stimulated in cyst fluid from malignant in comparison 
to benign tumours (Nowak, Glowacka et al.; Ivarsson, Runesson et al. 1998). Thirdly, 
most EOC cell lines constitutively express IL-8 (Toutirais, Chartier et al. 2003). 
Lastly, expression of IL-8 protein in the tissue increases with lower differentiation 
status of the tumours. Both types of IL-8 receptors are detected in most specimens. 
There is a typical expression pattern for IL-8 receptor A, with expression limited to 
the luminal side of the epithelial tumour cells, whereas IL-8 receptor B is more 
equally distributed in the samples (Ivarsson, Ekerydh et al. 2000). Nearly half of 102 
cancer samples have high IL-8 expression and the remainders have little or no IL-8 
expression. High IL-8 expression is associated with advanced tumour stage, high 
tumour grade and poorer survival. Ovarian cancer growth can be inhibited through 




The human IL-10 gene is located on chromosome 1 and encodes for 5 exons (Spits 
and de Waal Malefyt 1992). IL-10 exerts its action by binding to its specific cell 
surface receptor, which is composed of two subunits, α and β, that are members of 
the interferon receptor (IFNR) family (Kotenko, Krause et al. 1997). The receptor is 
present on many types of cell, in particular immune cells. The IL-10 promoter 
contains several transcription factor-responsive elements. Thus the production of IL-
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10 by the cells can be promoted by several endogenous and exogenous factors such 
as endotoxin, TNF-α, catecholamines, and 3'-5'-cyclic adenosine monophosphate 
(cAMP)-elevating drugs (Asadullah, Sterry et al. 2003). Particularly, the stress axis is 
an important regulator of IL-10 expression in vivo. The main biological effect of IL-
10 is to limit and terminate inflammatory responses and then regulate the 
differentiation and proliferation of immune cells such as T cells, B cells, natural 
killer cells and granulocytes (Asadullah, Sterry et al. 2003). In addition, many 
investigations indicate a major role of IL-10 in inflammatory and malignant diseases. 
Enhanced expression of IL-10 is found in many tumours and is considered to 
promote further tumour development. 
  
There have been several reports of increased IL-10 expression in ovarian cancer. In 
one study, enhanced levels of IL-10 were detected in ascites of ovarian cancer 
patients compared to plasma (Giuntoli, Webb et al. 2009). In another study, ten of 
eleven tumour biopsies expressed mRNA of IL-10 whereas the eight normal ovaries 
studied did not (Pisa, Halapi et al. 1992). In other studies, total mRNA expression of 
IL-10 was detected in 17 of 20 malignant ovarian cancer specimens while there was 
no expression in 10 benign samples (Merogi, Marrogi et al. 1997). It was also 
reported that a majority of solid EOC samples expressed transcripts for IL-10 (Nash, 
Lenzi et al. 1998).  
 
1.2 Ovarian cancer 
1.2.1 Clinical features of ovarian cancer 
1.2.1.1  Incidence and mortality 
Ovarian cancer is the 5th most common cancer in women, after breast, bowel, lung 
and uterine cancer, with approximately 6720 women being diagnosed in 2007 in the 
UK (Cancer Research UK Statistics). It has the highest mortality rate of all 
gynaecological cancers and is the 4th most common cause of cancer related death in 
women in the UK. About 4,370 women died of ovarian cancer in 2008 in the UK 
(Cancer Research UK Statistics). The main reason for this poor prognosis is the rapid 
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and asymptomatic progression of the tumour along with the absence of efficient 
screening tests, resulting in its presence at late stage of disease and less responsive to 
treatment and cure. Ovarian cancer can occur at any age but is predominantly a 
disease of older, post-menopausal women with over 80% of cases being diagnosed in 
women over 50 years, peaking in women aged 65 and over (Cancer Research UK 
Statistics).  
 
1.2.1.2 Classification of ovarian cancer 
According to the World’s Health Organization (WHO) Classification of Ovarian 
Tumours, made in 1973 and updated in 1999, ovarian tumours can be classified into 
three major categories: surface epithelial-stromal tumours, sex cord-stromal tumours 
and germ cell tumours, depending on their originating anatomic structure. Tumours 
with combinations of different subtypes either intermixed or side-by-side within a 
single tumour can sometimes be found and are designated as mixed, with the 
contributing subtypes specified in the designation. Among various ovarian tumours, 
the most common types are surface epithelial-stromal tumours, also known as 
epithelial ovarian tumours, which originate from the surface epithelium of the ovary 
and account for approximately 60% of all the ovarian tumours and 90% of malignant 
ovarian tumours. Depending on histological features, epithelial ovarian tumours are 
subcategorised into five major subtypes, serous, mucinous, endometrioid, clear cell 
and transitional cell tumours. Highly malignant epithelial-stromal tumours lacking 
any specific differentiation are classified as undifferentiated. Each subtype of 
epithelial ovarian tumour can be further classified as benign if they lack exuberant 
cellular proliferation and invasive behaviour; borderline if there is exuberant cellular 
proliferation but no invasive behaviour and malignant if there is invasive behaviour. 
The malignant epithelial ovarian tumours, also named epithelial ovarian cancer or 
carcinoma (EOC), will be introduced in detail as follows. 
 
The most common types of EOC are malignant serous tumours, representing 
approximately 50% of all malignant ovarian tumours. Serous ovarian carcinomas are 
classified as tumours that resemble the epithelium of the oviduct or Fallopian tube. 
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Most of them are partially cystic, containing multiple cyst chambers and also solid 
areas, and display an abundance of delicate papillae that project into the cyst cavities 
or outward from the external surface of the tumour. Most of them occur in women in 
their sixties and two-thirds of them are bilateral.  
 
Malignant endometrioid ovarian tumours, which have features of endometrial 
glandular epithelium, are the second most common EOC, accounting for 10–25% of 
EOC. They may be cystic or predominantly solid. Most of the tumours are confined 
to the ovaries and adjacent pelvic structures and are considered to have a better 
prognosis than either mucinous or serous carcinomas. These tumours usually appear 
in the sixth decade of women’s life and about 13–28% of them are bilateral.  
 
Malignant mucinous tumours, which have features of the uterine cervical or 
intestinal epithelium, represent 5–10% of EOC. Malignant mucinous tumours may 
contain papillary projections within the cyst cavities, larger solid areas, and necrosis 
and haemorrhage regions as well. Most of them appear in the sixth decade of life and 
6%-20% of malignant mucinous tumours are bilateral. Late extra-peritoneal 
recurrences, particularly in the lungs, are characteristic of malignant mucinous 
tumours.  
 
Malignant clear cell tumours consisting of cells with clear cytoplasm make up 4–5% 
of EOC. Usually, they are diagnosed in the fifth decade of life. Two-thirds of all 
women with this type of tumours are nulliparous, and 50–70% of them are affected 
by endometriosis. Survival rates for clear cell carcinomas are poorer than the other 
EOC. 
 
Transitional cell tumours consist of cells that resemble transitional epithelium or 
urothelium of the urinary bladder. They contain solid and cystic regions with internal 
papillary projections. About one-tenth of these tumours are bilateral. They are rare 




1.2.1.3 Stage and grade of ovarian cancer 
Staging of ovarian tumour, also known as the extent of tumoural spread, is performed 
according to the TNM system, with T standing for extent of primary tumour, N 
standing for degree of spread to lymph nodes and M standing for metastasis 
(Flemming ID 1997). The system is established by the American Joint Committee on 
Cancer (AJCC) and it is comparable to the staging system approved by the 
International Federation of Gynaecology and Obstetrics (FIGO) (Table 1.1). This 
international system of staging of the ovarian cancer is useful for therapeutic 
strategies, prognosis of the disease and also clinical research, which need comparable 
global standard.  
 
The grade (G) of ovarian cancer, also known as the degree of tumour differentiation, 
represents the degree to which the tumour has similarity to the normal tissue. G1 
refers to tumours that are well-differentiated, demonstrating little cellular atypia and 
few mitoses. G2 refers to moderately-differentiated tumours, exhibiting enhanced 
cellular atypia and more frequent mitoses but retention of histological differentiation. 
G3 refers to poorly-differentiated tumours with frequent mitoses, and containing 
poorly or undifferentiated cells with few distinguishing features (Chen, Ruiz et al. 









The standard care for EOC patients involves staging and cytoreduction surgery 
followed by chemotherapy with a platinum and taxane combination (Williams, 
Toups et al. 2007). Adjuvant treatments such as radiotherapy and hormonal therapies 
have demonstrated effectiveness in certain patients.  
 
The main aims of surgery for primary cancer are accurate diagnosis, staging and 
removal of tumour to the maximum extent. The surgical plans are variable depending 
on the individual stages and histology subtypes. In the treatment of advanced disease, 
cytoreductive surgery, which eradicates tumour incompletely but can improve the 
chances of response to chemotherapy, is a common intervention. The main 
procedures include, but are not limited to, total abdominal hysterectomy (removal of 
the uterus), bilateral salpingo oophorectomy (removal of fallopian tubes and ovaries), 
infracolic, omentectomy (excision of the omentum beneath the transverse colon), and 
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lymph-adenectomy (lymph node dissection) (Stratton, Tidy et al. 2001). The overall 
survival of EOC patients can be significantly increased if cytoreductive surgery 
decreases tumour size to less than 1 cm, and the size of any remaining tumour is a 
very important prognostic factor (Cannistra 1993). 
 
Standard chemotherapy usually consists of a combination of Carboplatin and 
Paclitaxel. Carboplatin elicits cell death by forming inter- and intra-strand cross-links 
with DNA or DNA adducts and also by disrupting DNA replication. Furthermore, 
Carboplatin activates signal transduction pathways by damaging the protein structure 
of receptor or ligand molecules by interaction with their thiol groups. This drug can 
also damage DNA beyond repair, causing apoptosis (Williams, Toups et al. 2007). 
Paclitaxel acts through hyperstabilization of microtubules, thus compromising 
flexibility of the cellular cytoskeleton (Williams, Toups et al. 2007). Chemotherapy 
frequently produces clinical remissions but relapse is a common event and when 
drug resistance occurs it is usually fatal (Kaye 1996). Studies have shown that 
approximately 50-75% of patients will eventually experience a relapse of EOC 
(Johnston 2004). Thorough understanding of underlying mechanisms by which the 
drug resistance develops, and development of therapeutic drugs for resistant EOC, 
remain active areas of research. 
 
Radiotherapy and hormonal therapies have demonstrated benefit for some patients. 
Radiotherapy is usually used as a palliative treatment for the recurrent ovarian cancer 
patients, controlling symptoms such as bleeding and pain. The main reason for the 
limited use of radiotherapy in EOC is that spread of the disease throughout the 
peritoneal cavity limits the delivery of safe doses.  
 
Hormonal therapies have often been applied as a safe and effective complementary 
or alternative treatment for recurrent ovarian cancer. Tamoxifen, a synthetic selective 
ER modulator, which acts by competitive binding of ER and used widely in the 
treatment of breast cancer, has also been used in treatment of ovarian cancer. A 
review of 18 studies including 648 patients found the overall response rate to 
tamoxifen was 13%, including a 4% complete response rate, a 9% partial response 
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rate, and 38% stabilization of disease (Perez-Gracia and Carrasco 2002). Tamoxifen 
usually has a mild toxicity so it can be a choice for heavily treated patients with 
recurrent disease, especially for those with poor response. Aromatase inhibitors (AIs) 
like letrozole and anastrozole have been tested in phase II clinical trials in which AIs 
have been conducted in recurrent or persistent ovarian cancer (Bowman, Gabra et al. 
2002; del Carmen, Fuller et al. 2003; Papadimitriou, Markaki et al. 2004). The 
results indicate that AIs have modest activity in recurrent ovarian cancer. Similar to 
other hormonal therapies, progesterone has been tried mostly in recurrent ovarian 
cancer patients who have failed one or more chemotherapeutic therapies. A review of 
13 studies including 432 patients treated by megestrol acetate (MA) or 
medroxyprogesterone acetate (MPA) revealed a complete response rate of 2.3%, a 
partial response rate of 4.9% and stable disease in 10.9% of patients (Zheng, 
Kavanagh et al. 2007). High-dose progesterone therapy (MA, 400–800 mg/day) has 
not been proven to be more effective than regular dose (MA, 160 mg/day) (Veenhof, 
van der Burg et al. 1994). RU486 (mifepristone) is a synthetic antiprogestin which 
competitively binds the PR. It has been tested in one study in the treatment of 
cisplatin and paclitaxel-resistant ovarian cancer patients. There is an overall response 
rate of 26.5%, including a complete response rate of 9% and partial response in 
17.5% of patients. In addition, a few clinical trials have shown GnRH agonists 
(leuprolide acetate, goserelin, triptorelin) may provide modest efficacy in patients 
with relapsed ovarian cancer. As treatment with a GnRH agonist has few side effects, 
it can be a valid choice in patients who cannot tolerate or accept chemotherapy 
(Emons, Grundker et al. 2003; Grundker and Emons 2003). A clinical trial of the 
GnRH antagonist cetrorelix has shown it has a clear effect on refractory ovarian 
cancer and may be tried on more patients in the future (Verschraegen, Westphalen et 
al. 2003). Lastly, the effectiveness of antiandrogen therapy has been explored in a 
small number of studies. Response rate and disease stabilization of ovarian cancer 
patients to flutamide (nonsteroidal antiandrogenic drug) are 4.3% and 8.7% in one 
study (Vassilomanolakis, Koumakis et al. 1997), and 6.3% and 28% in another study 




1.2.2 Origin of ovarian cancer  
Traditionally, OSE and OSE lining inclusion cysts are thought to be the source of 
EOC (Auersperg, Wong et al. 2001; Murdoch and McDonnel 2002). The evidence 
for EOC arising from OSE is indirect, based on the epidemiological finding that the 
risk of developing EOC rises with increased number of lifetime ovulations and OSE 
is repetitively injured during each ovulation (Espey 1994; Ness, Grisso et al. 2000; 
Fleming, Beaugie et al. 2006). Many authors hypothesize that physical trauma 
inflicted by ovulation and DNA damage caused by ovulation-associated 
inflammatory cytokines and reactive oxygen species increase OSE vulnerability to 
genetic mutation and susceptibility to oncogenic transformation. This is supported by 
experiments showing that OSE, from both rats and mice, which has been 
continuously cultured to mimic the repetitive injury and repair that OSE undergoes 
spontaneously transforms into cancerous cells (Godwin, Testa et al. 1992; Testa, 
Getts et al. 1994; Roby, Taylor et al. 2000).  
 
After ovulation, epithelial inclusion cysts are formed by invaginations of OSE into 
the cortical stroma, where they become trapped. There is some evidence linking their 
presence to EOC development. Firstly, inclusion cysts are more numerous in patients 
with family histories of ovarian cancer (Mittal, Zeleniuch-Jacquotte et al. 1993; 
Werness, Afify et al. 1999). Secondly, the incidence of inclusion cysts is 
significantly higher in normal ovaries with contralateral ovarian tumours, compared 
with those examined after incidental oophorectomy, 82% vs. 61% (Okamura and 
Katabuchi 2001). Thirdly, inclusion cysts are more frequently observed in post-
menopausal women than in premenopausal women, 66% vs. 51% (Okamura and 
Katabuchi 2001). Since the peak incidence of EOC is after menopause, the 
occurrence rate of inclusion cysts is intriguing. Moreover, mitotic activity is 
demonstrated in some OSE cells lining the inclusion cysts by immunohistochemical 
methods, and p53 protein is also present in such OSE cells (Okamura and Katabuchi 
2001). Finally, c-myc gene is reportedly activated in the OSE cells of inclusion cysts 
in normal human ovaries (Tashiro H 1993). Consequently, in response to genetic 
alterations and the accumulation of additional mutant proteins, especially in inclusion 
cysts resulting from the process of surface epithelium repair as a consequence of 
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ovulation, the inclusion cysts may become committed to form preneoplastic lesions 
(Okamura, Katabuchi et al. 2006).  
 
Inside the ovary, inclusion cysts are exposed to a hormone-rich environment, where 
gonadotrophins, androgen, progesterone and oestrogen act together and induce 
proliferation of OSE lining the inclusion cyst, eventually giving rise to ovarian 
carcinoma (Wong and Leung 2007). The effect of different sex steroids will be 
reviewed in detail in next section. 
 
The OSE-inclusion cyst model can explain many important features of ovarian 
tumourigenesis, however, it also has its limitations.  For instance, it does not explain 
why invasive endometrioid and mucinous carcinomas are frequently associated with 
borderline tumours in the ovary, while invasive serous carcinomas are not (Karst and 
Drapkin 2010). Moreover, this model does not address the clear differences in 
genetic alterations that exist between tumour subtypes. If all ovarian tumours derive 
from inclusion cysts, why do they have such different genotypes and outcomes 
(Karst and Drapkin 2010)?  
 
The fimbrial end of the fallopian tubes has also recently been proposed as a possible 
origin of EOC (Brown and Palmer 2009; Karst and Drapkin 2010). This concept 
arises from the studies exploring occult ovarian and fallopian tube cancer in women 
with breast cancer (BRCA) gene mutations. Inherited mutations in BRCA1 or 
BRCA2 are associated with familial ovarian cancer, which accounts for 11–15% of 
ovarian carcinomas (Risch, McLaughlin et al. 2006) and mutations in either gene 
hold a 15–40% lifetime risk of developing ovarian cancer (Wooster and Weber 2003). 
These results indicate that many ovarian tumours may actually arise from the distal 
region of the fallopian tube, but afterwards spread to the adjacent ovary. However, 




1.2.3 Hormones and ovarian cancer 
Based on epidemiological data, three hypotheses exist to explain the initiation and 
development of EOC. In addition to the incessant ovulation and inflammation 
hypotheses discussed in previous sections, gonadotrophins and sex hormones are 
thought to play roles in the pathogenesis of EOC, as will now be considered. 
 
1.2.3.1 Gonadotrophins 
The gonadotrophins, FSH and LH, are glycoprotein hormones synthesized in the 
anterior pituitary that play key endocrine roles in regulating ovarian steroidogenesis 
and gametogenesis. They are also suggested regulators of EOC. The ‘gonadotrophin 
hypothesis’ is one of the three hypotheses that have been proposed to explain ovarian 
cancer pathogenesis. It proposes that ovarian cancer develops as a result of excessive 
stimulation of ovarian tissue by gonadotrophins. Gonadotrophins may directly 
activate gonadotrophin-responsive genes in those cells experiencing malignant 
transformation or indirectly stimulate sex steroids that could influence malignant 
transformation through paracrine or endocrine mechanisms (Risch 1998). 
 
Epidemiologic studies indirectly support the gonadotrophin hypothesis. Decreased 
risk for ovarian cancer is associated with breastfeeding and oral contraceptive use, 
both of which are associated with suppressed secretion and reduced exposure to 
gonadotrophins ((Rao and Slotman 1991; Rossing, Daling et al. 1994; Shoham 1994). 
Conversely, increased risk of ovarian cancer is associated with conditions where 
gonadotrophin levels are elevated, such as in post-menopausal women, in women 
who have received treatment for the induction of ovulation and in women with 
polycystic ovarian syndrome (PCOS) (Whittemore, Harris et al. 1992; Balen 1995). 
However, the lack of increase in risk related to early age at menopause and with twin 
pregnancies, both of which are associated with increased gonadotrophin levels 
(Martin, Robertson et al. 1991; Lambalk, Boomsma et al. 1998), and decreased blood 
levels of FSH and LH in ovarian cancer cases compared with controls (Helzlsouer, 
Alberg et al. 1995), indicate that gonadotrophins may not be responsible for changes 




There is also experimental evidence suggesting that gonadotrophins might act 
directly on OSE and thereby contribute to EOC. For example, gonadotrophins have 
been shown to enhance tumour angiogenesis and adhesion in ovarian cancer cells 
(Schiffenbauer, Meir et al. 2002; Zygmunt, Herr et al. 2002). However, the direct 
effect of gonadotrophins on the proliferation of normal OSE cells and ovarian cancer 
cells is still controversial, with different studies showing either an increase (Syed, 
Ulinski et al. 2001; Choi, Kang et al. 2002) or no effect (Zheng, Lu et al. 2000; 
Ivarsson, Sundfeldt et al. 2001). Two complementary DNA (cDNA) microarray 
studies which investigated the gene expression profiles of normal and neoplastic cells 
following FSH treatment, have shown FSH regulates a set of oncogenic and tumour-
suppressor genes, although no matching genes were found between the two studies 
(Ho, Lau et al. 2003; Ji, Liu et al. 2004).  
 
In conclusion, more experimental evidence is needed to establish the role of 
gonadotrophins in normal OSE biology and ovarian cancer development, to 
understand their possible mechanisms of action. 
 
1.2.3.2 Androgens  
Androgens are also implicated in the pathogenesis of ovarian cancer. Various 
epidemiologic data indicate a cancer promoting effect of androgen. Women taking 
oral contraceptives, which decrease androgen levels, have a decreased risk of ovarian 
cancer (Coenen, Thomas et al. 1996). Conversely, women with PCOS, a disease 
associated with hyperandrogenaemia, have a higher risk of developing ovarian 
cancer (Schildkraut, Schwingl et al. 1996). Moreover, patients with endometriosis, 
treated with Danazol (which depresses secretion of gonadotrophins but has 
androgenic properties) have 3-fold elevated risk of ovarian cancer compared with 
patients with no treatment, while patients who take leuprolide/nafarelin (GnRH 
agonists) are not at significantly elevated risk in comparison to patients with no 




Experimental data also support the concept that androgens are involved in the 
development of ovarian cancer. Thus AR is expressed in the majority of ovarian 
cancers (Chadha, Rao et al. 1993; Cardillo, Petrangeli et al. 1998) and several in 
vitro studies have shown androgen can promote cell proliferation of normal OSE 
cells (Karlan, Jones et al. 1995; Syed, Ulinski et al. 2001; Edmondson, Monaghan et 
al. 2002). Moreover, 5α-dihydrotestosterone (5α-DHT) reverses the growth-
inhibitory effect of transforming growth factor-β1 (TGF-β1) on SKOV-3 cells and 
primary ovarian cancer cells recovered from ascitic fluid, suggesting that androgens 
may help ovarian cancer cells to escape from the growth inhibitory effects of TGF-
β1 (Evangelou, Jindal et al. 2000). Furthermore, in an in vivo study, the growth of 
ovarian epithelial cells of guinea pigs was stimulated by testosterone treatment, 
resulting in the production of benign cysts and small adenomas in the ovarian 
parenchyma and papillomas on the ovarian surface (Silva, Tornos et al. 1997). 
 
In conclusion, preliminary epidemiologic and experimental data have indicated 
accelerating effects of androgen in ovarian cancer development but more studies are 
necessary to ascertain a definitive role. 
 
1.2.3.3 Progesterone   
Epidemiologic evidence suggests that progesterone (P4) might protect against 
ovarian tumour development. Multiparity, associated with high levels of P4 in every 
pregnancy, has been reported to reduce the risk of ovarian cancer (Adami, Hsieh et al. 
1994; Salazar-Martinez, Lazcano-Ponce et al. 1999). Moreover, twin pregnancy is 
also reported to be one protective factor of ovarian cancer. P4 levels during multiple 
pregnancies are higher compared with singleton pregnancies (Johnson, Abbas et al. 
1994; Thomas, Murphy et al. 1998), and mothers of dizygotic twins may also have 
higher follicular phase serum P4 than women with single pregnancies (Gilfillan, 
Robertson et al. 1996). Furthermore, progestin-only oral contraceptives, which exert 
their effect through thickening of the cervical mucus and reduction of the 
endometrial receptivity to implantation, are reported to have a protective effect 
against ovarian cancer (Kumle, Weiderpass et al. 2004). Additionally, one study has 
shown that combination oral contraceptive formulations with high progestin potency 
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provide greater protection than those with low-progestin potency (Schildkraut, 
Calingaert et al. 2002), and risk of ovarian cancer is higher in users of oestrogen-only 
HRT than in combined oestrogen-progestin HRT users (Lacey, Mink et al. 2002; 
Riman, Dickman et al. 2002). 
 
Experimental evidence is also consistent with a protective role of P4 in ovarian 
cancer. Firstly, in vitro studies have demonstrated that higher doses of P4 inhibit cell 
growth in rhesus monkey OSE (Wright et al. 2002). Secondly, in addition to the 
negative role in cell growth, P4 also inhibits invasion of ovarian cancer cells. For 
example, P4 significantly reduced invasion of SKOV-3 cells into Matrigel and 
secretion of uPA (McDonnel and Murdoch 2001), and an in vivo study using athymic 
mice inoculated with SKOV-3 cells has show that treatment with P4 decreases 
invasion into host tissues (McDonnel, Van Kirk et al. 2005). Thirdly, the expression 
of PRs is associated with better survival of ovarian cancer and is considered to be a 
favourable prognostic marker in ovarian cancer (Lee, Rosen et al. 2005). The 
expression of PR-A protein was significantly lower in malignant tissue than in 
normal ovarian tissues, suggesting down-regulation of PR-A is associated with the 
development of ovarian epithelial carcinoma (Akahira, Suzuki et al. 2002).  Lastly, 
recent cDNA microarray studies have revealed that P4 induces putative 
antitumorigenic genes including ATF-3 (an apoptosis inducer), NM23-H2 (a motility 
suppressor), and caveolin-1 and DLC-1 (tumour suppressors) (Syed, Mukherjee et al. 
2005).   
 
In summary, accumulating evidence indicates that P4 may be protective against 
ovarian cancer but once again, definitive confirmation is awaited. 
 
1.2.3.4 Oestrogens 
Oestrogens are most likely candidates as hormonal tumour promoters. The 
relationship between oestrogen-containing hormone replacement therapy (HRT) and 
the risk of ovarian cancer is still controversial.  Some studies show a promoting 
effect (Negri, Tzonou et al. 1999) whilst others suggest no effect (Coughlin, 
Giustozzi et al. 2000). However, more recent epidemiological studies on post-
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menopausal women have indicated that oestrogen replacement therapy (ERT) 
increases ovarian cancer incidence and mortality (Rodriguez, Patel et al. 2001; Lacey, 
Brinton et al. 2006; Beral, Bull et al. 2007).   
 
Paradoxically, although oral contraceptives also involve administration of exogenous 
oestrogens, they show a protective effect on ovarian cancer. This may in part be 
because they also contain progestins, which as discussed above may be anti-
tumourgenic. Oral contraceptives also suppress ovulation, which as discussed above 
would also confer protection. Apart from the contribution to suppression of ovulation 
and protective effect of progestins, another reason may be reduction of endogenous 
17β-oestradiol (E2) production by oral contraceptives. The 24-hour total serum 
ethinyl oestradiol (or equivalent) level in women on oral contraceptives is 
comparable to the naturally low E2 level of the early- to mid-follicular phase 
(Humpel, Tuber et al. 1990; Dibbelt, Knuppen et al. 1991), which in turn is lower 
than late follicular- or luteal-phase E2 levels. Breastfeeding is also likely to be 
protective with fewer ovulations, higher concentrations of progesterone and reduced 
serum concentrations of E2 potentially combining to contribute to the protective 
effect (Liu, Rebar et al. 1983). 
 
Classical oestrogen signalling, via oestrogen binding to ER located in the nucleus, 
induces transcriptional activation of oestrogen-regulated genes in ovarian cancer. 
Some of these genes are key components of the complex carcinogenesis process that 
includes proliferation, migration and invasion (Hayashido, Lucas et al. 1998). Up-
regulation of c-myc has been shown to mediate oestrogen-induced ovarian cancer 
cell growth (Chien, Wang et al. 1994). Ezrin (Song, Fadiel et al. 2005), fibulin-1 
(Clinton, Rougeot et al. 1996; Bardin, Moll et al. 2005), cathepsin D (Galtier-
Dereure, Capony et al. 1992) and kallikreins (Yousef and Diamandis 2002), which 
are involved in motility and invasion of EOC cells, are reported to be regulated by 
oestrogen. In addition, oestrogen may interact with cytokines and growth factors in 
ovarian cancer cells. For example, oestrogen increases IL-6 mRNA and protein 
expression, resulting in the activation of the signal transducers and activators of 
transcription protein (STAT)-3 signalling pathway (Syed, Ulinski et al. 2002). An 
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EGF receptor-targeted antibody decreases the stimulatory effects of oestrogen on 
growth of PEO-1 ovarian cancer cells (Simpson et al. 1998). Oestrogen enhances 
EGF- and insulin growth factor (IGF)-I-mediated ovarian cancer cell growth by 
modulation of properties of receptors for the two growth factors (Wimalasena, 
Meehan et al. 1993). Lastly, E2 decreases insulin-like growth factor binding protein 
(IGFBP)-3 and increases IGFBP-5 mRNA levels in PEO-4 ovarian cancer cells 
(Krywicki, Figueroa et al. 1993).  
 
In summary, the epidemiological data together with experimental evidence indicate 
an involvement of oestrogen in the carcinogenesis and progression of ovarian cancer. 
The molecular mechanisms of the promoting effect and blockade of the effect by 
novel therapeutics will be of particular interest. 
 
1.3 Oestrogen biosynthesis and mechanism of action 
To appreciate the potential relevance of oestrogen signalling to the development of 
EOC it is necessary to understand the biochemical pathways of oestrogen formation 
and metabolism, the basis of which will now be assessed. 
 
1.3.1 Pathway of oestrogen formation and metabolism 
Endogenous oestrogens are responsible for the development and maintenance of the 
female reproductive system. Circulating oestrogens exist in a dynamic equilibrium of 
metabolic interconversion, but E2 is the primary intracellular oestrogen and is 
substantially more active than either oestrone (E1) or oestriol (E3) at the receptor 
level. Before menopause, the primary source of oestrogen in adult women is the 
ovarian follicle through conversion of cholesterol, while after menopause, most 
endogenous oestrogen is formed by peripheral tissues through conversion of 
androstenedione (A), secreted by the adrenal cortex, to E1 (Fig. 1.2). A major 
proportion of the oestrogens circulating in the body are conjugated (glucuronidated 
or sulphated) at hepatic sites in order to allow for rapid urinary excretion. 
Consequently, E1 and oestrone sulphate (E1S), are the most abundant circulating 
oestrogens in postmenopausal women. Furthermore, E2 is produced and metabolized 
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locally via aromatase or STS pathways in some cancers and plays an important role 
locally in the development of these cancers. The underlying metabolic pathways in 
pre- and post-menopausal women will now be reviewed. 
 
                             
Figure 1.2: Major pathway of oestrogen biosynthesis and metabolism. Adapted from  
http://www.nature.com/nrurol/journal/v8/n7/fig_tab/nrurol.2011.67_F1.html#figure-title. 
DHEAS: dehydroepiandrosterone sulphate; DHT: dihydrotestosterone; EST: oestrogen 
sulfotransferase; E1S: oestrone sulphate; STS: steroid sulphatase; 3β-HSD: 3β hydroxysteroid 
dehydrogenase; 17β-HSD: 17β hydroxysteroid dehydrogenase. 
 
1.3.1.1 Pre-menopausal oestrogen dynamics  
In pre-menopausal adult women, most ostrogen is secreted by granulosa cells of the 
pre-ovulatory ovarian follicle and their derivatives (granulosa lutein cells) in the 
corpus luteum (Fig. 1.3). Small amounts of oestrogen are also produced by the 
adrenal cortex. During pregnancy, the placenta becomes the major source of 










The cellular and biochemical interactions underpinning ovarian oestrogen 
biosynthesis and metabolism are summarized in Fig. 1.3. 
 
Figure 1.3: Two-cell, two-gonadotropin hypothesis of regulation of oestrogen synthesis in the 
human ovary. Adapted from http://www.endotext.org/female/female3/femaleframe3.htm. cAMP: 
3'-5'-cyclic adenosine monophosphate; CYP11A1: cytochrome P450, family 11, subfamily A, 
polypeptide 1; CYP17: cytochrome P450, family 17, subfamily A, polypeptide 1; DHEA: 
dehydroepiandrosterone; FSH: follicle-stimulating hormone; LH: luteinising hormone; 
P450arom: aromatase; R: receptor; 3βHSD: 3β hydroxysteroid dehydrogenase; 17βHSD: 17β 
hydroxysteroid dehydrogenase type 1. 
 
There are two peaks of oestrogen secretion during menstrual cycle. One is on day 12 
or 13, before ovulation and the other is during the mid-luteal phase. The main effects 
of oestrogen are to promote growth of ovarian follicles, increase motility of uterine 
tubes, stimulate the growth of endometrium, enhance uterine blood flow, produce 
duct growth in the breasts and regulate the development of female secondary sex 
characteristics during puberty.  
 
1.3.1.2 Post-menopausal oestrogen dynamics 
In post-menopausal women, the ovaries cease to produce oestrogen, hence the ovary 
is no longer the main source of oestrogen. However, oestrogens are still produced at 
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a number of extragonadal peripheral sites, including fat, muscle, skin and liver, and 
by certain cancers of breast and endometrium (Miller 2004).  
 
These sites express the aromatase enzyme necessary for conversion of androgens to 
oestrogens (Fig. 1.2), utilising precursor androgen produced by the adrenal cortex.   
Moreover, the post-menopausal ovary still produces substantial amounts of androgen, 
which can also be used as the precursor. Although aromatase activity has been 
identified in all of these tissues, levels remain substantially lower compared to 
primary endocrine organs like ovary and placenta. However, there are large masses 
of fat and muscle throughout the body and the combined metabolic capacity at these 
sites leads to the formation of micrograms of oestrogen per day. In vivo，muscle 
accounts for up to 30% and adipose tissue up to 15% of peripheral conversion of 
androgen to oestrogens (Miller 2004). Therefore, there is a positive correlation 
between body weight and serum oestrogen levels in post-menopausal women. In the 
same tissue of variable body areas, aromatase activities are different. For example, 
aromatase activity is much higher in adipose tissue from the buttocks than from the 
thighs, perhaps due to different local controls (Killinger, Perel et al. 1987). 
 
The total quantity of oestrogen produced by these extragonadal sites may be 
relatively small but the local concentrations in the tissue are sufficient to act locally. 
As a consequence, circulating levels of oestrogens in post-menopausal women do not 
reflect direct oestrogen action in post-menopausal women. 
 
1.3.1.3 Local production and metabolism of oestrogen 
Various oestrogen-dependent cancers of the female reproductive tract have the 
ability to produce biologically active oestrogens. These locally formed oestrogens are 
considered to play a vital role in the development of such cancers by acting in the 
cells where they are produced without necessarily entering the extracellular space. 
This mechanism of formation and action, which differs from autocrine or paracrine 




From many studies of breast cancers, we know there are two main pathways for the 
production of oestrogen in situ, the aromatase and STS pathways, which may also be 
involved in ovarian cancer. The start of the aromatase pathway would involve 
circulating dehydroepiandrosterone (DHEA) or A entering the cancer tissue. DHEA 
can then be converted to A by 3βHSDs or converted to androstenediol by 17βHSDs. 
A which comes from the circulation or converted from DHEA is then converted 
either to E1 by aromatase or to testosterone (T) by 17βHSDs depending on the tissue. 
T is catalyzed further to E2 by aromatase and E1 is catalyzed to E2 by 17βHSD1 or 
17βHSD5 (Dufort, Rheault et al. 1999; Penning, Burczynski et al. 2000; Byrns and 
Penning 2009) depending on the tissue. In this pathway aromatase catalyzes 
conversion of A and T into E1 and E2 respectively. For the STS pathway, there are 
two sources of substrates. One substrate is E1S which diffuses from the vessels. STS 
hydrolyzes E1S to E1. E1 can subsequently be converted to E2 by 17βHSD1 or 
17βHSD5. Another substrate of STS is DHEAS which also diffuse from the vessels 
into the tissues. STS converts DHEAS to DHEA and DHEA is finally converted to 
E2 via aromatase pathway. The resulting E2 exerts its action on cancer cells through 
ER. At the site of active oestrogen synthesis, there may be opposing enzymes that 
convert active to inactive oestrogens. For example, oestrogen sulfotransferase (EST) 
which acts in the opposite direction to STS is responsible for the conversion of E1 to 
E1S or E2 to E2S. 17βHSD2 has the opposite effect to 17βHSD1 or 17βHSD5, 
converting E2 to E1 (Fig. 1.4). Therefore, the expression of oestrogen metabolizing 
enzymes producing biologically inactive oestrogen are equally important in 
determining the local oestrogen levels in cancers (Suzuki, Miki et al. 2005). In 
addition to the above enzymes, there is evidence that the uptake of E1S by the cancer 
cells is mediated by special transporters, which are also important for the local 
formation of E2. Studies of breast cancer and placenta have demonstrated OATP-B, 
OATP-D, OATP-E and OAT4 are the main candidate transporters of E1S (Pizzagalli, 
Varga et al. 2003; Wlcek, Svoboda et al. 2008).  
 
Both before and after menopause, there are high concentrations of circulating 
DHEAS, DHEA and A, which are precursor substrates of local oestrogen production 
via the aromatase pathway. DHEAS is secreted uniquely by the adrenal gland, with 
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circulating concentrations between 3µM and 12µM (Burger and Davis 2002). There 
are no significant changes in concentration during the menstrual cycle or related to 
the menopause (Burger et al. 2000). 50% of DHEA is formed by the adrenal gland, 
20% by ovarian stroma and theca interna and the remaining is converted from 
circulating DHEAS by STS. The circulating level is in the range of 3-35nM (Burger 
and Davis, 2002). A is synthesized equally in the adrenal zona and ovary with the 
circulating levels between 2 and 8nM (Burger and Davis 2002). If there is STS and 
3βHSD expression in the local area, DHEAS and DHEA which diffuse from the 
vessels can be converted to A, which therefore increases the concentration of A 
entering the local area directly from the vessels. The pre-menopausal E1S serum 
concentration measured by radioimmunoassay is around 3nM in the follicular phase 
and 5nM in the luteal phase. After menopause it decreases to 0.4nM, but increases to 
7nM in the women on HRT treatment (Ranadive, Mistry et al. 1998). Therefore the 
serum concentrations of precursors are high enough to facilitate the local production 
of significant amounts of oestrogen.  
 
As discussed in Section 1.2.3.4, epidemiological data and experimental evidence 
suggest the involvement of oestrogen in the carcinogenesis and progression of 
ovarian cancer. Since the precursors for the aromatase and STS pathways exist, if the 
transporters and enzymes of these two pathways are present and active in ovarian 
cancer, E2 can then be produced locally by cancer cells and consequently influence 
the development of ovarian cancer. Therefore it is very useful to investigate the 
expression and function of these enzymes and transporters involving in the two 
pathways to identify the specific important enzymes or transporter in ovarian cancer 
in order to apply relevant inhibitors to block the local formation of active estrogen to 











Figure 1.4: Representative pathways of  in situ production of sex steroids in human breast 
carcinoma tissues. Adapted from Suzuki et al. (2005). AR: antrogen receptor; DHEA: 
dehydroepiandrosterone; DHT: dihydrotestosterone; ER: oestrogen receptor; EST: oestrogen 
sulfotransferase; STS: steroid sulphatase; 3βHSD: 3β hydroxysteroid dehydrogenase; 17βHSD: 
17β hydroxysteroid dehydrogenase. 
 
 
1.3.2 Mechanism of oestrogen action: receptors  
Oestrogen exerts its major biological effect through interaction with classical ERs 
that reside mainly in the nucleus, although G protein-coupled receptor 30 (GPR30) 
has been proposed as a membrane-associated ER that mediates the nongenomic 
signalling of E2. Since the studies of GPR30 are limited, only the classical ERs are 
reviewed in this section. There are two different forms of ERs, ERα and ERβ, 
encoded by different genes, ESR1 and ESR2 respectively. Classically, these receptor 
proteins function as transcription factors in the nucleus when they are bound to their 
respective ligands. ERα and ERβ have a similar structure that is shared by all the 
members of the steroid hormone receptor family. Both are composed of six 
functional domains A–F: the amino-terminal A/B domain with the hormone-
    3βHSD 





  5α-reductase 






independent activation function (AF)-1; the middle C domain contains the DNA 
binding domain (DBD) which is responsible for ER binding to oestrogen response 
elements (EREs); the D domain, named the hinge region, is involved in co-regulatory 
protein binding; the carboxy-terminal domains E and F contain the ligand binding 
domain (LBD), which comprises the ligand-dependent transcription activation 
functions AF-2 (Sommer and Fuqua 2001).  
 
Classically, the model for ER activation and inhibition is relatively simple. Upon 
agonist binding ER it undergoes conformational changes, and then the ER complex 
binds to DNA at the ERE site of specific genes which is highly specific for ER, and 
induces expression of the genes. Antagonists, on the other hand, compete for binding 
of agonists to the receptor and abrogate receptor interaction with target sequences, 
and this effect can be reversed by an excess of agonist (Sommer and Fuqua 2001). In 
the process, transcriptional activation of ER-regulated genes is mediated by the AF-1 
and AF-2 regions, which can function either independently or synergistically in a 
promoter and target cell specific manner (Tora, White et al. 1989). Recently, an 
increasing number of co-regulatory factors that bind to ER have been discovered, 
facilitating or disrupting activation of target genes (McKenna, Lanz et al. 1999). 
 
ERα and ERβ are co-expressed in many tissues, including the central nervous system, 
cardiovascular system, urogenital tract, breast, and bone. In the uterus and mammary 
gland, ERα is much more highly expressed than ERβ. In contrast, only ERβ is 
expressed in the gastro-intestinal tract (Gustafsson 1999). There have been many 
studies on ER expression in different cancers, especially in breast cancer. ERs are 
present in about 60-70% of breast tumours and are regarded as an important 
parameter in determining the hormonal sensitivity of the tumour and its likely 
response to anti-oestrogen therapy. The presence of ERs in ovarian cancers has also 
been studied. ERs are expressed in normal OSE cells and also in ovarian cancers 
(Hillier, Anderson et al. 1998; Pujol, Rey et al. 1998; Lau, Mok et al. 1999). Serous 
tumours are often ER-positive while mucinous and endometrioid tumours have lower 
amounts of ER (Quinn, Pearce et al. 1982). In addition, ERα is expressed in up to 
60% of ovarian epithelial tumours and its levels are higher than in benign tumours or 
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normal ovaries (Willcocks, Toppila et al. 1983; Risch 1998). Moreover, expression 
of ERβ mRNA and protein has been reported in normal OSE cells as well as in 
ovarian cancer cell lines (Brandenberger, Tee et al. 1998). However, some studies 
suggest an increased ERα:ERβ ratio in ovarian cancer, which is thought to be a 
possible marker of ovarian carcinogenesis (Brandenberger, Tee et al. 1998; Pujol, 
Rey et al. 1998). 
 
1.3.3 Therapeutic blockade of oestrogen action 
It is well established that oestrogen has important roles in physiological and 
pathological conditions, especially an involvement in the risk towards and 
progression of oestrogen-related diseases like breast, endometrial and ovarian cancer. 
It is therefore not surprising that many studies have been carried out to develop 
potent inhibitors of oestrogen, which can be attractive measures both to prevent these 
diseases and to treat established tumours. Generally, there are two major strategies to 
influence the effect of oestrogen. One strategy is ER blockade by using drugs that 
block oestrogen signalling at the level of ER, thereby affecting oestrogen signal 
transduction. The other strategy is to reduce the biosynthesis of oestrogen. This 
approach can work by directly decreasing the conversion of androgen into oestrogen 
(inhibition of aromatase) or alternatively by blockade of the enzymes required for 
conversion of E1S into E1 (STS) or conversion of E1 to E2 (17βHSDs). In pre-
menopausal women, reducing androgen substrate and aromatase in the ovary by LH 
releasing hormone agonist is an indirect method to reduce the production of 
oestrogen (Miller 2004) (Fig. 1.5). The following section will concentrate on the 




         
Figure 1. 5: Major strategies of reduction of oestrogen effect. (i) ER blockade (ii) inhibition of 
synthesis of oestrogen. Modified from Miller (2004). A: androgen; E: oestrogen; ER: oestrogen 
receptor; ET: oestrogen signal transduction; E1S: oestrone sulphate.   
Several potent irreversible STS inhibitors have now been identified, most of which 
have an aryl ring to which a sulfamate ester is attached as their active pharmacophore 
(Reed, Purohit et al. 2005). The first-generation STS inhibitor, STX64 (BN83495, 
also known as 667 Coumate, Fig. 1.6), is a nonsteroid-based tricyclic coumarin 
sulfamate. It is shown to block the stimulatory effect of E1S on the growth of 
carcinogen-induced mammary tumours in ovariectomized rats (Purohit, Woo et al. 
2000). Second-generation STS inhibitors, such as STX213 (Fig. 1.6), have now been 
developed. Its inhibitory effect on STS activity lasts for a much longer period of time 
than STX64 after a single dose in rodents (Fischer, Chander et al. 2003). These STS 
inhibitors are orally active with a high level of bioavailability, due to their hepatic 
transit without undergoing first-pass metabolism by binding to carbonic anhydrase II 
in erythrocytes after absorption (Ho, Purohit et al. 2003). 
 
STX64 has been tested in one phase I clinical trial in post-menopausal women with 
advanced or metastatic breast cancer. The trial demonstrated that STX64 is well 
tolerated, with only a few minor side effects noted. At a dose of 5mg, more than 90% 
of STS activity was inhibited in blood lymphocytes, and the higher dose, 20mg, 





As expected, serum E1, E2 and androstenediol concentrations were significantly 
reduced with the administration of STX64. Unexpectedly, serum concentrations of A, 
the main aromatase substrate in post-menopausal women, were also reduced by up to 
86%, suggesting that A in postmenopausal women derives mainly from peripheral 
conversion of DHEAS, not directly from the adrenal cortex (Stanway, Purohit et al. 
2006). Since STX64 effectively blocks the production of androgens in addition to 
oestrogens in breast cancer, it is also likely to have therapeutic benefit in other 
hormone-dependent tumours, such as prostate, endometrial or ovarian cancer. 
 
                                      
 
Figure 1.6: Molecular structures of STX64 and the second-generation steroid sulphatase 
inhibitor STX213. Adapted from Stanway et al. (2006) 
 
1.3.4 Hormone replacement therapy   
Women enter the period of menopause either by the natural cessation of ovulation or 
by artificial methods such as surgical intervention. The main changes include 
decreased ovarian oestrogen synthesis and an increase in gonadotrophin levels, 
resulting in some short-term symptoms including hot flushes and sweats, vaginal 
discomfort, recurrent lower urinary tract infection, urinary incontinence, and mood 
changes. Long-term consequences of menopause including cardiovascular disease, 
osteoporosis and Alzheimer’s disease affect the health of post-menopausal women. 
HRT is medication prescribed to supplement the decreased levels of hormones in 
post-menopausal women to combat the symptoms. Primarily, HRT is used for short-
term treatment of post-menopausal symptoms; as HRT become well studied, it has 
demonstrated protective benefits for some age-related disease, such as osteoporosis, 
heart disease, Alzheimer’s disease, colon cancer and others, and therefore been 
prescribed for long-term treatment to protect the patients from these diseases. 
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However, apart from benefits, HRT has potential risks for the patients. It is reported 
HRT increase the risks of endometrial cancer (Grady, Gebretsadik et al. 1995), breast 
cancer (Beral, Banks et al. 1997) and venous thromboembolism (Perez Gutthann, 
Garcia Rodriguez et al. 1997). The relationship of HRT and ovarian cancer has been 
reviewed in Section 1.2.3.4. There are a few unwanted side-effects of HRT including 
weight gain, headaches, breast tenderness, vaginal bleeding, resulting in 
unwillingness to use HRT continuously.  
 
HRT includes a variety of different regimens. In its simplest form, oestrogen 
replacement therapy (ERT) is used without combination of other hormones. Since 
oestrogens themselves are effective at relieving menopausal symptoms, women 
without a uterus need only take continuous oestrogens. However, for all women who 
have not had a hysterectomy, a progestogen is added for at least 10 days of each 
month to prevent endometrial hyperplasia and carcinoma. The sequential preparation, 
which is suitable for women in the peri-menopausal situation, has oestrogen in the 
first half of a 28-day cycle with progestogen in the second half. Continuous 
combined preparation, which is appropriate for those women who experience 
menopause for several years and wish to prevent vaginal bleeding, has oestrogen and 
progestogen daily. Other regimes prescribed to older women to protect their skeletal 
and cardiovascular system including tibolone, which combines oestrogenic and 
pregestogenic activity with weak androgenic actions and selective oestrogen receptor 
modulators (SERMs). 
 
HRT is available in different preparations, such as tablets, patches, implants, gels, 
creams, and vaginal rings. Oral oestrogens are well tolerated, cheaper and are the 
most popular form. They are absorbed through the gut and transported to the hepatic 
portal circulation where most are metabolized by first pass effect. The disadvantages 
of oral oestrogens include nausea and variable levels due to hepatic metabolism, 
elevated serum triglyceride and a reduction in glucose tolerance. Oestrogens can be 
well absorbed through skin, subcutaneous fat and vaginal epithelium and these routes 
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of administration avoid the metabolism in liver, although they also have their own 
disadvantages, resulting in less use than oral forms.  
 
There are three main oestrogens typically used for HRT: E2, E3 and conjugated 
equine oestrogens (CEEs). E2 can be given by mouth, as a patch, implant or gel. 
CEEs and E3 can only be administered by mouth (Studd John  and Roger 1998). 
Preparations containing natural oestrogens are the most commonly used in Europe, 
while CEEs have been used most widely around the world, especially in North 
America (Sturdee 1997).   
 
Due to their widespread use, the next section will concentrate on CEEs. 
 
1.3.4.1 Conjugated equine oestrogens 
CEEs contain a mixture of conjugated oestrogens obtained from urine of pregnant 
mares. Premarin is the commercial name of CEEs used for oral administration, in 
which the main ingredients are sodium oestrone sulphate (NaE1S) and sodium equilin 
sulphate (NaEqS), comprising 48% and 26% respectively (Whittaker, Morgan et al. 
1980). The other oestrogenic components are sulphated form of E2, 17α-oestradiol, 
17β-dihydroequilin, 17α-dihydroequilin, equilenin, 17β-dihydroequilenin, 17α-
dihydroequilenin and delta 8-Oestrone (Bhavnani 2003). In addition, there are some 
carrier ingredients including calcium phosphate tribasic, calcium sulphate, cellulose, 
glyceryl monooleate, lactose, magnesium stearate and methylcellulose. Tablets are 
available in 0.3mg, 0.45mg, 0.625mg, 0.9mg, and 1.25mg. CEEs are well absorbed 
from the gastrointestinal tract after release from the tablet and are distributed and 
metabolized in the same manner as endogenous oestrogens. In one study of women 
taking Premarin, serum unconjugated oestrogens were measured by 
radioimmunoassay. Mean concentrations were E2 393pM, E1 599pM and equilin 
6840pM (Whittaker, Morgan et al. 1980). The indications for usage include 
vasomotor symptoms, vulvar and vaginal atrophy associated with the menopause, 
hypoestrogenism due to hypogonadism, castration or primary ovarian failure and 
prevention of osteoporosis. The contraindications include undiagnosed abnormal 
vaginal bleeding, diagnosed, suspected, or history of breast cancer, oestrogen-
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dependent neoplasia and pregnancy, liver diseases, and thromboembolic diseases 
(Introduction to Premarin, Wyeth Pharmaceuticals Inc.).  
 
Given the prevalence of EOC in post-menopausal women, and the widespread use of 
CEE’s discussed above, some of the known oestrogen responsive genes in cancer 
will now be discussed. 
 
1.4 Oestrogen responsive genes in cancer 
Oestrogen binding to its receptors activates post-receptor pathways, regulating the 
transcription of a number of genes involved in diverse aspects of cellular function 
including DNA repair, extracellular matrix remodelling, apoptosis and signal 
transduction. Identifying the downstream genes regulated by oestrogen will reveal 
the genetic basis of the wide range of biological activities of oestrogen, and provide a 
deeper understanding of the role of oestrogen in ovarian cancer. To date a few 
oestrogen-regulated genes have been revealed in ovarian cancer and the following 
sections will concentrate on reviews of four proteins encoded by oestrogen-regulated 
genes: insulin-like growth factor binding protein 3 (IGFBP3), Fibronectin (FN1), 
lysyl oxidase (LOX) and E-cadherin. 
 
1.4.1 Insulin-like growth factor binding protein 3  
IGFBP-3 is a component of the IGF system, comprising two growth factors, IGF-I 
and IGF-II; three cell membrane receptors, IGF-I receptor (IGF-IR), insulin receptor 
(IR), and IGF-II receptor (IGF-IIR); and six high-affinity binding proteins (IGFBP-1 
to IGFBP-6) (Samani, Yakar et al. 2007).  IGFBP-3 is predominantly expressed in 
the liver as well as a variety of non-hepatic normal and malignant tissues. Serum 
IGFBP-3 levels have been reported to be lower in patients with breast cancer 
(Bruning, Van Doorn et al. 1995) and colon cancer risk has been correlated with 
decreased IGFBP-3 levels (Ma, Pollak et al. 1999). Moreover, a prospective study 
showed that decreased serum IGFBP-3 levels are associated with the presence of 
high-risk colorectal adenomas, suggesting that the IGFBP3 may predict adenoma 
progression (Renehan, Painter et al. 2001). Furthermore, it has been suggested that 
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IGFBP-3 levels are reportedly lower in the serum of patients with ovarian cancer 
(Flyvbjerg, Mogensen et al. 1997).  
 
In many cancer cell lines, IGFBP-3 has been demonstrated to inhibit IGF function. 
For example, IGFBP-3 activates a phosphotyrosine phosphatase that 
dephosphorylates IGF-IR, thereby decreasing its function in MCF-7 breast cancer 
cells (Ricort and Binoux 2002). Moreover, IGFBP-3 exerts an inhibitory effect on 
IGF-IR signalling by interfering with phosphatidyl-inositol-3 kinase (PI-3K)/Akt and 
MAPK pathways, resulting in induced apoptosis and arrested growth in non-small 
cell lung cancer cell lines (Lee, Chun et al. 2002). Furthermore, IGFBP-3 can also 
affect cell function in an IGF-independent manner. Thus, IGFBP-3 exerts IGF-I-
independent growth-inhibitory effects in breast (Oh, Muller et al. 1993) and colon 
(Williams, Collard et al. 2000) cancers. Decreased IGFBP-3 levels can, therefore, 
influence cell growth both by reducing an inhibitory effect on the IGF system and 
attenuating IGF-independent growth inhibitory effects. 
 
The expression of IGFBP3 can be regulated by many factors. The pure antiestrogen 
ICI 182,780 increases IGFBP-3 expression in conditioned medium of MCF7 cells 
(Pratt and Pollak 1993). Hypermethylation of the IGFBP-3 promoter can down-
regulate IGFBP-3 synthesis, resulting in stimulation of the IGF response in non-
small cell lung cancer, and is associated with poor prognosis (Chang, Kong et al. 
2002a; Chang, Wang et al. 2002b). Given the multiple inhibitory effects of IGFBP3 
on the promotion of many cancers, agents that stimulate expression of IGFBP-3, 
such as anti-oestrogens, anti-androgens, and retinoic acid analogues, may have an 
anti-tumour effect in vitro and in vivo (Baserga 1996). Therefore, these agents, 
together with administration of IGFBP-3 itself, may be potent anticancer agents in 
future clinical treatments.  
 
1.4.2 Fibronectin  
FN1 is a high-molecular-weight adhesive glycoprotein that is involved in cellular 
adhesion and migration processes including embryogenesis, wound healing, blood 
coagulation and metastasis. It presents in the extracellular matrix (ECM) as an 
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insoluble form and in body fluids as a soluble form. The insoluble molecule is widely 
distributed in healthy connective tissue, in the lamina propria, in vessel structures, 
nerves and smooth-muscle cell layers (Waalkes, Atschekzei et al. 2010). A single 
gene encodes FN1 but alternative splicing of pre-mRNA as well as post-translational 
modifications produce up to 20 variant isoforms in humans (ffrench-Constant 1995). 
FN1 binds to a number of important molecules, including integrins, heparin, collagen 
and fibrin, among which integrins are regarded most important since they are 
structurally and functionally related cell-surface heterodimeric receptors that link the 
ECM with the intracellular cytoskeleton (Pankov and Yamada 2002). 
 
There are many reports about the involvement of FN1 in different cancers but its 
function varies among these cancers. For example, over expression of FN1 protein is 
found in hepatocellular carcinoma (Torbenson, Wang et al. 2002). FN1 is reported to 
be related to the twist-(EMT inducer), regulating cell motility and invasion in gastric 
cancer cell lines (Yang, Zhang et al. 2007). Moreover, FN1 promotes invasion of the 
colorectal cancer cell line Colo320 (Ding, Li et al. 2008) and tyrosine 
phosphorylation of paxillin together with cell invasiveness in the gastric cancer cell 
line AGS (Li, Ding et al. 2009). Oxidative stress that accompanies senescence may 
stimulate FN1 produced by human omentum-derived peritoneal mesothelial cells 
(HOMCs) and thus promote binding and dissemination of ovarian cancer cells 
(Ksiazek, Mikula-Pietrasik et al. 2009). In contrast, FN1 strongly decreases invasion 
of ovarian cancer cell line SKOV-3 in a matrigel transfilter assay (Zand, Qiang et al. 
2003). Lastly, FN1 mediates activation of Akt2 which protects human ovarian and 
breast cancer cells from apoptosis induced by docetaxel via inhibition of the p38 
pathway (Xing, Cao et al. 2008).  
 
FN1 can be regulated by oestrogen.  E2 inhibits FN1 expression in the breast cancer 
cell line MCF-7 in vitro and FN1 expression in the tumours of E2- treated mice is 
lower than that of control mice in vivo (Horii, Takei et al. 2006). In RUCA-I rat 
endometrial adenocarcinoma cells, the formation and secretion of FN1 is inhibited by 
E2 and induced by the anti-oestrogen ICI 164, 384 (Vollmer, Hopert et al. 1995). 
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Moreover, FN1 mRNA expression is significantly stimulated by E2 in PEO-1ovarian 
cancer cell line cells (O'Donnell, Macleod et al. 2005).  
 
1.4.3 Lysyl oxidase  
LOX is a secreted, copper-dependent amine oxidase, which catalyzes the production 
of aldehydes from lysine residues in collagen and elastin precursors. The subsequent 
condensation of the aldehydes forms the cross-links between collagen and elastin 
monomers in the ECM (Smith-Mungo and Kagan 1998). The cross-links created by 
LOX lead to an increased tensile strength and structural integrity, and are essential 
for normal connective tissue function, embryonic development, and wound healing 
(Casey and MacDonald 1997). Therefore, aberrant LOX expression or enzymatic 
activity causes diseases. In fibrotic disease of the lung and atherosclerosis, LOX 
activity is found to be stimulated. 
 
In addition to its action in ECM, there is evidence suggesting LOX may be a tumour 
regulator, involved in the development of different cancers. The expression of LOX 
is reduced progressively with the transition from normal prostate epithelium to 
malignant prostate epithelium (Ren, Yang et al. 1998). Decreased LOX levels have 
also been reported in colon tumours (Csiszar, Fong et al. 2002), ductal breast 
carcinoma cells (Peyrol, Raccurt et al. 1997) and bronchogenic carcinoma (Woznick, 
Braddock et al. 2005). Paradoxically, it has also been shown that LOX plays a key 
role in hypoxia-induced metastasis. Studies show that LOX expression is enhanced 
by hypoxia-inducible factor (HIF) and is associated with hypoxia related metastasis 
in human breast, head and neck tumours (Erler, Bennewith et al. 2006).  
 
There is evidence that the enzymic activity of LOX can be regulated by oestrogen. In 
one study, LOX was significantly activated by oestrogen in both skin and bone of 
mice, suggesting that oestrogen stimulates LOX activity and maturation of collagen 
and elastin in the extracellular space (Sanada, Shikata et al. 1978). In another study, 
LOX activity in the mouse cervix was raised after the injection of 1µg E2 for 10 days 
following ovariectomy, indicating that LOX activity in the mouse cervix is under the 
control of oestrogen (Ozasa, Tominaga et al. 1981). Taken together, the above data 
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indicate that LOX is a cancer-associated and oestrogen-regulated gene that may play 
an important role in tumour development, deserving further investigation of its effect 
in cancer. 
 
1.4.4 E-cadherin    
E-cadherin, encoded by CDH1 gene and a member of the cadherin super family, is a 
calcium-dependent cell-cell adhesion membrane glycoprotein. It comprises five 
extracellular cadherin repeats in the extracellular domain, a transmembrane region, 
and an intracellular domain that binds catenin. It mediates calcium-dependent 
homophilic interactions, as the major adhesion receptor in adherens junctions, which 
is vital to establish and maintain cell-cell junctions (Takeichi 1995; Aberle, Schwartz 
et al. 1996). Intracellularly, E-cadherin is connected to the catenins, which link E-
cadherin to the actin cytoskeleton. Failure either to assemble the E-cadherin/catenin 
complex or to connect to the actin cytoskeleton correctly leads to the loss of cell 
adhesion (Semb and Christofori 1998). 
 
Apart from the role in cell–cell adhesion, E-cadherin also functions as a tumour 
suppressor protein. Loss of function is thought to contribute to progression in cancer 
by increasing proliferation, invasion, and/or metastasis. It has been reported that 
some types of tumour lose E-cadherin expression partially or completely as they 
develop towards malignancy (Birchmeier and Behrens 1994). Ovarian cancer cells 
with low E-cadherin expression are more invasive (Veatch, Carson et al. 1994), and 
the absence of E-cadherin expression in ovarian cancers demonstrates poor patient 
survival in comparison to ovarian tumours with E-cadherin expression (Darai, 
Scoazec et al. 1997). Furthermore, the reestablishment of a functional cadherin 
reverses invasive tumour cells to a benign, epithelial cellular phenotype (Vleminckx, 
Vakaet et al. 1991; Birchmeier and Behrens 1994), indicating the suppressive 
function of E-cadherin in tumour progression.   
 
There is evidence that oestrogen can regulate the expression and action of E-cadherin.   
Thus, E2 suppresses E-cadherin expression by stimulating the expression of the 
transcription factors, Snail and Slug in an ovarian cancer cell line (Park, Cheung et al. 
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2008). Moreover, E2 down-regulates E-cadherin in both normal and tumourigenic 
breast epithelial cells (Oesterreich, Deng et al. 2003). It is therefore likely that E-
cadherin is also a cancer-associated and oestrogen-regulated gene and its action in 
ovarian cancer needs to be further studied.  
 
1.5 Hypotheses and aims  
The hypotheses of the thesis are: 
1. There is increasing evidence showing that oestrogens are involved in the 
development of ovarian cancer. Given that EOC frequently occurs in post- 
menopausal women, it is hypothesised the oestrogen producing and 
metabolizing enzymes exist in EOC facilitating local production of E2, the 
active oestrogen. 
2. Inflammation is involved in the development of EOC, thus it is hypothesised 
that inflammatory cytokines promote oestrogen biosynthesis in EOC. 
3. ERT users have higher risk of EOC, thus it is hypothesised exogenous CEEs 
can be converted to active oestrogens locally, playing an important role in the 
development of EOC by regulating oestrogen-responsive genes. 
 
Therefore, the main aims of the studies in this thesis are: 
1. To investigate oestrogen signalling in OSE and EOC by studying expression 
patterns of oestrogen producing and metabolizing enzymes and ERs in OSE 
and EOC.  
2. To investigate the STS/EST pathway further by studying the regulation of the 
oestrogen metabolizing enzymes by ovarian-associated inflammatory 
cytokines, specifically IL-1α, in OSE and EOC in vitro. 
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3. To investigate the effect of ERT on EOC by studying the regulation of 
cancer-associated genes: FN1, IGFBP3, LOX and E-cadherin by ingredients 






























2.1 Clinical tissue resource and collection 
2.1.1 OSE cells and normal ovary tissue 
Normal OSE cells for in vitro experiments were collected from patients undergoing 
surgery for benign gynaecological diseases, such as fibroids, heavy menstruation 
bleeding, pelvic pain and infertility. All the patients were of reproductive age and 
pre-menopausal. Exclusion criteria included malignancy, current pelvic 
inflammatory disease, endometriosis and use of gonadotrophin-releasing hormone 
agonists or antagonists. While the use of hormonal contraception was not an 
exclusion criterion, information of exogenous hormone use was documented in 
patient files. All samples were allocated a research number and were then 
anonymised. Before the surgery, formal written consent was obtained from all 
patients with local ethics committee approval (reference number S1103/36, Chief 
Investigator Dr K S Fegan). Individual details of each patient used for the project are 
listed in the relevant chapters. 
 
Normal ovarian tissues for histological studies were obtained from two sources. 
Some pre-menopausal and post-menopausal ovaries were collected from patients 
with benign gynaecological disease who had their ovaries removed during surgery. 
The inclusion and exclusion criteria were similar to those for the collection of OSE 
cells stated above. The rest of the ovaries were kindly provided by Dr Alistair 
Williams, University of Edinburgh. Basic clinical information for every patient is 
given in the relevant chapters. 
 
2.1.2 Ovarian cancer tissue 
Ovarian cancer tissues were donated by patients who were suspected of having 
ovarian cancer and attended for initial laparotomy. They were asked to donate tissue 
for research in accordance with good clinical practice guidelines. The study was 
approved by the local ethics research committee (reference number S1103/44, Chief 
Investigator Dr K S Fegan) and formal written consent was obtained from all the 
patients. Clinical information for each patient is given in the appropriate chapter. 
During surgery the excised specimens were placed in sterile polythene bags and 
transferred to the pathology laboratory for specimen dissection by a consultant 
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pathologist. This step ensured that the sample represented real tumour tissue and 
avoided interference with the final pathology result. The obtained samples were 
placed immediately in a sterile universal container containing 20ml PBS (Gibco, 
Paisley, Scotland, UK) to obtain EOC cells by enzyme digestion or neutral buffered 
formalin (NBF; Sigma-Aldrich, Dorset, UK) for histological studies, placed on ice 
and transferred to the laboratory.  
 
2.2  Cell culture 
2.2.1 Establishment of cell monolayers 
OSE cells were collected by gently scraping the ovary at the start of surgery with a 
sterile wooden spatula at laparotomy or a Tao cytobrush (Cook, Ireland Ltd. 
Limerick, Ireland) at laparoscopy.  The collecting instruments were rinsed into 15ml 
pre-warmed HOSE І medium containing Medium 199:MCDB 105 (1:1, v/v; 
Invitrogen) supplemented with 15% (v/v) fetal bovine serum (FBS), 50IU/ml 
penicillin, 50ug/ml streptomycin and 2mM L-glutamine (Sigma-Aldrich) to dislodge 
the cells, which were then transferred to the laboratory at room temperature. The 
cells suspension was then transferred into a 75 cm2 flask (Corning, BV Life Sciences, 
Amsterdam, the Netherlands) and incubated in a humidified tissue culture incubator 
gassed with 95% air:5% CO2 at 37℃ for 7 days to allow cell attachment. The 
cultures were inspected weekly, with a medium change until cell confluence was 
reached. Cells were routinely examined by phase-contrast microscopy for 
contaminating cells such as fibroblasts. If flasks contained more than 10% 
contamination with fibroblast-like cells, the flasks would be discarded and not used 
for later experiments. Once reaching confluence, usually between 2 to 4 weeks, cells 
were used for the experiments or passaged with a split ratio of 1:3 into 3 new 75 cm2 
flasks to grow until confluence again for later use. All the OSE cells used for the 
project were within 3 passages. 
 
EOC cells from ovarian cancer tissue were kind gifts from Dr K S Fegan and the 
method to collect these cells was as follows.  In a Class 2 tissue culture hood, the 
tumour was placed in a 5cm diameter Petri dish and minced using two sterile scalpel 
 
 52 
blades.  The minced tumour was then transferred to a 50ml Falcon tube (Corning) for 
enzymatic tissue digestion. The ‘digestion mix’ was 0.25% trypsin (Gibco), 0.004% 
DNAseI (Sigma-Aldrich) in 20ml cold HOSE II medium, which was similar to 
HOSE I medium but with 0.01% (w/v) bovine serum albumin (BSA; Sigma-Aldrich) 
instead of FBS to prevent denaturing of enzyme activity.  The digest was left mixing 
on a shaker overnight at 4°C. The following morning the solid components were 
allowed to settle and the supernatant aspirated, combined with HOSE I medium to 
inactivate the trypsin and the cells were collected by centrifugation at 500×g for 5 
minutes. The cell pellet was resuspended in 15ml HOSE I medium and placed in a 
75cm2 tissue culture flask. The remaining minced tumour was mixed with another 
20ml digestion mix and placed in an agitated water bath at 37°C for 30min.  The 
supernatant fluid was then aspirated, inactivated with an equivalent volume HOSE I 
medium and centrifuged as above to form a pellet which was then resuspended in 
15ml fresh HOSE I medium and transferred to a second 75cm2 tissue culture flask.  
The tumour mince was washed and pelleted two more times so that four flasks were 
obtained from every piece of solid tumour. Flasks were left in an atmosphere of 5% 
CO2, 95% air at 37°C for one week to allow cells to attach. HOSE I medium was 
then changed twice weekly until confluence was reached. 
 
SKOV-3 and PEO-14 cell lines were kindly provided by P Pujol (INSERM, 
Montpellier, France) and PEO-1 cell line was a gift from Dr Simon Langdon 
(Cancer Research UK, Edinburgh Oncology Unit, Edinburgh, UK).  The cells were 
grown in 162 cm2 flasks (Corning) at 37°C, in an atmosphere of 95% air and 5% 
CO2,, with similar HOSE I medium to OSE cells but containing 10% instead of 15% 
FBS. Culture medium was changed twice per week and cells were split 1:2 or 1:3 
when they were confluent. Once the cells had been passaged 20 times, they were 
discarded and cells which had been frozen at the same initial passage number and in 




2.2.2 Experimental treatments 
After the cell monolayer had reached confluence, culture medium was removed and 
the cells were washed with 10ml Dulbecco’s phosphate buffered saline (DPBS; 
Sigma-Aldrich) twice and incubated in 5ml (75cm2 flasks) or 10ml (162 cm2 flasks) 
Trypsin/EDTA (0.05%, w/v trypsin, 0.5mM EDTA; Invitrogen) solution at 37°C for 
five minutes. After all the cells had detached from the flask, trypsin was neutralised 
with an equal volume of HOSE I medium. The cell suspension was transferred to 
50mL centrifuge tubes (Corning) and the cells were then collected by centrifugation 
at 800×g for 3 minutes, with the supernatant being discarded. The cell pellet was re-
suspended in 5ml pre-warmed fresh HOSE I medium, and the cell number was 
counted using a haemocytometer. Cell viability was assessed by Trypan Blue 
exclusion (Sigma-Aldrich): the viability of OSE cells and cell lines was between 
80% and 95%. The dispersed cells were plated into 6-well culture plates (Corning) 
with 300,000 cells per well for mRNA studies or 500,000 cells per well for enzyme 
activity studies. For in vitro scratch assay studies the suspended cells were seeded on 
12-well culture plates (Corning) with 150,000 cells per well. After incubation in the 
same environment used above for 24h, the cells formed monolayers. The medium 
was then discarded and cells were washed with DPBS twice, followed by culture in 
HOSE II culture medium for 24h. Cells were then treated with the factors of interest. 
Factor concentrations and incubation times are described in the relevant experimental 
chapters. 
 
2.3 Histological staining  
Expression patterns and localisation of proteins in the ovary and ovarian cancers 
were investigated by immunohistochemistry using a number of specific primary 
antibodies. A standard streptavidin-biotin horseradish peroxidase (HRP) method was 
employed. Briefly, the primary antibody binds specifically to the protein of interest, 
and the biotinylated secondary recognises and binds to antigenic sites on the primary 
antibody. HRP labelled streptavidin binds to the biotin on the secondary antibody 
and DAB binds the HRP and is oxidised. This causes a visible colour change, which 




2.3.1 Tissue processing   
Tissue samples for histology were collected in neutral buffered formalin (NBF) 
(Sigma-Aldrich) and fixed at 4°C for 24h, then transferred to 70% ethanol and stored 
at room temperature prior to wax embedding which was carried out in the Human 
Reproductive Sciences Unit (HRSU) Histology facility. Samples were placed in 
labelled cassettes in 70% ethanol for automatic processing. Using a Leica TP1050 
automatic processor, samples underwent dehydration in graded alcohols for 1.5h in 
each alcohol, 2x2h in absolute alcohol, then 3x3h in xylene, before going through 
three chambers of molten wax for 1, 1, and 1.5 h respectively. Samples were then 
aligned correctly in metal moulds, and molten paraffin wax poured into each mould. 
The cassette was placed on top of the molten wax and the mould placed on a cooling 
block to set. When set, the mould could be gently eased off. Embedded tissue 
sections were stored at room temperature. When required, the blocks were cooled on 
ice to make the blocks easier to cut and 5µm sections were cut by a hand-operated 
microtome (Leica Microsystems, Milton Keynes, UK). Sections were floated on 
distilled water at 37°C in a heated waterbath and gently picked up onto charged 
coated slides. Sections were dried overnight at 50°C in a drying oven (Lamb RA, 
East Sussex, UK) then stored at room temperature until used. 
 
2.3.2  Dewaxing and rehydration  
Slides were appropriately labelled, dewaxed in xylene for 10min (2x5min), then 
rehydrated in graded alcohols [100%, 100%, 95% (v/v), 70% (v/v), 50% (v/v)] for 
20sec each. Slides were washed in distilled water for 10min. 
 
2.3.3  Antigen Retrieval 
Antigen retrieval was performed by pressure cooking in 10mM sodium citrate buffer 
(pH 6.0). 2L of buffer was placed inside a pressure cooker on an electronic plate 
heater and allowed to heat. When the buffer was almost boiling, the slides were 
gently placed inside the pressure cooker, ensuring they were completely immersed in 
buffer and the lid sealed. When at full pressure which was indicated by steady 
hissing, the slides were heated for 5min, then the cooker was moved away from the 
heater immediately and pressure was released slowly. After the sections cooled in the 
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citrate buffer for 20min, the lid was removed and the sections were allowed to cool 
further by slowly mixing tap water with the buffer. Following cooling, the sections 
were washed in distilled water twice for 10min. 
 
2.3.4  Blocking procedures 
Endogenous peroxidases were blocked to prevent excess background staining. A 
300mL 3% hydrogen peroxide solution was made by diluting 30mL 30% stock 
hydrogen peroxide (VWR International Ltd, Lutterworth, Leicestershire, UK) in 
270mL pure methanol (Fisher Scientific, Loughborough, Leicestershire, UK). Slides 
were immersed in the solution for 30min at room temperature, and then washed in 
50mM Tris buffered saline (TBS) for 2x5min. The slides were agitated gently on a 
rocker during the whole procedure to ensure thorough blocking and washing. 
Background staining was further prevented by the inclusion of a non-immune serum 
block to prevent non-specific binding of the secondary antibody. A blocking solution 
was prepared by diluting non-immune serum of the species in which the secondary 
antibody had been raised 1:5 (v/v) in TBS containing 5% (w/v) BSA (Sigma-
Aldrich). This solution was applied to slides in a humidified chamber and incubated 
for 20min at room temperature. There was no wash following this step. Endogenous 
streptavidin and biotin also need to be blocked to prevent excess background 
staining. A streptavidin-biotin blocking kit (Vector Laboratories Ltd, Peterborough, 
UK) was used. The slides were put back into the humidified chamber and one or two 
drops of streptavidin were applied on every slide, depending on the size of the 
section. The slides were then incubated for 15min followed by washing in TBS for 
2x5min with agitation and returning to the humidified chamber where one or two 
drops of biotin were applied to each slide. Sections were incubated at room 
temperature for a further 15min, and then washed again in TBS for 2x5min with 
agitation. 
 
2.3.5 Primary antibody 
Primary antibodies were diluted to the appropriate concentration in the serum used 
for blocking. The primary antibodies used and the working dilutions are shown in 
Table 2.1 below. Generic immunoglobulins from the same species, or green 
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fluorescent protein (GFP) antibody raised in the same species at the same 
concentration as the primary antibody, were used as a negative control. Positive 
controls were tissue sections known to express high levels of the protein of interest. 
Details of specific positive and negative controls are given in Table 2.1 below. 
Primary antibodies and negative controls were applied to sections in a humidified 
chamber to prevent drying. Sections were incubated overnight (approx. 18h) at 4°C, 
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Table 2. 1: Primary antibodies used in the project, which were purchased 
(HPA0020904) or generously donated, as follows. 
Gift 1: Prof. Masahiko Negishi (Song, Qian et al. 1997) 
Gift 2: Prof. WR Miller (Sasano, Anderson et al. 2005) 
Gift 3: Prof. Yves Tremblay (Drolet, Simard et al. 2007) 





2.3.6 Secondary antibodies 
Biotinylated secondary antibodies (Dako, Cambridge, UK) were diluted 1:500 in the 
serum solutions used for the non-immune block. The antibody was applied to 
sections in a humidified chamber and incubated for 1 hour at room temperature. 
Following incubation slides were washed in TBS for 2x5min with gentle agitation. 
 
2.3.7 Antigen detection 
Streptavidin HRP was used to amplify the signal from the biotinylated secondary 
antibody. The streptavidin HRP solution was prepared by adding 1µl streptavidin 
HRP into 1000µl TBS. The solution was added to the slides in a humidified chamber, 
incubated for 30min at room temperature, and then washed for 2x5min in TBS with 
gentle agitation. Slides were developed and stained with 3,3-diaminobenzidine 
(DAB; Dako). One drop of DAB solution was added to 1ml of DAB buffer and two 
drops of DAB mix were added onto sections in a humidified chamber. When brown 
staining was visualised, DAB was washed off with copious distilled water. Sections 
were then counterstained in haematoxylin (Sigma-Aldrich) for 30sec followed by a 
wash in running tap-water and in Scott’s tap water (Pioneer Research Chemicals 
Ltd.) for 10sec followed by a wash in running water. Slides were then dehydrated 
through increasing alcohol concentrations [70% (v/v), 80% (v/v), 95% (v/v), 100%, 
100%; 20sec in every concentration] and cleared in xylene for 2x5min before 
mounting under a glass cover slip (VWR) using Pertex mounting medium (Cellpath 
Plc, Hemel Hempstead, UK). 
 
2.4 Molecular studies 
2.4.1 RNA extraction 
2.4.1.1  RNeasy Mini Kit extraction 
Total RNA was extracted from cultured cells using the RNeasy Mini Kit (Qiagen Ltd, 
West Sussex, UK) following the manufacturer’s instructions. Culture medium was 
removed from the wells and 350µl lysis buffer (RLT buffer) supplemented with 1% 
β-mercaptoethanol (v/v) added directly onto each culture well and repeatedly 
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pipetted to ensure complete cell lysis. The suspension was transferred to a 1.5ml 
tube, and frozen at -70°C. Cell lysates were removed from storage and thawed in a 
waterbath at 37°C for 15min prior to extraction. 
 
350µl 70% ethanol was added to the lysate and mixed by pipetting. The mixture was 
transferred to an RNeasy mini spin column and centrifuged at 9520×g (Hettich 
MICRO 200, GMI Inc, Minnesota, USA) for 15sec. The flow-through was discarded. 
The column was then washed with 350µl Buffer RW1 supplied with the kit and 
centrifuged at 9520×g for 15sec. The flow-through was again discarded. To preclude 
the presence of genomic DNA that could influence the accuracy of the results, on-
column DNase digestion was performed using RNase-Free DNase set (Qiagen).  
DNase digestion was performed by diluting DNase I 1:7 (v/v) in Buffer RDD, adding 
80µl of the mixture to each column and incubating at room temperature for 15min. 
DNase was removed by washing with 350µl Buffer RW1 and centrifuging at 9520×g 
for 15sec. Two more washes were performed with 500µl Buffer RPE, centrifuged at 
9520×g for 15sec and 2min respectively. The flow-through was discarded after each 
contrifugation. The RNeasy column was then put in a new 2ml tube and centrifuged 
at 18700×g for 1min to dry the column. The column was then transferred to a fresh 
RNase-free 1.5ml collection tube, with 30µl of RNase-free water added directly to 
the column membrane to elute the extracted RNA. After centrifuging at 9520×g for 
1min, the eluate was removed from the tube and passed through the column once 
again followed by centrifuging at 9520×g for 1min to obtain a higher concentration 
of RNA.  The RNA in solution was stored at -70°C. 
 
2.4.1.2 Measuring RNA concentration and quality 
The RNA was quantified using the Nanodrop-1000 Spectrophotometer (Nanodrop 
Technologies Inc, Wilmington, DE, USA). A 260/280 ratio above 2.0 indicates no 
detectable protein contamination. Only RNA samples with ratios above 2.0 were 




2.4.2 Reverse transcription  
Reverse transcription was conducted on samples with a suitable RNA yield using a 
High Capacity complementary DNA (cDNA) Reverse Transcriptase Kit (Applied 
Biosystems, Warrington, UK). 3.4µl of reagent mixture (outlined in Table 2.2), 
200ng RNA and RNase-free water made a 10µl cDNA reaction mixture. Two 
negative controls were also included, a “RT-negative” containing no MultiScribe 
Reverse Transcriptase and a “RT-water” containing nuclease-free water in place of 
RNA. The reaction mixtures were thoroughly vortexed and briefly centrifuged in a 
micro centrifuge to ensure all contents were at the bottom of the tube. The tubes were 
loaded into a GRI G-storm Thermal cycler (GRI, Braintree, Essex, UK) and 
incubated for 25°C for 10 minutes (annealing of random hexamers), 37°C for 120 
minutes (reverse transcription), 85°C for 5 minutes (denaturation of RNA-cDNA 
double strand and RNA degradation) and 4°C on hold cycle. The cDNA was then 






10x RT Buffer  10x 1.0 
10x RT Random 
Primers 
5µM 1.0 




RNase Inhibitor 1U/µl 0.5 
Table 2.2: Reagents for reverse transcription. Volumes shown are for one reaction when 
combined with RNA (200ng) with RNase-free water to give a total reaction volume of 10µl. 
2.4.3  Quantitative Real-Time polymerase chain reaction (PCR) 
Quantitative Real-Time PCR (qRT-PCR) measures levels of a gene-specific 
sequence of cDNA generated in a reverse-transcriptase PCR reaction, and thus 
provides a measure of RNA expression in a tissue. QRT-PCR was carried out using 
the Taqman system and ABI Prism 7900HT sequence detection system (Applied 
Biosystems). This works by producing a fluorescent signal during the amplification 
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of the PCR product. Forward and reverse primers are designed for a target DNA 
sequence and the probes are 20-30bp oligonucleotides that are complementary to a 
sequence flanked by the forward and reverse primers of the target genes. The probe 
has two labels, a reporter label at the 5’ end (FAM; 6-carboxyfluorosceine) and a 
quencher at the 3’ end (TAMRA; 6-carboxytetramethylrhodamine). In each reaction, 
when the probe is intact, the quencher suppresses the fluorescence of the reporter 
primarily by Forster-type energy transfer (Forster, 1948; Lakowicz, 1983). During 
PCR, if the target cDNA of interest is present, the probe specifically anneals between 
the forward and reverse primer sites. The 5’ to 3’ nucleolytic activity of the 
AmpliTaq Gold polymerase (within Taqman Universal PCR Master Mix, PE Applied 
Biosystems) cleaves the 5’- end of the probe and the reporter and quencher are 
separated. Fluorescence can now be detected. The amount of fluorescence is directly 
proportional to the amount of PCR product, and non-specific amplification does not 
cause fluorescence (Taqman PCR Reagent Kit Protocol, Applied Biosystems). This 






















                        
Figure 2.1: Diagrammatic representation of Taqman qRT-PCR. Adapted from Taqman PCR 
Reagent Kit Protocol (Applied Biosystems). 
 
For the relative quantification of the results, 18S ribosomal RNA detection is used as 
an internal control in this system. The 18S probe also has a reporter (VIC), which 
emits fluorescence at a different wavelength to the FAM reporter on the gene of 
interest probe. Quantification is relative to 18S since expression levels remain 
relatively constant in cells under different conditions.  
 
Taqman primers and probes of target genes were either designed in-house by 
ProbeFinder version 2.45 (Roche Diagnostics Ltd., Burgess Hill, UK) or by Primer 
Express software or purchased as Assay on Demand (Applied Biosystems). Probes 
designed in-house by ProbeFinder (EST, FN1, IGFBP3 and E-cadherin) were 
selected from the Universal Probe Library (Roche Diagnostics Ltd.) and primers that 
matched the probes were synthesized by Genosys Biotechnologies (Cambridge, UK) 
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and diluted to 250nM in nuclease-free water (Sigma). Primers designed in-house by 
Primer Express software (ERα, ERβ and 17βHSD2) were manufactured by 
Biosource (Nivelles, Belgium) or Eurogentec (Southampton, UK) and diluted to 
250nM, and probes to 50nM in nuclease-free water (Sigma). Probes and primers 
were all validated before use. Assay on Demand primer/probe sets were used directly 
in the reactions as they were provided pre-optimised at a final concentration of 
900nM primer and 250µM probe and primer/probe sets were pre-validated by ABI. 
Details of primers and probes used are given in Table 2.3.  
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Table 2.3: Sequences of primer/probes sets and positive control of every gene for qRT-PCR. 
FW: forward, RV: reverse  
Sequences of assay-on-demand primers and probes were unavailable but were pre-validated by 
ABI. 
Probe number referred to the number of the probe in the Universal Probe Library and 




0.8μl or 2μl cDNA was analyzed in a 10µl or 25µl reaction mixtures respectively. 
Each reaction contained the following reagents (final concentration): 1) 1x TaqMan 
Universal PCR Master Mix which included 10x PCR buffer, 5.5mM MgCl2, 200μM 
dNTPs (400μM dUTP), 1.25U/μl AmpliTaq DNA Polymerase and Uracil-N-
glycosylase (UNG) (Applied Biosystems); 2) 50nM 18s primers and probes (Applied 
Biosystems); 3) specific primers and probes of target genes and 4) nuclease-free 
water up to 10 or 23μl. All samples were run in duplicate or triplicate in either 384-
well (for 10μl system) or 96-well plates (for 25μl system) (Applied Biosystems). 
Three negative controls were included on each plate, 1) negative reverse transcribed 
sample (RNA sample no reverse transcriptase enzyme); 2) reverse transcribed H2O 
(water in place of mRNA sample); and 3) TaqMan reaction negative control (cDNA 
replaced with H2O). Suitable positive controls used for every target genes are listed 
in Table 2.3. Wells were sealed using an optical cover (Applied Biosystems) and 
Taqman reactions were carried out in an ABI Prism 7900 Sequence Detector 
(Applied Biosystems) following the default protocol (Table 2.4, Dorak 2004, 
Applied Biosystems Manual): 
 
Step Programme Function 
1 50°C for 2 minutes Activation of UNG which prevents 
reamplification of carry-over PCR products by 
removing any uracil incorporated into 
amplicons (Dorak, 2004) 
2 95°C for 10 minutes Activation of the AmpliTaq enzyme 
3 40 cycles of: 
95°C for 15 seconds 
60°C for 1 minute 
 
Denaturation 
Annealing and extension 
Table 2.4: Protocol for Taqman qRT-PCR. 
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Data were acquired when PCR amplification was in the exponential phase. The data 
output are in the form of the cycle number where the fluorescence of the reporter dye 
rises above a threshold, this value is the threshold cycle, CT. A CT value was 
obtained for both the gene of interest and 18S. These data were transferred to a 
Microsoft Excel spreadsheet for analysis. When the CT value for the mRNA was 
more than 38, the mRNA expression of the gene in the sample was regarded 
undetectable. There were four calculations performed on the data. Firstly, the CT 
value for the mRNA of the gene of interest was normalised to the CT value for the 
18S ribosomal RNA used as an internal control, by subtracting the 18S CT value 
from the CT value of the gene of interest, which equals the ΔCT value. As each 
sample was run in duplicate or triplicate, the average ΔCT was then calculated as the 
mean of the 2 or 3 ΔCT values for each sample. The next step was the calculation of 
ΔΔCT by subtracting the ΔCT of a comparator which varied in different experiments 
from the average ΔCT of each sample. The comparators for every experiment were 
denoted in relevant chapters. The final calculation was to get [2^ (- ΔΔCT)] value for 
each sample, to give a fold increase in expression over comparator. The mean fold 
increase (or decrease) for each sample group was then calculated and compared.  
 
2.5 Enzyme activity assays 
As described above, cells in the 6-well plates (500, 000 cells/well) were prepared for 
the assays. The following morning the culture medium was changed to serum-free 
HOSE II medium and incubated for a further 24h. On the third day culture medium 
was removed from the wells and replaced with treatments in fresh HOSE II medium. 
The medium contained 3nM E1S and 150,000cpm/μl [6,7-3H(N)]-E1S (PerkinElmer, 
USA) or 3nM E1 and 150,000cpm/μl [2,4,6,7-3H]-E1 (PerkinElmer, USA), depending 
on the experiments. Following incubation for the desired time, medium was collected 
into 15ml glass centrifuge tubes and mixed well with 10ml dichloromethane (Fisher 
Scientific) to stop the reaction and extract steroids. Samples were then centrifuged at 
800×g for 15min, the aqueous phase was discarded and the organic phase evaporated 
to dryness under a nitrogen stream with the steroids remaining in the solvent phase 
concentrated at the same time. The dry steroid extract was then reconstituted in 
100µl fresh dichloromethane with unlabelled E1 (10µM), E2 (10µM) and E1S (10µM) 
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as carriers for the labelled steroid. Following adequate vortexing, samples were 
spotted onto silica-gel pre-coated sheets (PE, SILG; Whatman, Maidston, Kent, UK) 
and run for 1.5h in a sealed tank with chloroform:ethanol (92:8, v/v) as the mobile 
phase, which separated the steroid components. Finally, the thin layer 
chromatography (TLC) sheet was taken out of the tank, dried and the radio-labelled 
steroid was identified on the chromatogram and quantified using a Bioscan 200 
imaging detector (Lablogic Systems, Sheffield, UK). The data output is in the forms 
of region counts. See the Fig.2.2 and Table 2.5 below. 
FORBES: XR261108.R09 

















Figure 2.2: Readout from TLC plates where y-axis shows counts of radioactivity and x-axis 
demonstrates the distance along the plate. 
 




Table 2.5: Data output from Bioscan 200 imaging detector. 
The calculation of final conversion of E1S and E1 followed the steps below: 
Counts of E1S peak (Peak 1) = X 
Counts of E1 peak (Peak 3) = Y 
Counts of E2 peak (Peak 2) = Z 




A = X/0.5238 
B =Y/0.8276 
C =Z/0.8276 
D (conversion rate of E1S to E1) = (B+C) / (A+B+C) X 100 
E (conversion rate of E1S to E2) = C / (A+B+C) X 100 
Since we started with 2ml of HOSE II medium with 3nM of E1S, total E1S is 
equivalent to 6 pmoles. Therefore conversion of E1S to E1 will be D / 100 X 6 / 
number of hours / number of cells and conversion of E1S to E2 will be E / 100 X 6 / 
number of hours / number of cells. Activity data were computed as fmoles of 
substrate conversion per hour per 105 cells (fmol/h/105 cells). 
 
Because the solubilities of E1S and E1 or E2 in dichloramethane are different, the 
extraction efficiency of E1S and E1 or E2 by dichloramethane is therefore different. A 
recovery experiment was done to decide the efficiency of extraction. In the recovery 
experiment, 20ml HOSE II medium was mixed with 3nM E1S and 150,000cpm/μl 
[6,7-3H(N)]-E1S. Mixture was then aliquoted into 6 glass centrifuge tubes with each 
tube containing 2ml mixture. 3 tubes went through the extraction process stated 
above while the other 3 tubes did not undergo the extraction. After extraction, the 
aqueous phase was discarded and the organic phase evaporated to dryness under a 
nitrogen stream. The dry steroid extract was then redissolved in 2ml HOSE II 
medium overnight. The total radioactivity in each tube was then measured by adding 
scintillation fluid, Ecoscint A (National Diagnostics, Hull, England) and counting on 
a Beta counter, Tri-carb 2100TR (Packard, USA). The extraction efficiency of E1S 
was then calculated as follows:  
 average count of E1S without extraction                   x 100% 
average count of E1S extracted by dicloromethane  
 
The extraction efficiency of E1or E2 was calculated using the same method as above. 
The extraction efficiency of E1S was 52.38% and the extraction efficiency of E1 or E2 
was 82.76%. The extraction process was carried out in HOSE II medium plus or 




2.6 In vitro wound healing assay 
PEO-1 cells were grown as a monolayer on 12-well culture plates (Corning) in 
HOSE I medium for 24h before being changed to phenol-red free medium 199 
(Invitrogen) supplemented with charcoal-stripped FBS (10%, v/v), penicillin 
(50IU/ml), streptomycin (50μg/ml) and L-glutamine (2mmol/l) for a further 24h. The 
cells were then incubated with E2 or Eq (10-8M) for 72h, with or without oestrogen 
antagonist ICI 182, 780 (10-6M), which was added to the above medium one hour 
before E2 or Eq treatment. The treatment medium was then removed from the cells 
and stored at 37°C for later use and replaced with DPBS. The cell monolayer was 
then scraped gently in a straight line across the full width of the well to create the 
wound using a p200 pipette tip. To remove excess debris produced by scratching, the 
cells were then washed twice by DPBS. The saved treatment medium was then 
replaced into the appropriate treatment wells. The width of the scratch wound was 
measured using Zeiss Axiovert 5100 Microscope and Openlab software, with 
measurements made in pixels. Each scratch width was measured at three equally 
spaced points along its length and treatment groups were measured in triplicate. Cells 
were incubated in the different treatments for 24h and the distance of each scratch at 
the same noted point was measured again.  Cell migration over 24h was assessed by 
subtracting the width at 24h from the width measured after scratching, which was 
called ΔWidth. As each width was measured at three points an average ΔWidth was 
calculated as the mean of the 3 widths for each wound. The final result was presented 
as a ratio of ΔWidth of treatment / ΔWidth of the control x 100% and the mean of the 
ratio for each treatment group was then calculated and compared. 
 
2.7 Statistical analysis  
The statistical analyses were variable depending on different experimental methods 













Survey of oestrogen metabolizing enzymes in pre-

















Oestrogen has been implicated as a causative and promotive factor in many 
oestrogen-related cancers such as breast and endometrial cancer. Anti-oestrogen 
therapy has been used as an adjuvant treatment clinically, having benefited patients 
with ER-positive cancer. Although the question whether ovarian cancer is an 
oestrogen-dependent disease is still controversial, increasing evidence suggests 
oestrogen is linked to and promotes the development of ovarian cancer. As described 
in Chapter 1, some epidemiological data have suggested HRT users have a higher 
risk of ovarian cancer and this effect is primarily related to the use of oestrogen-only 
HRT (Lacey, Mink et al. 2002; Lacey, Brinton et al. 2006; Beral, Bull et al. 2007). In 
addition, oestrogen receptors are expressed in 61%-79% of EOC (Lindgren, 
Backstrom et al. 2001; Lee, Rosen et al. 2005). Some experimental data 
demonstrated oestrogen can stimulate the growth of ovarian tumour cell lines that 
express oestrogen receptors (Langdon, Hawkes et al. 1990). In vivo studies in 
animals revealed oestrogen accelerates tumour onset and decreases survival in a 
transgenic mouse model of ovarian cancer (Laviolette, Garson et al. 2010). 
Furthermore, clinical trials with an aromatase inhibitor (AI), which acts by reducing 
the levels of oestrogen available to ER, have shown clinical benefit in a sub-group of 
ovarian cancer patients. Data from Phase II trials have indicated that patients with 
EOC and ER-positive tumours might benefit from AI therapy (Bowman, Gabra et al. 
2002; Smyth, Gourley et al. 2007). 
 
Together these results indicate that ovarian cancer is oestrogen responsive in some, 
but not all subtypes of ovarian cancer. Paradoxically, ovarian cancer generally occurs 
in post-menopausal women, in which ovulation has ceased and ovarian E1 and E2 
production rates are reduced compared to pre-menopause. So the question arises if 
oestrogen is involved, where does it come from? We hypothesize that the conjugated 
(inactive) oestrogens circulating in post-menopausal women are substrates for 
formation of active oestrogen in EOC locally, and that local enzymes can 




The local production of oestrogen is mediated by a number of enzymes. Aromatase 
catalyzes conversion of T into E2 and A into E1. STS hydrolyzes E1S to E1. 17βHSD1 
or 17βHSD5 subsequently convert E1 to E2. By contrast, 17βHSD2 and EST act in 
the opposite direction to convert E2 to E1 and E1 to E1S respectively. Thus the local 
expression of these enzymes is important in regulating oestrogen metabolism and 
consequently may have a role in ovarian cancer onset and development.  
 
As described in Chapter 1, OSE cells from which EOC is thought to be derived, can 
become trapped in an inclusion cyst and subsequently develop into ovarian cancer 
under the influence of the local environment in or around the inclusion cyst. 
Therefore to investigate the local production of E2 and its promotive effect on ovarian 
cancer, this chapter examines the expression of oestrogen metabolizing enzymes in 
normal OSE cells, OSE cells lining inclusion cysts and ovarian cancer cells. Since 
ovarian cancer usually occurs after the menopause, it is also necessary to compare 
the difference in expression of these genes between pre- and post-menopausal 
women. 
 
Specifically, the aims of this chapter are to study the protein expression patterns of 
STS, EST, aromatase, 17βHSD2 and 17βHSD5 using immunohistochemistry (IHC) 
in human pre-menopausal and post-menopausal ovaries, in epithelial ovarian cancer 









3.2 Materials and methods 
3.2.1 Ovary and ovarian cancer tissue 
Pre- and post-menopausal ovaries, ovaries containing inclusion cysts and ovarian 
cancer tissues were collected as described in Sections 2.1.1 and 2.1.2. Briefly, 3 pre-
menopausal ovaries, 6 post-menopausal ovaries, 7 ovarian cancers and 1 post-
menopausal ovary with a few inclusion cysts were collected. The relevant clinical 









Ovary diseases Pre/post menopausal 
1  
12408/09 
47 Fibroids No Pre-menopausal 
2  
13209/09 
45 Fibroids No Pre-menopausal 
3 
1106 
29 N/A No Pre-menopausal 







































43 Ovarian cancer Ovarian cancer: Mixed 
differentiation carcinoma 








































Inclusion cysts Post-menopausal 
Table 3.1: Patient information for IHC studies.  
N/A: not available 
 
3.2.2 IHC 




3.3.1 Expression of STS protein in human ovary and ovarian 
cancer 
IHC revealed STS protein expression in pre- and post-menopausal ovaries, inclusion 
cysts and ovarian cancers. Expression was mainly localised to OSE in normal ovary, 
epithelium of inclusion cysts and ovarian cancer cells in ovarian cancer, with very 
low expression seen in the endothelial and stromal cells in some samples and low 
expression in granulosa and theca cells of one pre-menopausal ovary (data not 
shown). There was no difference in expression patterns between pre-menopausal and 
post-menopausal ovaries. Intensity of expression did not differ among pre-
menopausal OSE, post-menopausal OSE, OSE embedded in inclusion cysts and 











Figure 3.1: Immunostaining of STS in human pre-menopausal ovaries, post-menopausal ovaries 
and ovarian cancers. All the tissues were fixed and stained with STS antibody as described in 
Section 2.3. A, B) Pre-menopausal ovary with OSE; C, D) Post-menopausal ovary with OSE, 
insert shows negative control; E) Serous ovarian adenocarcinoma; F) Mixed differentiation 
ovarian carcinoma with mucinous, serous and endometrioid features; G) Serous and 
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3.3.2 Expression of EST protein in human ovary and ovarian 
cancer 
EST protein was expressed in pre-menopausal ovary, post-menopausal ovary, 
inclusion cysts and ovarian cancer. Expression was mainly localised to OSE in 
normal ovary, epithelium of inclusion cysts and ovarian cancer cells in ovarian 
cancer, with relatively low expression seen in the endothelial cells and stromal cells 
in all the samples. Low expression of EST in granulosa and theca cells was observed 
in one pre-menopausal ovary (data not shown). There was no difference in 
expression patterns between pre-menopausal and post-menopausal ovaries. Intensity 
of expression did not differ among pre-menopausal OSE, post-menopausal OSE, 
















Figure 3.2: Immunostaining of EST in human pre-menopausal, post-menopausal ovaries and 
ovarian cancers. All the tissues were fixed and stained with EST antibody as described in 
Section 2.3. A, B) Pre-menopausal ovary with OSE, insert shows negative control; C, D) Post-
menopausal ovary with OSE; E) Serous ovarian adenocarcinoma; F) Endometrioid ovarian 
adenocarcinoma; G) Serous and endometrioid ovarian adenocarcinoma; H) Pre-menopausal 
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3.3.3 Expression of 17βHSD5 protein in human ovary and ovarian 
cancer 
17βHSD5 protein was expressed in pre-menopausal ovary, post-menopausal ovary, 
inclusion cysts and ovarian cancer. Expression was mainly localised to OSE in 
normal ovary, epithelium of inclusion cysts, ovarian cancer cells in ovarian cancer 
and endothelial cells in all the samples, with very low expression seen in stromal 
cells in some samples and in granulosa and theca cells of one pre-menopausal ovary 
(data not shown). There was no difference in expression patterns between pre-
menopausal and post-menopausal ovaries. Intensity of expression did not differ 
among pre-menopausal OSE, post-menopausal OSE, OSE embedded in inclusion 


















Figure 3.3: Immunostaining of 17βHSD5 in human pre-menopausal, post-menopausal ovaries 
and ovarian cancers. All the tissues were fixed and stained with 17βHSD5 antibody as described 
in Section 2.3. A, B) Pre-menopausal ovary with OSE; C, D) Post-menopausal ovary with OSE; 
E) Serous ovarian adenocarcinoma; F) Endometrioid ovarian adenocarcinoma; G) Serous and 
endometrioid ovarian adenocarcinoma, insert shows negative control; H) Pre-menopausal ovary 
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3.3.4 Expression of 17βHSD2 protein in human ovary and ovarian 
cancer  
17βHSD2 protein was expressed in pre-menopausal ovary, post-menopausal ovary, 
inclusion cysts and ovarian cancer. Expression was mainly localised to OSE in 
normal ovary, epithelium of inclusion cysts and ovarian cancer cells in ovarian 
cancer, with moderate expression in granulosa cells and low expression in theca cells 
of two pre-menopausal ovaries (data not shown). The expression seen in the 
endothelial and stromal cells in most of the samples was very low. There was no 
difference in expression patterns between pre-menopausal and post-menopausal 
ovaries. Intensity of expression did not differ between pre-menopausal OSE, post-
menopausal OSE, OSE embedded in inclusion cysts and ovarian cancer cells. These 


















Figure 3.4: Immunostaining of 17βHSD2 in human pre-menopausal, post-menopausal ovaries 
and ovarian cancers. All the tissues were fixed and stained with 17βHSD2 antibody as described 
in Section 2.3. A, B) Pre-menopausal ovary with OSE; C, D) Post-menopausal ovary with OSE; 
E) Serous ovarian adenocarcinoma; F) Endometrioid ovarian adenocarcinoma, insert shows 
negative control; G) Serous and endometrioid ovarian adenocarcinoma; H) Pre-menopausal 
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3.3.5 Expression of aromatase protein in human ovary and 
ovarian cancer 
IHC revealed no aromatase protein expressed in pre-menopausal ovary, post-
menopausal ovary, inclusion cysts and ovarian cancer samples. Term-birth placenta 





















Figure 3.5: Immunostaining of aromatase in human placenta, pre-menopausal, post-menopausal 
ovaries and ovarian cancers. All the tissues were fixed and stained with aromatase antibody as 
described in Section 2.3. A) Placenta, insert shows negative control; B) Pre-menopausal ovary 
with OSE; C, D) Post-menopausal ovary with OSE; E) Serous ovarian adenocarcinoma; F) 
Endometrioid ovarian adenocarcinoma; G) Mixed differentiation ovarian carcinoma with 
mucinous, serous and endometrioid features; H) Pre-menopausal ovary with inclusion cysts. 
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3.4  Discussion 
These studies show that STS, EST, 17βHSD2 and 17βHSD5 proteins are all 
expressed in pre- and post-menopausal OSE, epithelium lining inclusion cysts and 
ovarian cancer cells, although the levels of expression did not vary between these 
cells. Aromatase protein was undetectable in any of the samples, although the 
positive control sample showed intense expression. These data demonstrate for the 
first time the expression and localisation of EST protein in human ovary, ovarian 
cancer and inclusion cysts, and show for the first time expression of these oestrogen-
producing enzymes in ovarian inclusion cysts.  
 
STS is the enzyme responsible for the conversation of E1S to E1. In this study STS 
protein was present in pre- and post-menopausal OSE and OSE of inclusion cysts. 
This is the first report showing STS protein expression in OSE cells, and indicates 
the possibility of local production of E1 through STS activity in OSE cells. 
Interestingly, there was also STS protein expression in OSE cells lining inclusion 
cysts. Since the microenviroment around inclusion cysts is vital for the 
transformation of the normal cells to cancer cells, E2 biosynthesized locally may be a 
very important factor involved in the tumourigenic process, if STS is active in these 
OSE cells. The expression of STS protein in ovarian cancer tissues was consistent 
with previously published data. Okuda and co-workers showed STS immunostaining 
in 70% of ovarian clear cell adenocarcinoma (32/45), 33.3% of serous 
adenocarcinoma (6/18) and 50% of mucinous adenocarcinoma (4/8) (Okuda, Saito et 
al. 2001). All 6 of the ovarian cancer samples in this study, including 3 serous 
carcinoma samples, 2 endometrioid samples, 1 mixed differentiation carcinoma with 
mucinous, serous and endometrioid features and 1 mixed serous and endometrioid 
carcinoma, demonstrated positive STS staining. These results confirm the previous 
study (Okuda, Saito et al. 2001), showing that STS protein is widely expressed in 
different kinds of epithelial ovarian cancers. Chura and co-workers detected STS 
enzymatic activity in 36 of 37 advanced ovarian cancer specimens by TLC, further 
supporting the involvement of STS in local oestrogen production in EOC (Chura, 
Blomquist et al. 2009). The expression of STS protein in OSE cells and ovarian 
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cancer cells suggested its potential role in the biosynthesis of E1 in these cells, 
however, its enzymatic activity need to be tested to confirm local E1 formation. 
 
EST, which opposes the action of STS, sulphonates E1 to biologically inactive E1S. 
Therefore EST is considered to be involved in the regulation of E2 levels in situ 
together with STS. The local production of E2 depends on the balance between 
activities of these two enzymes. EST protein was reported previously in the 
cytoplasm of invasive ductal breast carcinoma cells by IHC (Suzuki, Nakata et al. 
2003). In addition, EST protein was found in prostate carcinoma cells (Nakamura, 
Suzuki et al. 2006) and in 45% of colon carcinomas (Sato, Suzuki et al. 2009). 
However, there are no previous reports of EST expression patterns in human ovary 
and ovarian cancer. In the present study a polyclonal antibody for mouse EST was 
used to localize EST protein. Because human and mouse EST are 77% homologous 
at the amino acid level, it was expected that this mouse antibody would also bind to 
the human EST, as demonstrated in a study showing that the mouse EST antibody 
was able to recognize human EST (Song, Qian et al. 1998). However, the antibody 
also cross-reacted with the expressed human phenol sulfotransferases (PST) which 
are responsible for sulpho-conjugating monoamine neurotransmitters and drugs or 
xenobiotic compounds such as phenols (Song, Qian et al. 1998). Nevertheless this 
was the only available antibody for the current study. EST protein was firstly 
reported in pre- and post-menopausal OSE cells, OSE cells lining inclusion cysts and 
ovarian cancer cells, suggesting EST may play an important role together with STS 
in regulating the local production of E2 in OSE and ovarian cancer and then influence 
the development of ovarian cancer. Although there is no quantifiable difference of 
the EST expression between different OSE cells and ovarian cancer cells, given the 
limitation of the analysis of IHC and the specificity of the antibody, quantitative 
analysis of STS and EST mRNA and measurement of enzymatic activities in 
different cell types was performed to compare the local formation of E2 via the STS 




A previous study reported aromatase immunostaining in OSE cells but did not clarify 
the percentage of positive staining among all the tested samples, and the multilayered 
OSE described is unlike the OSE in the present study, being more representative of 
the granulosa cell layer in a large antral follicle (Cunat, Rabenoelina et al. 2005). 
Okubo measured aromatase activity in a human OSE cell line (HOSE17) but did not 
test it on primary OSE cells (Okubo, Mok et al. 2000). Aromatase expression in 
ovarian cancer has been extensively studied. For example, active aromatase 
enzymatic activity was found in three epithelial ovarian adenocarcinoma cell lines 
suggesting that at least some adenocarcinoma possess sufficient aromatase activity to 
convert ovarian stromal androgen to oestrogen (Thompson, Adelson et al. 1988). In 
addition, Noguchi determined aromatase activity in 81% of 35 ovarian tumours 
(Noguchi, Kitawaki et al. 1993) and Kitawaki detected aromatase activity in 68% 
(17/25) of the malignant ovarian tumours and 82% (22/27) of benign tumours 
(Kitawaki, Noguchi et al. 1996). Interestingly, Kaga found aromatase expression in 
stromal cells surrounding the carcinomatous nests of 79.5% ovarian carcinomas but 
not in cancer cells (Kaga, Sasano et al. 1996). In Cunat’s study, aromatase mRNA 
expression was detected in 49% of ovarian cancer specimens and BG1, PEO-4 and 
PEO-14, but not in SKOV-3 and OVCAR-3 cell lines. Aromatase activity was also 
confirmed in BG1 and PEO-14 cell lines (Cunat, Rabenoelina et al. 2005). In 
contrast, Imai did not detect aromatase mRNA expression or enzyme activity in three 
mucinous and one serous cystadenocarcinoma specimens (Imai, Ohno et al. 1994). It 
therefore remains unclear whether both EOC and OSE produce active oestrogen 
through aromatase activity. There are two main reasons why our study may have 
failed to detect aromatase activity in the ovarian and EOC samples. Firstly, we used 
only 6 post- and 3 pre-menopausal ovaries, and 7 ovarian cancer samples. Given the 
limited numbers it was possible there was no aromatase expression in these samples, 
since previous studies have demonstrated aromatase expression exists in only a 
proportion of ovarian cancers. Secondly, aromatase protein in the ovary and ovarian 
cancer might be much lower than in placenta, which could explain why the 
expression appeared negative in OSE and EOC cells while positive in trophoblast 
cells despite the same experimental primary antibody concentration. The positive 
staining in trophoblast cells was the same expression pattern reported in previous 
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paper (Colette, Lousse et al. 2009). Use of a higher concentration of antibody might 
have revealed low expression of aromatase in OSE and EOC cells. 
 
17βHSD2 possesses oxidative activity, inactiving E2 by converting it into E1 whereas 
17βHSD5 acts as reductase converting E1 into E2. Therefore the interconversion of 
E1 and E2 is a bi-directional equilibrium reaction rather than unidirectional 
metabolism, and the balance of the expression and activity of these two enzymes is 
important for determining the local production of E2. There are a few reports 
showing their presence in ovarian cancer, but not in OSE cells. Vierikko detected 
17βHSD activities in a series of benign and malignant epithelial tumours (Vierikko, 
Kauppila et al. 1983). Blomquist demonstrated both 17βHSD2 and 17βHSD5 
activities in seven mucinous, three serous and two endometrioid tumours (Blomquist, 
Bonenfant et al. 2002) and Provost detected 17βHSD2 and17βHSD5 activities in one 
ovarian cancer cell line, OV-90, which was derived from patients unexposed to 
radiation or chemotherapy (Provost, Lima et al. 2010). Our results are in agreement 
with the above studies confirming the expression of both 17βHSD2 and 17βHSD5 
proteins in ovarian cancer. Furthermore, we show for the first time the expression of 
these two proteins in pre- and post-menopausal OSE cells as well as epithelial cells 
lining the inclusion cysts, suggesting a potential role of these two enzymes in 
maintaining the balance between E1 and E2 in these cells. 
 
One aspect of interest that arose from our immunohistochemical studies was the 
weak positive expression of STS, EST, 17βHSD2 and 17βHSD5 proteins in stromal 
cells in some of the ovary and ovarian cancer samples. This provides a clue that the 
production of E2 might occur not only in OSE or ovarian cancer cells but also in 
some stromal cells. Therefore the E2 formed by OSE and cancer cells might act in an 
intracrine manner and E2 produced by stromal cells influence the cancer cells as a 
paracrine factor. Thus stromal cells might interact together with the epithelium and 
cancer cells during the development of ovarian cancer. This is supported by a clinical 
case reported by Tokunaga, in which an ovarian epithelial carcinoma patient had a 
higher serum E2 due to intratumoural oestrogen production by both cancer and 
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stromal cells, with enzymes required for the production of oestrogen present in both 
cancer and stromal cells (Tokunaga, Akahira et al. 2007). 
  
One weakness of the study in this chapter is the limited number of the samples. The 
results would be more convincing and we would be able to compare the differences 
in the target gene expression between different EOC subtypes if we had been able to 
include more samples for each type of EOC. Although IHC is very suitable for 
localizing the cellular origin of protein it does not permit accurate quantification. In 
Chapter 4, Taqman quantitative RT-PCR was used to test the mRNA levels of these 
genes. 
 
In summary, STS, EST, 17βHSD2 and 17βHSD5 proteins are expressed at different 
levels in pre-menopausal OSE, post-menopausal OSE, epithelium lining inclusion 
cysts and ovarian cancer cells and there is no clear difference in expression of these 
genes between different types of cells. Aromatase protein was not detected in these 
cells. Thus we can conclude that there might be the local production of E2 by these 
active genes in the above cells. Table 3.1 shows a summary of the data presented in 





 Pre-menopausal ovary Post-menopausal ovary EOC Inclusio
n cysts 
OSE  Stroma Endothelium OSE Stroma Endothelium Cancer 
cells 
 
Stroma Endothelium OSE  
STS ++ + + ++ + + ++ + + ++ 
EST +++ + ++ +++ + ++ +++ + ++ +++ 
Aromatase - - - - - - - - - - 
17βHSD2 ++ + + ++ + + ++ + + ++ 
17βHSD5 ++ + ++ ++ + ++ ++ + ++ ++ 
 
Table 3.1:  Summary of relative protein expression of different oestrogen metabolizing genes. 













Expression of genes encoding the metabolism and action 
of oestrogen in pre-menopausal OSE, EOC and ovarian 















Having established the protein expression of oestrogen metabolizing genes in OSE, 
EOC and OSE lining the inclusion cysts in Chapter 3, and demonstrating the 
possibility of local oestrogen production in these cells, it was then important to 
investigate differences in relative mRNA levels between these cells and also test the 
enzyme activities to investigate if these cells have differential capacities to produce 
E2. 
 
The expression of STS and 17βHSD5 proteins in the OSE and EOC confirmed by 
IHC in Chapter 3 indicates the possible production of E2 in these cells from E1S via 
the STS pathway, rather than from androgens via the aromatase pathway. However, 
E1S carries a net negative charge at physiological pH levels and, as such, its transfer 
across cell membranes is carrier mediated. Steroid sulphates have been identified as 
substrates for distinct members of two organic anion carrier gene families: OATP 
super family and OAT family.  There are many subtypes of OATPs and OATs but 
studies of breast cancer and placenta have demonstrated OATP-B, OATP-D, OATP-
E and OAT4 are the main candidate transporters of E1S (Pizzagalli, Varga et al. 2003; 
Wlcek, Svoboda et al. 2008). Because the transport processes operative in the tissue 
will govern the cellular entry of conjugated steroid, these transporters may be 
determinants of downstream oestrogen exposure in target cells. Therefore, a further 
aim of this chapter is to identify and characterize the organic anion uptake system for 
E1S, namely to compare OATP-B, OATP-D, OATP-E and OAT4 mRNA expression 
in OSE and EOC. 
 
Since most of ovarian cancers occur after menopause and they are thought to derive 
from the OSE cells trapped as an epithelium in inclusion cysts, it would be ideal to 
compare gene expression in pre-menopausal, post-menopausal and inclusion cyst 
OSE. However in this chapter it was only possible to study pre-menopausal OSE 
cells because there are very few patients undergoing operations due to benign 
diseases after menopause, which means very limited access to post-menopausal OSE. 
Moreover, it is extremely difficult to obtain OSE cells lining inclusion cysts due to 
technical limitations and limited cell numbers. Due to the limited availability of 
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primary cancer tissue, we also chose three cancer cell lines, PEO-1, SKOV-3 and 
PEO-14. The first two are both from poorly-differentiated serous ovarian cancer 
patients and have high expression of oestrogen receptors while the latter is from a 
well-differentiated serous ovarian cancer patient and has low expression of oestrogen 
receptors.  
 
In summary, the objective of this chapter is to compare mRNA levels of different 
oestrogen metabolism and action genes between pre-menopausal OSE and cancer 



















4.2 Materials and methods 
4.2.1 OSE, EOC cells and ovarian cancer cell lines 
Pre-menopausal OSE and EOC cells were collected and cultured as described in 
Sections 2.1 and 2.2. The basic clinical profiles of patients involved in the respective 
assays are presented Table 4.1 below. Information on the ovarian cancer cell lines 
was listed previously in Section 2.2.1.  
Patient 
No 




1 6321 04/S1103/36 26 Pelvic pain DiagLapar qRT-PCR 
2 6800 04/S1103/36 50 Fibroids TAHBSO qRT-PCR 
3 7527 04/S1103/36 38 Prophylactic LapSter qRT-PCR 
4 7538 04/S1103/36 21 Pelvic pain DiagLapar qRT-PCR 
5 7543 04/S1103/36 26 Prophylactic LapSter qRT-PCR 
6 7548 04/S1103/36 31 Prophylactic LapSter qRT-PCR 
7 7549 04/S1103/36 29 Prophylactic LapSter qRT-PCR 
8 7565 04/S1103/36 32 Pelvic pain DiagLapar qRT-PCR 
9 7566 04/S1103/36 41 Pelvic pain DiagLapar qRT-PCR 
10 7606 04/S1103/36 36 Prophylactic LapSter qRT-PCR 
11 7613 04/S1103/36 48 Fibroids TAH qRT-PCR 
12 7623 04/S1103/36 49 Fibroids TAHBSO qRT-PCR 
13 6394 04/S1103/36 29  HMB  DiagLapar qRT-PCR 
14 6829 04/S1103/36 45 Fibroids  TAHBSO  qRT-PCR 
15 6825 04/S1103/36 43 Fibroids TAHBSO  qRT-PCR 
16 CA11 04/S1103/44 N/A N/A N/A qRT-PCR 
17 CA9B 04/S1103/44 N/A N/A N/A qRT-PCR 
18 44021 04/S1103/44 55 EOC  N/A qRT-PCR 
19 44028 04/S1103/44 59 EOC N/A qRT-PCR 









21 44035 04/S1103/44 66 EOC N/A qRT-PCR 
22 3028 04/S1103/36 29 Pelvic pain DiagLapar TLC 
23 5617 04/S1103/36 27 Prophylactic LapSter TLC 
24 6316 04/S1103/36 43 HMB and 
pelvic pain 
TAHBSO TLC 
25 6318 04/S1103/36 41 Hydrosalpinx Romoval of 
Hydrosalpinx 
TLC 
3 7527 04/S1103/36 38 Prophylactic LapSter TLC 
4 7538 04/S1103/36 21 Pelvic pain DiagLapar TLC 
26 7541 04/S1103/36 33 Prophylactic LapSter TLC 
27 7544 04/S1103/36 34 Prophylactic LapSter TLC 
28 7546 04/S1103/36 19 Left  ovarian 
 cyst 
DiagLapar TLC 
29 7550 04/S1103/36 31 Prophylactic LapSter TLC 
Table 4.1: clinical profile of patients used for qRT-PCR and TLC. 
DiagLapar: diagnostic laparoscopy; LapSter: laparoscopic sterilization; HMB: heavy 
menstruation bleeding; LREC: Lothian Research Ethical Committee; N/A: not available; TAH: 
total abdominal hysterectomy; TAHBSO: total abdominal hysterectomy and bilateral salpingo-
oophorectomy; TLC: thin layer chromatography. 
 
4.2.2 RNA extraction and reverse transcription 
RNA was extracted using methods described in Section 2.4.1 and RT-PCR was 
performed using standard conditions as described in Section 2.4.2. Equal 
concentrations (200ng) of DNase-treated RNA extracted from OSE and EOC 
samples of 17 and 4 patients respectively were reverse transcribed and measured for 




4.2.3 Taqman qRT-PCR 
QRT-PCR was performed using an ABI 7900 sequence detection system and 
analysed as described in Section 2.4.3. The probes and primers used were 
commercially available pre-validated from Applied Biosystems Assay on Demand or 
designed in house. The information on the primers and probes is shown in Table 2.3. 
 
4.2.4 Enzyme activity assay 
The activities of the target enzymes were tested using the method described in 
Section 2.5. 
 
4.2.5 Statistical analysis 
Statistical analysis was performed using GraphPad Prism 5. QRT-PCR data were 
analyzed by Mann Whitney test. Data from enzyme activity assay were analyzed by 
one-way analysis of variance (ANOVA) with Tukey post-hoc test. Data for the 
Glusulase (Glu) treatment were analyzed by paired T tests. Statistical difference was 












4.3.1 Expression of oestrogen metabolic pathway genes in pre-
menopausal OSE and EOC 
STS mRNA was expressed in all the OSE and EOC samples although there was no 
significant difference between OSE and EOC samples (Fig. 4.1, A). EST mRNA was 
expressed at detectable levels in 16 of 17 OSE and 2 of 4 EOC samples and the 
expression of EST in EOC was significantly lower than in OSE samples (Fig. 4.1, B; 
P<0.05). Aromatase mRNA was detectable in 11 of 17 OSE and all the EOC samples. 
Although the median OSE mRNA was lower than EOC mRNA there was no 
statistically significant difference. For aromatase, placenta mRNA was used as the 
standard and its level was more than 103 times higher than the expression in OSE and 
EOC samples (Fig. 4.1, C). 17βHSD1 mRNA was expressed in all the OSE and 2 of 
4 EOC samples and there was no significant difference between OSE and EOC 
samples (Fig. 4.2, A). 17βHSD2 mRNA was expressed in all the OSE and 3 of 4 
EOC samples and there was no significant difference between OSE and EOC 
samples (Fig. 4.2, B). 17βHSD5 mRNA was expressed in all the OSE and EOC 
samples and there was no significant difference between OSE and EOC samples (Fig. 
4.2, C). ERα mRNA was detectable in all the OSE and EOC samples and there was 
no significant difference between OSE and EOC samples. There was one EOC 
sample with significantly high ERα mRNA, about 50 times higher than the other 3 
EOC samples (Fig. 4.3, A). ERβ mRNA was detectable in less than half of the OSE 
samples (8 of 17) and 3 of 4 EOC samples and there was no significant difference 
between OSE and EOC samples (Fig. 4.3, B). OATP-B mRNA was detectable in 15 
of 17 OSE and all the EOC samples. Its expression was significantly higher in EOC 
than in OSE cells (Fig. 4.4, A, P<0.05). OATP-D and OATP-E were expressed in all 
the OSE and EOC samples and there was no significant difference between OSE and 
EOC samples (Fig. 4.4, B and C). OAT4 mRNA expression was much lower than the 
placenta standard and was expressed in 6 of 17 OSE and 1 of 4 EOC samples and 





















































































Figure 4.1: Measurement of STS (A), EST (B) and aromatase (C) mRNA expression in OSE 
(n=17) and EOC (n=4) by Taqman qRT-PCR. The standards were placenta (A, C) and 
proliferative endometrium (B). Horizontal bars indicate median value. (*=P<0.05) 
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Figure 4.2: Measurement of 17βHSD1 (A), 17βHSD2 (B) and 17βHSD5 (C) mRNA expression in 
OSE (n=17) and EOC (n=4) by Taqman qRT-PCR. The standards were placenta (A, C) and 





















































Figure 4.3: Measurement of ERα (A) and ERβ (B) mRNA expression in OSE (n=17) and EOC 
















































































































Figure 4.4: Measurement of OATP-B (A), OATP-D (B), OATP-E (C) and OAT4 (D) mRNA 
expression in OSE (n=17; for OATP-E, n=16) and EOC (n=4) by Taqman qRT-PCR. The 










4.3.2 Expression of oestrogen metabolic pathway genes in pre-
menopausal OSE, EOC and ovarian cancer cell lines 
To complement and extend the data on the limited primary ovarian cancer cells 
described above (Section 4.3.1), comparisons were then made between primary cells 
and PEO-14, SKOV-3 and PEO-1 ovarian cancer cell lines. Gene expression levels 
are presented in Figures 4.5, 4.6 and 4.7. Due to the mix of primary and cell line data, 
statistical comparisons of gene expression were not made. STS mRNA was 
expressed in OSE, EOC, PEO-14, SKOV-3 and PEO-1 cells and its expression was 
relatively lower in PEO-14 and SKOV-3 cells (Fig. 4.5, A). EST mRNA was highest 
in OSE, about 10-fold lower in EOC and PEO-14 and undetectable in SKOV-3 and 
PEO-1 cells (Fig. 4.5, B). For aromatase, placenta mRNA was used as the standard 
and its level was more than 103 times higher than the expression in OSE, EOC and 
PEO-14 cells. Aromatase mRNA was undetectable in SKOV-3 and PEO-1 cells (Fig. 
4.5, C). 17βHSD1 mRNA was expressed in all the tested cells except PEO-1, and the 
level was higher in SKOV-3 cells than the other cell types (Fig. 4.6, A). 17βHSD2 
mRNA was expressed in OSE, EOC and PEO-1 cells but the expression in all these 
cells was much lower than the expression in placenta standard. There was no 
17βHSD2 mRNA expression detected in PEO-14 and SKOV-3 cells (Fig. 4.6, B). 
17βHSD5 mRNA was expressed in all the cell types and there was much higher 
expression in SKOV-3 cells (about 100-fold higher than OSE) and relatively higher 
expression in PEO-14 cells (about 40-fold higher than OSE) (Fig. 4.6, C). ERα 
mRNA was expressed in OSE, EOC and PEO-14 cells at low levels while the 
expression in SKOV-3 and PEO-1 was more than 100-fold higher than the mean 
expression in OSE cells (Fig. 4.7, A). Compared to ERα there was little variation in 
the level of ERβ, although the latter was relatively higher in PEO-14 cells compared 



























































































































Figure 4.5: Measurement of STS (A), EST (B) and aromatase (C) mRNA expression in OSE, 
EOC, PEO-14, SKOV-3 and PEO-1 cells by Taqman qRT-PCR. The standards were placenta 
(A, C) and proliferative endometrium (B). Bars indicate Mean±standard error of the mean 





























































































































Figure 4.6: Measurement of 17βHSD1 (A), 17βHSD2 (B) and 17βHSD5 (C) mRNA expression in 
OSE, EOC, PEO-14, SKOV-3 and PEO-1 cells by Taqman qRT-PCR. The standards were 
placenta (A, C) and proliferative endometrium (B). Bars indicate Mean±SEM. No statistical 



















































































Figure 4.7: Measurement of ERα (A) and ERβ (B) mRNA expression in OSE, EOC, PEO-14, 
SKOV-3 and PEO-1 cells by Taqman qRT-PCR. The standards were placenta. Bars indicate 









4.3.3 Oestrogen metabolizing enzyme activities in pre-
menopausal OSE cells and ovarian cancer cell lines 
4.3.3.1  Metabolism of [3H]-E1S in pre-menopausal OSE, SKOV-3 
and PEO-1 cells 
Oestrogen metabolizing enzyme activities in pre-menopausal OSE, SKOV-3 and 
PEO-1 cells were measured using a radiometric substrate conversion assay that 
involved measurement of [3H]-E1 and [3H]-E2 after treatment of the cells with [3H]-
E1S as a substrate for 72h and separation according to their polarity/mobility on TLC. 
500,000 cells were plated and serum-depleted for 24h before investigating the 
enzyme activities in vitro. In OSE cells there was no [3H]-E1 or [3H]-E2 converted 
from [3H]-E1S detected (Fig. 4.8, A). In contrast, SKOV-3 and PEO-1 cells 
converted [3H]-E1S to [3H]-E1 and further to [3H]-E2 (Fig. 4.8, B and C). When the 
radiographs were quantified as described in Section 2.5, the conversion rate of E1S to 
E1 or E2 was significantly different between OSE and SKOV-3 or PEO-1 cells (Fig. 




























































































































































Figure 4.8: Radiochromatograph analysis of oestrogen pre-receptor metabolites in OSE (A, 
n=10), SKOV-3 (B, n=3) and PEO-1 (C, n=3) cells. Cells were cultured for 72h with [3H]-E1S 
and tritium labeled metabolites were detected by TLC and quantified by radioactivity scanner. 
Representative graphs indicate readout from TLC plates where y-axis shows counts of 
radioactivity and x-axis demonstrates the distance along the plate. Histograms show conversion 
rate of E1S to E1 (D) and E1S to E2 (E) calculated as described in Section 2.5. Bars indicate 




4.3.3.2 Metabolism of [3H]-E1 in pre-menopausal OSE, SKOV-3 and 
PEO-1 cells 
4.3.3.2.1 Metabolism of [3H]-E1  
To investigate oestrogen metabolism enzyme activities in pre-menopausal OSE, 
SKOV-3 and PEO-1 cells further, and to determine whether E1 is preferentially 
metabolized to E1S or E2, [3H]-E1 instead of [3H]-E1S was added as a substrate to 
treat the cells for 72h and radioactive metabolites after treatment were separated by 
TLC and measured by radioactivity scanner. 500,000 cells were plated and serum-
depleted for 24h before investigating the enzymes activity in vitro. OSE cells 
converted most of [3H]-E1 back to the original position of [3H]-E1S on the 
chromatograph (Fig. 4.9, A) and this was confirmed by the glusulase experiment as 
described in Section 4.3.3.2.2. In contrast, SKOV-3 and PEO-1 cells converted part 
of [3H]-E1 to [3H]-E2 and a little to original position of [3H]-E1S (Fig. 4.9, B and C). 
When the radiographs were quantified as described in Section 2.5, there was a 
statistically significant difference in conversion rate of E1 to E1S or E2 between OSE 























































































































Figure 4.9: Radiochromatographic analysis of oestrogen pre-receptor metabolites in OSE (A, 
n=10), SKOV-3 (B, n=3) and PEO-1 (C, n=3) cells. Cells were cultured for 72h with [3H]-E1 and 
tritium labeled metabolites were detected by TLC and quantified by radioactivity scanner. 
Representative graphs indicate readout from TLC plates where y-axis shows counts of 
radioactivity and x-axis demonstrates the distance along the plate. Histograms show conversion 
rate of E1 to E1S (D) and E1 to E2 (E) calculated as described in Section 2.5. Bars indicate 





4.3.3.2.2  Effect of Glusulase on [3H]-E1 metabolism in OSE cells 
To confirm that the majority of E1 radiometabolite was at the position of E1S, OSE 
cell extracts were incubated with an exogenous source of STS activity-Glusulase 
(Glu) and radio chromatography was then carried out. 500,000 cells were plated and 
serum-depleted for 24h before treatment. After treatment with [3H]-E1 for 72h, 
medium was collected and tritium-labelled steroids were extracted as described in 
Section 2.5.  The dry steroid extract was then reconstituted in buffer with or without 
Glu and kept in 37°C waterbath for 2h. The tubes were shaken every 15min to ensure 
a full reaction. The reaction was then stopped by adding 10mL dichloromethane for 
the extraction of the steroids. The subsequent steps were as described for the normal 
enzyme activity assay (Section 2.5). The OSE cells without Glu converted most of 
[3H]-E1 back to the original position of the [3H]-E1S (Fig. 4.10, A). The OSE cells 
from the same patient with Glu converted the above product back to the [3H]-E1 
position (Fig. 4.10, B). When the radiographs were quantified as described in Section 
2.5, the conversion rate of E1 to E1S was significantly decreased by Glu (Fig. 4.10, 
**=P<0.005).             
 













            
SHARRON: X261109G.R03 


























































Figure 4.10: Effect of Glusulase on oestrogen pre-receptor metabolites in OSE cells. Cells were 
cultured for 72h with [3H]-E1 and then treated further without (A) or with (B) Glu. Tritium 
labeled metabolites were detected by TLC and quantified by radioactivity scanner. 
Representative graphs indicate readout from TLC plates where y-axis shows counts of 
radioactivity and x-axis demonstrates the distance along the plate. Histograms show conversion 










In Chapter 3, we showed by IHC that STS, EST, 17βHSD2 and 17βHSD5, but not 
aromatase proteins are present in OSE of pre-menopausal ovary, post-menopausal 
ovary and inclusion cysts as well as EOC. In the present chapter, we investigated the 
genes encoding the metabolism and action of oestrogens further by comparing the 
mRNA expression of target genes in pre-menopausal OSE, EOC cells and ovarian 
cancer cell lines and studying activities of the encoded enzymes in pre-menopausal 
OSE cells and ovarian cancer cell lines.  
 
Similar STS mRNA expression in both OSE and EOC cells is consistent with the 
IHC result. Moreover STS mRNA was detected in PEO-14, SKOV-3 and PEO-1 cell 
lines and the mRNA levels are similar to OSE and EOC cells. Therefore, data from 
both primary cells and cancer cell lines are consistent with the possibility of E1 
synthesis from E1S in the normal and cancer cells by STS pathway, but suggest that 
any differences between normal OSE and cancer tissue is not determined at mRNA 
expression level. Since STS can also convert DHEAS to DHEA (a precursor of 
androgen) and 3βHSD (the enzyme responsible for the conversion of DHEA to A) is 
present in OSE and EOC (Papacleovoulou, Edmondson et al. 2009), it is still 
possible that some E1 and E2 are produced by the aromatase pathway in the samples 
which have aromatase expression and function, although given the low aromatase 
expression observed (see below) this seems unlikely to be a major pathway.      
 
In keeping with the tissue protein expression (Chapter 3), aromatase mRNA 
expression in OSE and EOC cells was roughly one thousand times lower than in 
placenta. This could explain why aromatase protein was detected in placenta tissue 
but not in normal ovary and ovarian cancer tissues run in the same round using the 
same concentration of primary antibody. Moreover its expression was undetectable 
in 6 OSE samples and there was no difference in expression between OSE and EOC 
cells. Among 3 cell lines tested, aromatase mRNA was only present in PEO-14 and 
not in SKOV-3 and PEO-1 cells, which was in agreement with the study performed 
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by Cunat (Cunat, Rabenoelina et al. 2005). Compared with STS mRNA and protein 
expression which were detected in all normal and cancer tissues, cells, and cell lines, 
aromatase mRNA and protein expression was not widely expressed and was 
undetectable in some samples.  
 
In contrast to STS mRNA expression, EST mRNA was much lower in EOC than in 
OSE cells with undetectable expression in half of the EOC samples. Additionally, 
EST mRNA expression was much lower in PEO-14 cells compared with OSE cells 
and was undetectable in PEO-1 and SKOV-3 cells, further confirming that EST 
mRNA expression was lower in ovarian cancer cells compared to normal cells. 
However, there was no difference in EST protein expression detected by IHC 
(Chapter 3), which conflicts with the mRNA data. One explanation might be that 
mRNA is only measuring the gene expression and does not always reflect the 
expression of the protein, which can be affected by mRNA stability and post-
translational modifications. This lower mRNA expression of EST in cancer cells 
indicated there is less protection against oestrogenic effects in EOC and therefore 
there would likely be more active oestrogen produced in cancer cells locally, 
providing an environment that is pro-tumourigenic.  
 
The pattern of expression of the 17βHSD genes observed in the cancer cell lines, 
OSE and EOC were consistent with the IHC results in which 17βHSD2 and 
17βHSD5 were expressed in not only OSE but also EOC cells. QRT-PCR confirmed 
17βHSD1 mRNA was expressed in most OSE and EOC samples, although we did 
not look for 17βHSD1 protein expression by IHC. The interconversion of E1 and E2 
is a bi-directional equilibrium reaction depending on the balance of 17βHSD1/5 and 
17βHSD2, and the amount of the E2 synthesized is determined by the level and 
activity of these enzymes. mRNA expression of 17βHSDs suggested again the 
possibility of the local production of E2 from E1 in OSE and EOC cells and the lack 
of difference in the 17βHSDs gene expression between OSE and EOC indicated the 
similar production of E2 production between the normal and cancer cells, although 
we have not tested their activities to finally determine the production of E2 by these 
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cells. Our results complement previous studies which have demonstrated 17βHSDs 
expression in normal and malignant ovaries. 17βHSD1 immunoreactivity was absent 
in the surface epithelium of the normal cycling human ovary and in tumour cells of 
12 benign cystadenomas while it was present in the cytoplasm of four out of eight 
specimens of low malignant potential and in 20 out of 30 specimens of invasive 
carcinoma (Sasano, Frost et al. 1996). Significant levels of 17βHSD1 and 17βHSD2 
mRNAs were observed in an ovarian cancer OV-90 cell line (Provost, Lima et al. 
2010). 
 
Studies of breast cancer demonstrated that 17βHSDs could be prognostic factors in 
breast cancer. Oduwole showed breast cancer patients with tumours expressing 
17βHSD1 mRNA or protein had significantly shorter overall and disease-free 
survival than the other patients. Moreover, the expression of 17βHSD5 was 
significantly higher in breast tumour specimens than in normal tissue. The group 
with 17βHSD5 over expression had a worse prognosis than the other patients 
(Oduwole, Li et al. 2004). Similarly, Gunnarsson reported ER positive patients with 
high expression levels of 17βHSD1 had a significantly higher risk for late relapse 
and ER-positive patients with low 17βHSD2:17βHSD1 ratio showed a significantly 
higher rate of recurrence than those with higher ratios (Gunnarsson, Hellqvist et al. 
2005). The relationship between the expression and prognosis of 17βHSDs in 
ovarian cancer has not been studied. We would predict that this relationship in 
ovarian cancer is similar to breast cancer, and ovarian cancer patients with higher 
17βHSD1 and 17βHSD5 or lower 17βHSD2 expression would have a poor prognosis, 
but this remains to be determined. 
 
To complement the above mRNA studies, protein expression was further assessed by 
functional studies of enzymic activity. STS and 17βHSD1/5 convert E1S to E2 in vivo 
while EST and 17βHSD2 have the opposite effect. In addition, there is the possibility 
that EST converts E2 to E2S. All the above actions result in equilibrium between 
these enzymes. Studies using tritiated E1S or E1 as substrate give a direct indication 
of the direction and extent of metabolism of E1S or E1 in normal and cancer cells. As 
expected, there was a clear cut difference in the direction of E1S and E1 metabolism 
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between OSE and ovarian cancer cell lines. When E1S was added as the substrate, 
SKOV-3 and PEO-1 cells converted E1S to E1 and then to E2 while there was no E1 
or E2 produced by OSE cells. Conversely, when E1 was added as substrate, SKOV-3 
and PEO-1 cells converted E1 to E2, while there was no E2 produced in OSE cells and 
most of E1 was converted to E1S or E2S at 72h. The difference can be explained by 
the mRNA expression of these genes. There was STS, 17βHSD1 and 17βHSD5 but 
no EST and 17βHSD2 mRNA expression in SKOV-3 cells. Therefore the 
metabolism of E1S to E1 in SKOV-3 cells could indicate active STS and the 
metabolism of E1 to E2 could suggest active 17βHSD1/5. There was STS, 17βHSD5 
and 17βHSD2 but no EST mRNA expression in PEO-1 cells. Therefore the 
metabolism of E1S to E1 in PEO-1 cells could indicate active STS and the 
metabolism of E1 to E2 could suggest 17βHSD5 was more active than 17βHSD2. 
mRNA of STS, 17βHSD1/5 and EST, 17βHSD2 are all expressed in OSE cells. 
Therefore the metabolism of E1S and E1 would be in equilibrium between these five 
enzymes if the mRNA expression was reflected in enzyme activity. When E1S was 
added as substrate, there were no peaks of E1 and E2 radioactivity but there was 
radioactivity peak at the place where the E1S peak should be. However the 
experiment could not specify which activity peak it was. There were two possibilities. 
It could be E1S peak if EST and 17βHSD2 were more active than STS and 
17βHSD1/5. It could be E2S peak if STS and 17βHSD1/5 were active and E2 has 
higher binding affinity with EST than E1. It would be interesting to clarify what the 
final products metabolized from E1S and E1 were, by investigating the binding 
affinity of E1 and E2 to EST and kinetics of these enzymes. Nevertheless, both E1S 
and E2S are oestrogen sulphates, conjugated estrogens that do not bind to ER and can 
not activate the ER pathway. Overall, these enzymatic studies confirm that STS, 
17βHSD1 and 17βHSD5 are active in some cancer cells to produce E2. In addition, 
17βHSD5 is more active than 17βHSD2 in some cancer cells, favouring oestrogen 
activation in the cancer cells. EST is more active than STS in OSE cells, favouring 




In the enzymatic assay, it would be arguable 72h was not the optimum experimental 
time point to test the enzyme activity, since the cells might not grow well after being 
cultured without serum for four days and enzyme degradation might occur. In 
addition, because the metabolism was potentially bidirectional, 72h was long enough 
to allow the reverse enzymes to act if the activites of only STS and 17βHSD1/5 were 
investigated. Therefore it would be not clear if the target enzymes were active or not. 
Before 72h was chosen as the experimental time, one time course enzymatic assay 
experiment, including 12h, 24h, 48h and 72h (data not shown) was performed on 
SKOV-3 cells. The production of E1 was seen at 48h but the formation of E2 was 
detected only at 72h. Additonally, the cells were checked before the medium was 
taken out and they appeared morphologically normal. However it would be of 
interest to perform a short-term time course including 1h, 2h and 4h time points in 
SKOV-3 and PEO-1 cells and also on OSE if more cells were available. 
 
ERα mRNA was expressed in all OSE and EOC and ERβ was detected in about half 
of OSE and all EOC samples. This is similar to the expression detected in human 
OSE expressed ERα and ERβ mRNA by Southern analysis (Hillier, Anderson et al. 
1998). Lau observed co-expression of ERα and ERβ mRNA along with AR and PR 
transcripts in normal human OSE cells (Lau, Mok et al. 1999). However, in contrast, 
Brandenberger found only ERα mRNA expression in IOSE-Van, an immortalized 
human OSE cell line (Brandenberger, Tee et al. 1998). Data from this report cannot 
be directly compared with the current findings because IOSE-Van is a human OSE 
cell line immortalized by SV40 and therefore the ER characteristics may be different 
from primary OSE cells. The current study did not show any difference in ERα and 
ERβ mRNA expression between OSE and EOC cells. Similarly, Lau found variable 
ERα mRNA expression in ovarian cancer cells and levels of ERβ mRNA were 
unaffected by malignant status (Lau, Mok et al. 1999). However, using Northern 
blotting techniques, Brandenberger found ERβ mRNA levels were markedly 
decreased in ovarian cancer tissue (Brandenberger, Tee et al. 1998) and Bardin found 
a marked decrease in ERβ mRNA levels in ovarian cancers compared with normal 
ovarian tissues by qRT-PCR (Bardin, Hoffmann et al. 2004). The explanation for this 
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discrepancy may be that Brandenberger and Bardin tested ER expression in normal 
ovary and ovarian cancer tissues which included not only OSE and EOC cells but 
also stromal or other cell types such as granulosa cells which express high levels of 
ERβ (Enmark, Pelto-Huikko et al. 1997) while Lau and the current study compared 
only OSE and EOC cells. Moreover, IHC experiments have demonstrated that ERβ 
protein levels are lower in ovarian tumours compared to normal ovary (Fujimura, 
Hidaka et al. 2001; Li, Baldwin et al. 2003; Lindgren, Cajander et al. 2004). 
Furthermore, there is decreased expression of ERβ in different cancers, such as 
breast cancer (Roger, Sahla et al. 2001), prostatic cancer (Horvath, Henshall et al. 
2001), lung cancer (Stabile, Davis et al. 2002) and colorectal cancer (Foley, Jazaeri 
et al. 2000). The mechanisms accounting for the decreased expression of ERβ in 
tumours remain elusive. Although it is still debatable which ER play a more 
important role in ovarian cancer, the finding that ERα and ERβ transcripts are 
expressed in OSE and EOC cells suggests that oestrogen, acting through one of its 
nuclear receptors, may play an important role in regulating oestrogen action in both 
normal and cancer cells.  
 
ERα mRNA expression is much higher in PEO-1 and SKOV-3 cell lines compared to 
OSE, EOC and PEO-14 cells, although there is no apparent difference of ERβ 
mRNA levels between these cells. The high ERα and detectable ERβ mRNA 
expression in SKOV-3 cell line would indicate there should be an oestrogenic effect 
on the growth of the cells. It is therefore intriguing that Hua found the growth of 
SKOV-3 cells was not influenced by E2 or the anti-oestrogens hydroxy-tamoxifen or 
ICI 164,384, despite the presence of functional ERs. The explanation for the 
oestrogen resistance may be a result of constitutive expression and loss of E2 
regulation of selected growth regulatory genes such as HER-2/neu and cathepsin D 
(Hua, Christianson et al. 1995). Since SKOV-3 cells do not respond to E2, the current 
study used PEO-1 rather than SKOV-3 cell line as the oestrogen-responsive ovarian 




Since E1S does not easily cross the plasma membrane by diffusion, transporters are 
important for the passage of E1S into the cells. The expression of different 
transporters may affect the net production of E2, and therefore it is important to 
investigate their expression in normal ovary and ovarian cancer. Transporters have 
been studied in most detail in breast cancers and cell lines derived from them. 
Nozawa demonstrated OATP-D and OATP-E mRNA expression in one breast cancer 
cell line T-47D by RT-PCR (Nozawa, Suzuki et al. 2004). Nozawa also revealed 
OATP-D and OATP-E mRNA expression in another breast cancer cell line MCF-7 
and found inhibition of E1S transporter suppressed the transcription and cell 
proliferation induced by E1S in MCF-7 cells (Nozawa, Suzuki et al. 2005). Al 
Sarakbi found mRNA of OATP-B was expressed in both malignant breast cancer and 
normal breast tissues, and OATP-B mRNA level was correlated with the grade and 
stage of the disease, but not with the clinical outcome (Al Sarakbi, Mokbel et al. 
2006). However, the expression of E1S transporters in normal and malignant ovaries 
is still poorly characterized. To the best of my knowledge this is the first study of the 
E1S transporters in OSE and EOC. Similar to breast cancer, OATP-B, OATP-D and 
OATP-E mRNAs were expressed in both OSE and EOC cells. This suggests the 
possibility of E1S uptake by OSE and EOC cells via these transporters. Interestingly, 
OATP-B mRNA was much higher in EOC than in OSE cells, indicating more E1S 
could be transported into cancer cells than into normal cells, potentially resulting in 
more production of E2. We also tested mRNA levels of OAT4 which was proved to 
be an important E1S transporter in placenta (Ugele, Bahn et al. 2008) but the 
expression was much lower than the placenta standard and undetectable in most of 
OSE and EOC cells, suggesting a less important role of OAT4 than the other three 
transporters. The study provides the initial evidence that OATP-B, OATP-D and 
OATP-E are important E1S transporters in normal and malignant ovarian cells, 
indicating a potential novel strategy for ovarian cancer treatment by blocking the 
transporters. In breast cancer bromosulfophthalein was demonstrated to be an 
effective E1S transporter inhibitor and significantly inhibited transcription of reporter 
gene via oestrogen response element and cell proliferation induced by E1S (Nozawa, 
Suzuki et al. 2005). Thus it would be interesting to investigate the effect of 
transporter inhibitors on the development of EOC. For example, the expression of 
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E1S transporters in SKOV-3 and PEO-1 cells can be tested, relevant inhibitors of E1S 
transporters can be then tried to invstigate its effect on the local formation of E2 and 
proliferation or migration of ovarian cancer cells.  
 
It could be argued that pre-menopausal OSE is an inappropriate cell type to use for 
comparison with EOC because the OSE was collected from pre-menopausal women 
whereas most of the ovarian cancers were collected from post-menopausal women. 
Thus the steroid backgrounds are likely to have been quite different for both tissues. 
Nevertheless, in terms of the primary nature of EOC cultures, primary OSE is more 
relevant as a comparator than OSE cell lines.  Since there are few post-menopausal 
women undergoing operations for benign diseases, it is more difficult to get enough 
post-menopausal OSE, and therefore it is only feasible to use pre-menopausal OSE. 
 
One weakness of the study is the limited numbers of primary OSE and EOC samples 
for comparison, which decreases the strength of statistical analysis. It could have 
been improved by increasing the numbers of primary samples used. However 
primary tissue is a rare and valuable resource and the OSE samples are limited.   
 
In conclusion, in Chapter 4, we have demonstrated STS, EST, aromatase, 17βHSD1, 
17βHSD2, 17βHSD5, ERα, ERβ, OATP-B, OATP-D, OATP-E and OAT4 mRNA 
are expressed in pre-menopausal OSE, EOC and ovarian cancer cell lines at different 
levels. There is no significant difference in mRNA expression of these target genes 
between pre-menopausal OSE and EOC, except EST mRNA, which is significantly 
lower in EOC compared to pre-menopausal OSE cells, and OATP-B which is much 
higher in EOC compared to pre-menopausal OSE cells. Moreover, STS and 
17βHSD1 or 17βHSD5 proteins are active in SKOV-3 and PEO-1 cells, resulting in 
the production of E2 in cancer cells when E1S or E1 is added as substrate. EST 
protein is more active than STS protein, resulting in the production of estogen 
sulphates and preventing formation of E2 in pre-menopausal OSE cells. The evidence 
presented indicates that E2 could be produced locally from circulating conjugated 
oestrogens by cancer cells, through activity of these oestrogen metabolizing enzymes 
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and therefore may be an important factor in the development of ovarian cancer even 
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As stated in Chapter1, factors that decrease a woman’s lifetime ovulation rate like 
pregnancy, multiparity, breastfeeding and oral contraception are associated with a 
reduced risk of ovarian cancer, suggesting that ovulation is linked to ovarian cancer. 
In addition, ovulation is proposed to be an acute inflammatory reaction (Espey 1980). 
Therefore ovulation-associated inflammation may link with ovarian cancer. 
Moreover, various initiators of local epithelial inflammation, such as PID, talc and 
asbestos exposures and endometriosis are proposed to contribute to ovarian 
carcinogenesis (Ness and Cottreau 1999). Taken together, this evidence suggests 
inflammation plays an important role in the pathogenesis and development of ovarian 
cancer. In this regard, studies focusing on how inflammation regulates oestrogen 
metabolizing genes could identify potential diagnostic or therapeutic targets for 
ovarian cancer. 
 
Around the time of ovulation, a number of cytokines are secreted not only from OSE 
itself but also from follicular and stromal cells. It is therefore quite reasonable to 
speculate that several cytokines could have paracrine or intracrine roles in 
inflammation-associated regulation of oestrogen pathway genes. For example, IL-1α, 
IL-6 and IL-8 that are released before ovulation, are pro-inflammatory cytokines and 
might well affect local steroid biosynthesis during ovulation. Moreover, IL-4 and IL-
10 are secreted peri- and post-ovulatory and might well mediate intracrine formation 
of steroids that mediate post-ovulatory responses. It is also of interest that all these 
cytokines or at least their receptors have been identified in the ovarian tumour 
microenviroment, suggesting that they may exert a tumourigenic or anti-
tumourigenic role in EOC, with the potential for implications in the treatment of the 
disease.  
 
In Chapters 3 and 4, we established that STS, EST, 17βHSD2 and 17βHSD5 mRNA 
and protein were present in OSE and EOC, and that E2 could be produced locally in 
cancer cells through the activity of these enzymes. In addition, ERα protein was 
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shown to be expressed in OSE and EOC previously and thus locally produced E2 
could activate the post-receptor pathway and act as a cancer-stimulating agent via its 
receptor. Consistent with its cancer-promoting action, it is predicted that during 
periods of inflammation, oestrogen pathway genes would be regulated by cytokines. 
The regulation of, production and action of E2 and ER by cytokines are consequently 
of interest. 
 
The hypothesis is that inflammation can regulate oestrogen metabolizing enzymes 
and ER expression in OSE or EOC and thus have a role in the development of 
ovarian cancer. Hence the aim of this chapter is to investigate regulation of STS, 
EST, 17βHSD2, 17βHSD5 and ERα by inflammatory and anti-inflammatory 















5.2 Materials and methods 
5.2.1 OSE, EOC cells and SKOV-3 cell line 
Pre-menopausal OSE and EOC cells were collected and cultured as described in 
Sections 2.1.1, 2.1.2 and 2.2.1. The cells were plated out as described in Sections 
2.2.2, treated with different cytokines and the RNA was collected as stated in Section 
2.4.1.1. The basic clinical profiles of patients involved in the respective assays are 





Code LREC No Age Reason for 
surgery 
Surgery Study 
1 6321 04/S1103/36 26 Pelvic pain DiagLapar qRT-PCR 
2 6800 04/S1103/36 50 Fibroids TAHBSO qRT-PCR 
3 7527 04/S1103/36 38 Prophylactic LapSter qRT-PCR 
4 7538 04/S1103/36 21 Pelvic pain DiagLapar qRT-PCR 
5 7543 04/S1103/36 26 Prophylactic LapSter qRT-PCR 
6 7548 04/S1103/36 31 Prophylactic LapSter qRT-PCR 
7 7549 04/S1103/36 29 Prophylactic LapSter qRT-PCR 
8 7565 04/S1103/36 32 Pelvic pain DiagLapar qRT-PCR 
9 7566 04/S1103/36 41 Pelvic pain DiagLapar qRT-PCR 
10 7606 04/S1103/36 36 Prophylactic LapSter qRT-PCR 
11 7613 04/S1103/36 48 Fibroids TAH qRT-PCR 
16 CA11 04/S1103/36 N/A N/A N/A qRT-PCR 
17 CA9B 04/S1103/36 N/A N/A N/A qRT-PCR 
18 44021 04/S1103/44 55 EOC N/A qRT-PCR 
19 44028 04/S1103/44 59 EOC N/A qRT-PCR 
20 44029 04/S1103/44 67 EOC N/A qRT-PCR 





Code LREC No Age Reason for 
surgery 
Surgery Study 
24 6316 04/S1103/36 43 HMB and 
pelvic pain 
TAHBSO TLC 
25 6318 04/S1103/36 41 Hydrosalpinx Romoval of 
Hydrosalpinx 
TLC 
3 7527 04/S1103/36 38 Prophylactic LapSter TLC 
4 7538 04/S1103/36 21 Pelvic pain DiagLapar TLC 
26 7541 04/S1103/36 33 Prophylactic LapSter TLC 
27 7544 04/S1103/36 34 Prophylactic LapSter TLC 
28 7546 04/S1103/36 19 Left  ovarian 
 cyst 
DiagLapar TLC 
29 7550 04/S1103/36 31 Prophylactic LapSter TLC 
Table 5.1: Clinical profile of patients used for qRT-PCR and TLC. 
DiagLapar: diagnostic laparoscopy; EOC: epithelial ovarian cancer; LapSter: laparoscopic 
sterilization; HMB: heavy menstruation bleeding; LREC: Lothian Research Ethical Committee; 
N/A: not available; TAH: total abdominal hysterectomy; TAHBSO: total abdominal 
hysterectomy and bilateral salpingo-oophorectomy; TLC: thin layer chromatography. 
 
5.2.2 RNA extraction and reverse transcription 
RNA was extracted using methods described in Section 2.4.1 and RT-PCR was 
performed using standard conditions as described in Section 2.4.2. 
 
5.2.3 Taqman qRT-PCR 
QRT-PCR was performed using an ABI 7900 sequence detection system and 
analysed as described in section 2.4.3. The probes and primers used were 
commercially available pre-validated from Applied Biosystems Assay on Demand or 




5.2.4 Enzyme activity assay 
The activities of the enzymes encoded by the target genes were tested using the 
method described in Section 2.5. 
 
5.2.5 Statistical analysis 
Statistical analysis was performed using GraphPad Prism 5. QRT-PCR data in 
Section 5.3.1 were analyzed by Wilcoxon matched pairs test. QRT-PCR data in 
Section 5.3.2.1 and 5.3.2.3 were analyzed by one-way ANOVA with Tukey post-hoc 
test. QRT-PCR data in Section 5.3.2.2 were analyzed by two-way ANOVA. Data 
from enzyme activity assays in Section 5.3.3 were analyzed by T test. QRT-PCR 
data in Section 5.3.4.1 were analyzed by Kruskal-Wallis test with Dunn’s post-hoc 
test. QRT-PCR data in Section 5.3.4.2 were analyzed by one-way ANOVA with 


















5.3.1 Effect of IL-1α on STS, EST, 17βHSD2, 17βHSD5 and ERα 
mRNA expression in pre-menopausal OSE and EOC cells 
Treatment of 13 individual OSE and 3 EOC cell monolayers with 0.5ng/ml IL-1α for 
48h resulted in different response of target genes. IL-1α had no effect on STS mRNA 
expression in either OSE or EOC cells (Fig. 5.1 A, B). Suppression of EST mRNA 
levels by IL-1α was observed in OSE but not in EOC cells (Fig. 5.1 C, D, P<0.01). 
Moreover, IL-1α inhibited 17βHSD2 mRNA expression significantly in OSE but not 
in EOC cells (Fig. 5.2 A, B, P<0.001) while it had no effect on 17βHSD5 mRNA 
expression in either OSE or EOC cells (Fig. 5.2 C, D). Furthermore, IL-1α stimulated 
ERα mRNA expression significantly in OSE (Fig. 5.3 A, P<0.001) but had no effect 
















































































































Figure 5.1:  Effect of IL-1α on STS and EST mRNA expression in OSE (n=13) and EOC (n=3) 
cells. OSE and EOC cells were treated with IL-1α (0.5ng/ml) for 48h and expression of STS (A, 
B) and EST (C, D) mRNA were measured using Taqman qRT-PCR. Horizontal bars indicate 

























































































































Figure 5.2: Effect of IL-1α on 17βHSD2 and 17βHSD5 mRNA expression in OSE (n=13) and 
EOC (n=3) cells. OSE and EOC cells were treated with IL-1α (0.5ng/ml) for 48h and expression 
of 17βHSD2 (A, B) and 17βHSD5 (C, D) mRNA were measured using Taqman qRT-PCR. 
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Figure 5.3: Effect of IL-1α on ERα mRNA expression in OSE (n=13) and EOC (n=3) cells. OSE 
(A) and EOC (B) cells were treated with IL-1α (0.5ng/ml) for 48h and expression of ERα mRNA 








5.3.2 Effect of IL-1α on STS and 17βHSD5 mRNA expression in 
SKOV-3 cell line 
5.3.2.1 Dose-dependent effect of IL-1α on STS and 17βHSD5 
transcripts        
Treatment of SKOV-3 cells with IL-1α in vitro for 48h resulted in a dose-dependent 
stimulation of STS mRNA levels (Fig. 5.4, A). The maximum (2.5-fold) increase 
occurred when 0.15ng/ml of IL-1α was used (P<0.01). No effect was observed with 
the lowest concentration tested. On the other hand, IL-1α did not have an effect on 




Figure 5.4: Effect of IL-1α on STS and 
17βHSD5 mRNA expression in SKOV-3 cells.  
SKOV-3 cells were treated with increasing 
doses of IL-1α (0.05-0.5ng/ml) for 48h and 
expression of STS (A) and 17βHSD5 (B) 
mRNA were measured with Taqman qRT-
PCR. Bars indicate Mean±SEM. Asterisks 
indicate significant difference from untreated 



















































5.3.2.2 Effect of incubation time on IL-1α effect on STS and 
17βHSD5 transcripts 
Time-course (12, 24, 48h) studies with 0.5ng/ml IL-1α were undertaken to further 
test its stimulatory effect on STS transcripts (Fig. 5.5A). The stimulatory effect was 
first observed at the 12h time-point although maximum stimulation was observed at 
the 48h time-point (Fig. 5.5, P<0.01, P<0.001). IL-1α treatment of OSE cells led to a 
2-fold increase of 17βHSD5 mRNA at 12h, which was reduced at 24h and 
disappeared at 48h (Fig. 5.5, P<0.001). 
            
 
Figure 5.5: Time-dependent effect of IL-1α 
on STS and 17βHSD5 mRNA expression 
in SKOV-3 cells. IL-1α treatment (0.5 
ng/ml) was applied for increasing panel of 
time (12, 24, 48h). Expression of STS (A) 
and 17βHSD5 (B) mRNA were measured 
by Taqman qRT-PCR. Bars indicate 
Mean±SEM. Asterisks indicate significant 
difference from untreated control at the 



























































5.3.2.3 Involvement of IL-1 receptor in IL-1α-mediated STS mRNA 
expression 
In order to examine if IL-1α exerts its effect on STS mRNA through activation of IL-
1 receptor pathway, SKOV-3 cells were treated in vitro with IL-1 receptor antagonist 
(IL-1RA), the inhibitor of IL-1R, in the presence or absence of 0.5ng/ml of IL-1α for 
48h. Addition of 25ng/ml IL-1RA reversed IL-1α-elevated STS mRNA level (Fig. 
5.6, P<0.001).                         





















Figure 5.6: Blockade of IL-1α stimulating STS mRNA expression by IL-1RA in SKOV-3 cells.  
SKOV-3 cells were treated with IL-1α (0.5ng/ml), IL-1RA (25ng/ml) or both for 48h and 












5.3.3 Effect of IL-1α on metabolism of E1S in OSE and SKOV-3 
cells 
After showing that IL-1α inhibited EST and 17βHSD2 mRNA expression in OSE 
cells and stimulated STS mRNA expression in SKOV-3 cells in vitro, the effect of 
IL-1α on the activity of these enzymes was examined. OSE cells were unable to 
convert [3H]-E1S to [3H]-E1 and [3H]-E2 even in the presence of IL-1α. In contrast, 
addition of IL-1α increased conversion of [3H]-E1S to [3H]-E1 2-fold in SKOV-3 cells 
(Fig. 5.7, *=P<0.05), although the effect of IL-1α on the conversion of [3H]-E1S to 









































































































































































Figure 5.7: Effect of IL-1α on oestrogen pre-receptor metabolizing enzyme activity in OSE (n=9) 
and SKOV-3 (n=3) cells. 500,000 cells were plated and serum-depleted for 24h before 
investigating the enzyme activity in vitro. [3H]-E1S was added as a substrate to treat the cells in 
the presence or absence of 0.5ng/ml of IL-1α for 72h. Radioactive metabolites were separated by 
TLC and measured by radioactivity scanner. A) Representative OSE sample in the absence of 
IL-1α; B) Representative SKOV-3 sample in the absence of IL-1α; C) Representative OSE 
sample after IL-1α treatment (0.5ng/ml); D) Representative SKOV-3 sample after IL-1α 
treatment (0.5ng/ml). These radiographs indicate readout from TLC plates where y-axis shows 
counts of radioactivity and x-axis demonstrates the distance along the plate. Different peaks 
represent E1S (substrate), E1 (product of STS) and E2 (product of STS and 17βHSD5) 
respectively, as labelled (A-D). Histograms show conversion rate of E1S to E1 (E) and E1S to E2 
(F) calculated as described in Section 2.5. Bars indicate Mean±SEM. (*=P=0.022) 
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5.3.4 Effect of cytokines on STS, EST, 17βHSD2, 17βHSD5 and 
ERα mRNA expression in OSE and SKOV-3 cells 
5.3.4.1 Effect of cytokines on STS, EST, 17βHSD2, 17βHSD5 and 
ERα mRNA expression in OSE cells       
Having shown the effects of IL-1α on STS, EST, 17βHSD2, 17βHSD5 and ERα 
mRNA expression, IL-4, IL-6, IL-8 and IL-10 effects were tested in OSE cells from 
3 patients. The cells were treated with IL-1α, IL-4, IL-6, IL-8 and IL-10 (all at 
0.5ng/ml) for 48h. None of the cytokines had any effect on STS mRNA expression in 
OSE cells (Fig. 5.8, A). IL-4 reduced EST mRNA level significantly (P<0.05), whilst 
IL-6, IL-8 and IL-10 did not have any effect on EST mRNA (Fig. 5.8, B).  Although 
IL-1α, IL-4 and IL-6 decreased 17βHSD2 mRNA this did not achieve statistical 
significance. IL-8 and IL-10 did not affect 17βHSD2 mRNA level (Fig. 5.9, A).  
Although IL-1α inhibited 17βHSD5 mRNA expression and IL-4 enhanced it, again 
this did not achieve statistical significance. IL-6, IL-8 and IL-10 did not affect 
17βHSD5 mRNA level (Fig. 5.9, B). Although IL-1α appeared to stimulate ERα 
mRNA expression this effect was not statistically significant. IL-4, IL-6, IL-8 and 
















































































Figure 5.8: Effect of inflammatory cytokines on STS and EST mRNA expression in OSE cells. 
OSE cells were treated with IL-1α, IL-4, IL-6, IL-8, IL-10 (0.5ng/ml) for 48h and expression of 
STS (A) and EST (B) mRNAs were measured using Taqman qRT-PCR. Different symbols 
represent different patients. Horizontal bars indicate median value. Asterisk indicates 
significant difference from untreated control. (n=3, *=P<0.05) 
 
 
                              
       
 
 138 










































































Figure 5.9: Effect of inflammatory cytokines on 17βHSD2 and 17βHSD5 mRNA expression in 
OSE cells. OSE cells were treated with IL-1α, IL-4, IL-6, IL-8, IL-10 (0.5ng/ml) for 48h and 
expression of 17βHSD2 (A) and 17βHSD5 (B) mRNA were measured using Taqman qRT-PCR. 
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Figure 5.10:  Effect of inflammatory cytokines on ERα mRNA expression in OSE cells. OSE 
cells were treated with IL-1α, IL-4, IL-6, IL-8, IL-10 (0.5ng/ml) for 48h and expression  of  ERα 
mRNA was measured using Taqman qRT-PCR. Different symbols represent different patients. 















5.3.4.2 Effect of cytokines on STS, 17βHSD5, and ERα mRNA 
expression in SKOV-3 cell line 
Having tested the effect of IL-1α, IL-4, IL-6, IL-8 and IL-10 on STS, EST, 17βHSD2, 
17βHSD5 and ERα mRNA expression in OSE cells, the effect of these cytokines on 
STS, 17βHSD5 and ERα expression in SKOV-3 cells was tested. The cells were 
treated with IL-1α, IL-4, IL-6, IL-8 and IL-10 (all at 0.5ng/ml) for 48h. Only IL-1α 
increased STS mRNA expression level significantly which was consistent with the 
results described in Section 5.3.2 (Fig. 5.11, P<0.001). None of the cytokines had 
any effect on 17βHSD5 mRNA expression (Fig. 5.12). IL-1α and IL-6 did not affect 
ERα mRNA level while IL-4 inhibited and IL-8 and IL-10 stimulated its expression 
(Fig. 5.13, P<0.05 and P<0.01). 

































Figure 5.11:  Effect of cytokines on STS mRNA expression in SKOV-3 cells. SKOV-3 cells were 
treated with IL-1α, IL-4, IL-6, IL-8, IL-10 (0.5ng/ml) for 48h and expression of STS mRNA was 
measured using Taqman qRT-PCR. Horizontal bars indicate Mean±SEM. Asterisk indicates 










































Figure 5.12:  Effect of cytokines on 17βHSD5 mRNA expression in SKOV-3 cells. Cells were 
treated with IL-1α, IL-4, IL-6, IL-8, IL-10 (0.5ng/ml) for 48h and expression of 17βHSD5 
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Figure 5.13:  Effect of cytokines on ERα mRNA expression in SKOV-3 cells. Cells were treated 
with IL-1α, IL-4, IL-6, IL-8, IL-10 (0.5ng/ml) for 48h and expression of ERα mRNA was 
measured using Taqman qRT-PCR. Horizontal bars indicate Mean±SEM. Asterisk indicates 






In Chapters 3 and 4, it was established that STS, EST, 17βHSD2 and 17βHSD5 
mRNA and protein are functionally present in OSE and EOC. The presence of ERα 
mRNA and protein has been demonstrated in OSE and EOC in many previous 
studies. The present chapter elaborates on the regulation of these genes by 
inflammatory associated mediators, highlighting the potential regulation of oestrogen 
formation in OSE and EOC under the control of these locally produced immune 
factors. As introduced in Chapter 1, all the cytokines tested are naturally secreted in 
the pre- and post-ovulatory ovary and are also part of the ovarian tumour 
microenvironment. Moreover, mRNAs for IL-1α, IL-6 and IL-8 are expressed in 
primary OSE and EOC along with their cognate receptors (Ziltener, Maines-Bandiera 
et al. 1993; Burke, Relf et al. 1996; Merogi, Marrogi et al. 1997), suggesting 
intracrine, autocrine and paracrine actions thereof in OSE and ovarian cancer cells. 
On the other hand, IL-4 and IL-10 are not likely to be secreted by OSE, although 
cognate receptors are present (Burke, Relf et al. 1996), implying possible paracrine 
roles in the normal epithelium. 
 
Firstly, IL-1α alone was used as a representative cytokine to test the response of 
these genes to inflammation in OSE and EOC. The rationale for this was firstly to 
minimise the number of variables in any experiment. Secondly, IL-1α is likely to 
exert a crucial role in ovulation induced inflammation; IL-1α activity has been 
identified in human follicular fluid (Barak, Yanai et al. 1992) and regulates key 
factors of the inflammatory cascade including PGs, NO and steroid hormone 
production (Gerard, Caillaud et al. 2004). Finally, IL-1α is secreted by ovarian 
cancer cells (Huleihel, Maymon et al. 1997). Following testing of IL-1α effects in 
OSE and EOC, its action on these genes in a cancer cell line, SKOV-3 was 





In OSE cells, although STS and 17βHSD5 mRNA was found to be expressed, it 
seems that STS and 17βHSD5 mRNA is not affected by regulatory factors such as 
cytokines since they did not respond to 0.5ng/ml IL-1α treatment. By contrast, there 
was a clear decrease in EST mRNA expression in response to this IL-1α treatment 
and a similar pattern of expression of 17βHSD2 mRNA was seen following the same 
IL-1α treatment. Given the effect of EST and 17βHSD2 in the local formation of 
oestrogen, this decrease in mRNA expression, if translated to decreased protein 
expression and enzyme activity, would lead to an increase in local oestrogen 
availability in OSE cells. However the difference between EST and 17βHSD2 with 
and without IL-1α observed at the mRNA level was not repeated at the enzyme level, 
and the cells had equivalent enzyme activities, with no E1 or E2 synthesized. One 
explanation for this could be that Taqman quantitative analysis is a more sensitive 
test and is better able to highlight differences. While attempts were made to keep the 
experimental conditions the same for both mRNA and protein studies, there were 
slight differences. The density and number of cells used in each type of experiment 
differed, the enzyme assay used 5x105 cells per well (2x105 per ml) while the mRNA 
studies included 3x105 cells per well (1.0-1.25x105 per ml). While it is unlikely that 
this difference in cell number had any significant effect, there remains the possibility 
that the lower density of cells could influence cell response. Indeed the differences in 
depth of culture medium in the wells could influence gaseous exchange in both 
experiments. Another explanation for this could be EST enzyme activity was much 
stronger than that of STS in OSE, and regardless of the effect of IL-1α decreasing 
EST activity by more than 50%, the reduced EST activity might still be enough to 
counteract the STS effect, resulting in a failure to produce any E1. Another 
explanation might be that the IL-1α effect on EST and 17βHSD2 transcripts was not 
translated into protein and consequently did not influence the enzyme activity. Since 
we did not have the chance to test IL-1α effect on post-menopausal OSE and OSE 
lining the inclusion cysts due to shortage of these cells, we do not know the exact 
effects of IL-1α on expression of the above genes, but we would anticipate the cells 
to have a similar response or even to be more sensitive to IL-1α, in which case E1 
and E2 could probably be produced with IL-1α stimulation. However, further work 
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needs to be done to test the hypothesis. As far as I know this is the first report that 
EST and 17βHSD2 mRNA expression can be down-regulated by IL-1α in OSE cells. 
 
Interestingly, we have found ERα to be up regulated significantly by 0.5ng/ml IL-1α 
in OSE cells. Although there is no E1 and E2 produced in OSE cells in the presence 
of IL-1α, there is a high concentration of E2 in the follicular fluid over the peri-
ovulatory period (Lobo, diZerega et al. 1985). OSE cells could therefore be exposed 
to locally high levels of E2, which, coupled with the increased expression of ERα 
may exert a potent influence oestrogen-regulated genes. This adds weight to the 
hypothesis that inflammation may promote ovarian cancer carcinogenesis and 
development by regulating the oestrogen pathway. There are two previous studies on 
the effect of IL-1α on ER expression. One microarray analysis study on OSE cells 
failed to show an effect of 0.5ng/ml IL-1α for 48h on ERα mRNA expression (Rae, 
Niven et al. 2004b). One explanation for these conflicting results could be the 
different patient numbers studied. The present study tested the effect in 13 patients 
compared with 5 in the previous study, which would give greater credibility to the 
current study. In contrast, in MCF-7 breast cancer cell line Danforth reported IL-1α 
down-regulated ER in vitro (Danforth and Sgagias 1991). However, no classification 
of ER into ERα and ERβ subtypes was made. 
 
Surprisingly, STS, EST, 17βHSD2, 17βHSD5 and ERα mRNA expression did not 
differ significantly in the presence of 0.5ng/ml IL-1α in any of the EOC samples, 
although there was a trend towards lower levels of EST and 17βHSD2 mRNA and a 
higher level of ERα mRNA in the presence of IL-1α, which is the similar to the case 
in OSE cells. The lack of significant differences may be due to the very small 
number of patient samples (n=3), and more samples should be tested before a 
definitive conclusion can be drawn. By contrast, in SKOV-3 cells, STS mRNA 
expression was observed to increase significantly with 0.15ng/ml IL-1α, and did not 
increase further with 0.5ng/ml. Thus 0.5ng/ml IL-1α was thought to be the optimal 
dose to induce STS expression. Time course studies in SKOV-3 cells showed once 
again a 2-fold increase in the expression of STS in response to 0.5ng/ml IL-1α from 
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12h to 48h. Moreover, there was a complete abrogation of the stimulatory response 
to IL-1α with the addition of IL-1RA. All of these experiments support the concept 
that IL-1α can enhance STS mRNA expression in SKOV-3 cells. In contrast to STS, 
the IL-1α stimulatory effect on 17βHSD5 mRNA was apparent at 12h and 24h but 
disappeared at 48h, and increasing the dose of IL-1α from 0.05ng/ml to 0.5ng/ml did 
not alter its expression at 48h. Though the effect was only transitory, it may increase 
the amount of 17βHSD5 protein and enzyme activity and enhance the local 
production of E2. Indeed, only having a transitory increase in 17βHSD5 mRNA after 
IL-1α treatment might explain why there was such a modest effect of IL-1α on the 
ability of SKOV-3 cells to metabolize E1S to E2 over 72h, if the waning mRNA level 
was matched by falling 17βHSD5 enzyme activity. Following the mRNA studies, 
protein expression of the genes was assessed by functional studies of enzymatic 
activity in OSE and SKOV-3 cells. Only SKOV-3 cells had significantly higher 
enzyme levels in response to IL-1α compared to their untreated controls, which was 
predicted from the mRNA analysis. Like in EOC, ERα in SKOV-3 cells was not 
modulated by IL-1α after 48h. Studies on the regulation of oestrogen metabolizing 
enzymes and ER in other cancers have shown that a number of factors including 
cytokines can modulate the expression of these enzymes. Of these factors, the actions 
of interleukins have been the subject of a number of studies. Honma reported IL-6 
and IL-1β enhanced proliferation of breast cancer cell lines by stimulating the 
activity of STS (Honma, Shimodaira et al. 2002). In contrast, Matsuoka showed that 
IL-1β suppressed STS mRNA and enzyme activity in endometrial stromal cells 
(Matsuoka, Yanaihara et al. 2002). These data suggest that the effect of cytokines on 
STS varies dependent on the tissue under investigation.  
 
It is noticeable that IL-1α stimulates STS mRNA expression in SKOV-3 cells but not 
in EOC cells. The difference between cell lines and primary cultures may be 
explained by the immortal status of the cell lines, and the fact that they may have 
acquired further genetic mutations after many passages and long term culture, and 
therefore do not reflect the true in vivo characteristics of cancer. However, primary 
cancer cells are scarce, which is why cell lines were chosen in this study as an 
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alternative. Another explanation for this discrepancy may be that STS expression 
could be up regulated by IL-1α in only a small proportion of ovarian cancer patients, 
and the EOC cells used might be from non-responders. Nevertheless, IL-1α 
stimulatory effect on STS expression and activity in SKOV-3 suggests inflammation 
could stimulate local production of E2 by regulating STS pathway in cancer cells 
from some patients. 
 
Whilst the inflammatory cytokine IL-1α decreased EST mRNA in OSE cells, it was 
perhaps surprising that EST mRNA expression was also significantly decreased by 
the anti-inflammatory cytokine IL-4, although this is the first report demonstrating 
regulation of EST mRNA expression by IL-4. Down-regulation of EST mRNA and 
activity, leading to enhanced local oestrogen biosynthesis, might be a key component 
of ovarian cancer progression. There are high levels of IL-4R in OSE cells although 
they do not have the capacity to secrete IL-4 de novo (Ziltener, Maines-Bandiera et al. 
1993; Burke, Relf et al. 1996). Blood mononuclear cells that infiltrate the peri-
ovulatory follicle and corpus luteum secret most of IL-4 in the pre-menopausal ovary 
(Hashii, Fujiwara et al. 1998). IL-4 binding to its receptors located on OSE can then 
inhibit the expression of EST. Given the same effect of IL-1α and IL-4 in OSE, it 
would be interesting to investigate if there is any synergism between these cytokines 
in the regulation of EST mRNA and total protein.  
 
It was not possible to test all the cytokines on EOC cells due to limited availability, 
but it was possible to test their effects in SKOV-3 cells. Since there is no EST or 
17βHSD2 mRNA expression in SKOV-3 cells, only the effects of cytokines on STS, 
17βHSD5 and ERα expression were tested. In contrast to the varied effect of 
different cytokines on OSE cells, there was no effect of cytokines on STS and 
17βHSD5 mRNA levels except for the stimulatory effect of IL-1α on STS mRNA 
expression. Moreover, IL-1α stimulates the conversion of E1S to E1 two fold, which 
indicates a two-fold increase in STS enzyme activity. It is interesting that IL-4 
inhibits, while IL-8 and IL-10 stimulate ERα mRNA expression, suggesting different 
cytokines may have different effects on the same gene expression. Although IL-4, 
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IL-8 and IL-10 do not influence the expression of STS or 17βHSD5, meaning these 
cytokines are unable to alter the local production of active E2, they do alter the 
expression of ERα providing an alternative way to affect the oestrogen responsive 
genes. Given the different effect of IL-4 and IL-8 or IL-10 and coexistence of these 
cytokines in ovarian cancer, it would be interesting to investigate if there is any 
synergism or antagonism between them in the regulation of ERα mRNA and total 
protein and thus influence the effect of E2 in ovarian cancer.  
 
It was noticeable that IL-1α inhibited EST mRNA expression in OSE cells (Fig. 5.1 
C) while in the subsequent experiment comparing different cytokines the effect of 
IL-1α, although inhibitory, was not significant  (Fig. 5.8 B). This can be explained by 
the small number of samples in the latter experiment and the variation between 
patient samples. Even in the former experiment, 2 of the 13 results had high EST 
mRNA after IL-1α treatment, but the larger number of overall samples meant the 
inhibitory effect of IL-1α was significant.  
 
Because it has been demonstrated the expression of aromatase is lower than STS 
expression in cancer cells, the effect of inflammatory cytokines on aromatase 
expression and enzyme activity was not tested in the current study. However 
aromatase expression is stimulated by a number of factors in breast cancers. It is 
reported that PGE2, which is produced and secreted by breast tumor epithelial cells 
and fibroblasts, is the most potent factor that enhances aromatase expression via 
cAMP (Zhao, Agarwal et al. 1996). Additionally, it has been shown that cytokines 
like insulin-growth factor types I and II, IL-1, and IL-6 stimulate aromatase activity 
in breast tumour-derived fibroblasts in the presence of dexamethasone (Reed and 
Purohit 1997). Therefore, it would of interest to study the effect of cytokines on the 
expression of PGE2 and subsequent effect on aromatase expression and their direct 
effect on aromatase. Although the expression of aromatase is low, the effect of 
cytokines on its expression may be very dramatic, resulting in high production of E2 
and development of EOC. Thus it would provide the support for the use of anti-
imflammatory and anti-aromatase treatment in EOC. 
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There are a few weaknesses in this part of study. Though it is better to test cytokine 
effects on the target genes in primary EOC cells and then compare them with OSE 
cells, primary EOC cells were limited. In addition, in light of the observation that 
different genes are maximally affected after different treatment times, it is better to 
perform a time course to find the optimum time for the different cytokines. However, 
due to limited availability of cells, and limited time and data from the result of IL-1α 
time course, 48h was chosen as the most suitable time point to reflect the response of 
the genes to different cytokines. Moreover, in previous chapters it was demonstrated 
that E1S transporters like OATP-B, OATP-D and OATP-E are present in OSE and 
EOC cells, so it would be interesting to study their response to inflammatory 
cytokines.  
 
In conclusion, Chapter 5 demonstrates that IL-1α decreases EST and 17βHSD2 and 
promotes ERα mRNA expression in OSE cells, suggesting a mechanism for 
inflammatory cytokines to promote local oestrogen biosynthesis even in the post-
menopausal ovary that could favour tumourigenesis. In addition, similar to IL-1α, IL-
4 decreases EST mRNA level in OSE cells. Therefore, gene transcripts of oestrogen 
production, metabolism and action appear to be under inflammatory control in OSE 
cells, and IL-1α and IL-4 are able to promote the production of E2 in OSE cells by 
influencing different target genes. Moreover, IL-1α stimulates STS mRNA and 
activity in SKOV-3 cells. IL-4 inhibits while IL-8 and IL-10 stimulate ERα mRNA 
levels in SKOV-3 cells. Therefore, similar to OSE cells, gene transcripts of oestrogen 
production, metabolism and action are likely to be also under inflammatory control 
in EOC cells. Different cytokines have opposing effects, with IL-1α, IL-8 and IL-10 
promoting the production or action of E2, while IL-4 inhibits the action of E2. Table 







Cytokines/genes STS EST 17βHSD2 17βHSD5 ERα 
IL-1α n/s ↓ ↓ n/s ↑ 
IL-4 n/s ↓ n/s n/s n/s 
IL-6 n/s n/s n/s n/s n/s 
IL-8 n/s n/s n/s n/s n/s 
IL-10 n/s n/s n/s n/s n/s 
Table 5.2: Summary of cytokine effects on STS, EST, 17βHSD2, 17βHSD5 and ERα mRNA in 
OSE cells.  n/s: non-significant;↑: up-regulation;↓: down-regulation.  
 
Cytokines/genes STS EST 17βHSD2 17βHSD5 ERα 
IL-1α n/s n/s n/s n/s n/s 
IL-4 n/s n/s n/s n/s n/s 
IL-6 n/s n/s n/s n/s n/s 
IL-8 n/s n/s n/s n/s n/s 
IL-10 n/s n/s n/s n/s n/s 
Table 5.3: Summary of cytokine effects on STS, EST, 17βHSD2, 17βHSD5 and ERα mRNA in 











Cytokines/genes STS EST 17βHSD2 17βHSD5 ERα 
IL-1α ↑ - - n/s n/s 
IL-4 n/s - - n/s ↓ 
IL-6 n/s - - n/s n/s 
IL-8 n/s - - n/s ↑ 
IL-10 n/s - - n/s ↑ 
Table 5.4: Summary of cytokine effects on STS, 17βHSD5 and ERα mRNA in SKOV-3 cells.  



























Oestrogenic regulation of cancer-associated cellular 

















As demonstrated in previous chapters, genes encoding the production and 
metabolism of oestrogens are present in ovarian cancer and active E2 could be 
produced by EOC cells through the STS pathway. Moreover, oestrogen receptors are 
expressed in EOC cells. It is therefore reasonable to ask the question: what is the 
effect of E2 in EOC cells? There are many scientific and clinical studies concerning 
different aspects of the effect oestrogen in ovarian cancer. Firstly, there is potential 
role of oestrogen in the initiation of ovarian cancer. One animal study demonstrated 
that E2 can induce ovarian serous cysts, and diethylstilbestrol (DES) can induce 
surface papillary neoplasm in guinea pigs (Silva, Tornos et al. 1998). Another study 
in mice revealed E2 accelerates the initiation of ovarian cancer resulting in decreased 
survival time in a transgenic mouse model (Laviolette, Garson et al. 2010). However, 
the molecular mechanisms by which oestrogen could give rise to cancer are poorly 
understood. Secondly, there is the role of oestrogen in the development of cancer. E2 
increases the growth rate of PEO-4, an ER positive EOC cell line and this stimulation 
can be blocked by tamoxifen (Langdon, Hawkes et al. 1990). Moreover, E2 can lead 
to clear morphological changes characteristic of epithelial-mesenchymal transition 
and enhance ovarian cancer cell migratory ability (Park, Cheung et al. 2008). 
However, the role of oestrogen is controversial. Rochefort showed oestrogen 
inhibited invasion and motility of ovarian cancer cells (Rochefort, Platet et al. 1998). 
Therefore the precise effect of oestrogen on the development of ovarian cancer 
remains to be clarified. Last but not least, some clinical trials complement these 
studies of effect of oestrogen on ovarian cancer. In a phase II study of letrozole, an 
AI, it was demonstrated that ER-positive ovarian cancer patients had no disease 
progression following 6 months of treatment (Smyth, Gourley et al. 2007).  
 
As discussed in Chapter 1, HRT including ERT has a longstanding tradition in the 
treatment of menopausal complaints and has benefited many women. However, 
alongside the benefits of HRT, there are some potential risks, such as breast cancer, 
endometrial cancer and venous thromboembolism. More and more epidemiological 
studies demonstrate higher ovarian cancer risks with ERT users, but there are few 
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studies on the mechanisms of this higher risk. There are many HRT regimes which 
rely on oral administration of CEEs and E2, which are the first two most widely used 
oral oestrogens. Premarin, commercial CEEs tablets, contains at least 10 oestrogens, 
the most abundant of which are E1S (48%) and EqS (26%) (Whittaker, Morgan et al. 
1980). Therefore to find the potential mechanism behind the higher risk of ovarian 
cancer with ERT users, Eq and EqS were selected as the exogenous oestrogen 
sources to treat the cells.  
 
In this chapter, it is hypothesised that exogenous oestrogens from the HRT can be 
converted to active oestrogen via STS pathway by EOC cells and cause the same 
alteration of cancer-associated genes as endogenous oestrogen, thereby assisting the 
development of EOC. In order to test this hypothesis, PEO-1, an ER-positive and 
ER-responsive EOC cell line, was chosen as an EOC model. The effect of E2, Eq and 
their sulphated products, E1S, EqS on the migration of the cells was tested. Moreover, 
effect of E2, Eq and E1S, EqS on four cancer-associated genes, IGFBP3, FN1, LOX 
and E-cadherin was investigated. Anti-oestrogen and anti-STS treatments were also 











6.2 Materials and methods 
6.2.1 Cell line 
PEO-1 cell line was from Dr Simon Langdon (Cancer Research UK, Edinburgh 
Oncology Unit, Edinburgh, UK).   
 
6.2.2 In vitro wound healing assay 
The wound healing assay was performed as described in Section 2.6. 
 
6.2.3 RNA extraction and reverse transcription 
RNA was extracted using methods described in Section 2.4.1 and RT-PCR was 
performed using standard conditions as described in Section 2.4.2. 
 
6.2.4 Taqman qRT-PCR 
QRT-PCR was performed using a 7900 sequence detection system and analysed as 
described in Section 2.4.3. The probes and primers used were commercially available 
pre-validated from Applied Biosystems Assay on Demand or designed in house. The 
information of the primers and probes are shown in Table 2.3. 
 
6.2.5 Statistical analysis 
Statistical analysis was performed using GraphPad Prism 5. Data from wound 
healing assays and qRT-PCR (except Sections 6.3.2.3 and 6.3.3.3) were analyzed by 
one-way ANOVA with Tukey post-hoc test. QRT-PCR data in Sections 6.3.2.3 and 










6.3.1 Effect of oestrogen on cell migration 
6.3.1.1 Effect of E2 and Eq on cell migration  
Treatment of PEO-1 cells with 10-8M E2 and Eq in vitro for 48h resulted in 
stimulation of cell migration measured as wound closure, although this effect was not 
statistically significant (Fig. 6.1, A). Addition of ICI 182,780 (10-6M) tended to 































































































Figure 6.1:  Effect of E2, Eq and ICI 182,780 on PEO-1 cell migration. Cells were cultured for 
48h with E2 (10-8M), Eq (10-8M) (A, B) or +/- ICI 182,780 (10-6M) (B) and wound closure 





6.3.1.2   Effect of E1S and EqS on cell migration           
Treatment of PEO-1 cells with 10-8M E1S in vitro for 72h resulted in a two-fold 
increase in wound closure and addition of the STS inhibitor, STX64, (10-5M, added 
twice at 0h and 48h respectively) significantly reversed this effect (Fig. 6.2, A, 
P<0.01). Treatment of PEO-1 cells with 10-8M NaEqS in vitro for 72h resulted in a 
non-significant increase in wound closure but addition of STX64 (10-5M) did not 
significantly reduce wound closure (Fig. 6.2, B).                        














































































Figure 6.2: Effect of E1S, NaEqS and STX64 on PEO-1 cell migration. Cells were cultured with 
E1S (10-8M) +/- STX (10-5M) (A) and NaEqS (10-8M-) +/- STX64 (10-5M) (B) for 72h and wound 
closure measured as the distance of cell migration was determined using a microscope. Bars 
indicate Mean±SEM. (n=3, **=P<0.01) 
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6.3.2 Effect of oestrogen on FN1 mRNA expression in PEO-1 cells 
6.3.2.1 Effect of E2 and Eq on FN1 mRNA expression  
PEO-1 cells were treated with 10-8M E2 or Eq in vitro for 48h. FN1 mRNA 
expression was significantly reduced by approximately 50% in the presence of either 


























Figure 6.3:  Effect of E2 and Eq on FN1 mRNA expression in PEO-1 cells. PEO-1 cells were 
treated with E2 (10-8M) or Eq (10-8M) for 48h and expression of FN1 mRNA was measured by 
Taqman qRT-PCR. Bars indicate Mean±SEM. Asterisks indicate significant difference from 












6.3.2.2 Dose-related effect of E2 and Eq on FN1 mRNA expression                     
PEO-1 cells were treated with increasing doses of E2 (10-12M, 10-10M and 10-8M) in 
vitro for 48h. FN1 mRNA expression was inhibited significantly by E2 (10-10 and 10-
8M) and the strongest suppression was with 10-10M E2 (Fig. 6.4, A, P<0.05, P<0.01). 
PEO-1 cells were also treated with increasing doses of Eq (10-12M, 10-10M and 10-8M) 
in vitro for 48h. FN1 mRNA expression was suppressed significantly by all doses of 
Eq and the strongest inhibition was with 10-10M Eq (Fig. 6.4, B, P<0.001).                       






















































Figure 6.4: Dose-related effect of E2 and Eq on FN1 mRNA expression in PEO-1 cells.  PEO-1 
cells were treated with increasing doses of E2 (A) and Eq (B) (10-12M-10-8M) for 48h and 
expression of FN1 mRNA was measured by Taqman qRT-PCR. Bars indicate Mean±SEM. 





6.3.2.3 Time-dependent effect of E2 on FN1 mRNA expression                     
As shown above, treatment of PEO-1 cells with increasing doses of E2 for 48h 
significantly inhibited FN1 mRNA. When a fixed dose of E2 (10-10M) was added to 
PEO-1 cells E2 inhibited FN1 mRNA in a time-dependent manner. Maximum 
inhibition (2-fold) was measured after 24h (Fig. 6.5, P<0.01). 


























Figure 6.5: Time-dependent effect of E2 on FN1 mRNA expression in PEO-1 cells. E2 treatment 
(10-8M) was applied in a time dependent manner (6, 12, 24, 48h). Expression of FN1 mRNA was 
measured by Taqman qRT-PCR. Bars indicate Mean±SEM. Asterisks indicate significant 











6.3.2.4 Effect of the ER antagonist, ICI 182,780 on E2 and Eq 
inhibition of FN1 mRNA expression 
Treatment of PEO-1 cells with 10-8M E2 and Eq in vitro for 48h resulted in 
significant inhibition of FN1 mRNA expression, as previously observed (Fig. 6.3). 
Addition of ICI 182,780 (10-6M) reversed E2 and Eq inhibitory effect (Fig. 6.6, 
P<0.01, P<0.001).                                          
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Figure 6.6: FN1 mRNA expression in PEO-1 cells treated with E2, Eq and ICI 182,780.  PEO-1 
cells were treated with E2 (10-8M) or Eq (10-8M) or +/- ICI 182,780 (10-6M) for 48h and 
expression of FN1 mRNA was measured with Taqman qRT-PCR. Bars indicate Mean±SEM. 








6.3.2.5 Dose-related effect of E1S and EqS on FN1 mRNA expression                     
PEO-1 cells were treated with increasing doses of E1S and NaEqS (10-10M, 10-8M 
and 10-6M) in vitro for 72h. FN1 mRNA expression was inhibited in a dose-
dependent manner by both E1S and NaEqS the strongest suppression was with 10-6M 
E1S (Fig. 6.7, A, B, P<0.001).  























































Figure 6.7:  Dose response of E1S and NaEqS on FN1 mRNA expression in PEO-1 cells.  PEO-1 
cells were treated with increasing doses of E1S (A) and NaEqS (B) (10-10M-10-6M) for 72h and 
expression of FN1 mRNA was measured with Taqman qRT-PCR. Bars indicate Mean±SEM. 





6.3.2.6 Effect of the STS inhibitor, STX64, on E1S and NaEqS 
inhibition of FN1 mRNA expression 
As observed previously (Fig. 6.7, A) treatment of PEO-1 cells with increasing doses 
of E1S (10-10M, 10-8M and 10-6M) for 72h resulted in dose-dependent suppression of 
FN1 mRNA expression, and the inhibitory effect of E1S (10-8M and 10-6M) was 
statistically significant. Addition of STX64 (10-5M) reversed the inhibitory effect of 
E1S (10-8M and 10-6M) and this was significant at E1S (10-6M) (Fig. 6.8, A, P<0.01, 
P<0.001).  Similarly, increasing dose of NaEqS (10-10M, 10-8M and 10-6M) tended to 
inhibit FN1 mRNA expression and STX64 (10-5M) tended to reverse the inhibitory 
effect although the differences were not statistically significant (Fig. 6.8, B).                                      




Figure 6.8:  FN1 mRNA expression in PEO-
1 cells treated with E1S, NaEqS and STX64.  
PEO-1 cells were treated with increasing 
dose of E1S (A), NaEqS (B) (10-10M-10-6M) 
or +/- STX64 (10-5M) for 72h and expression 
of FN1 mRNA was measured with Taqman 
























































































































































6.3.3 Effect of oestrogen on IGFBP3 mRNA expression in PEO-1 
cells 
6.3.3.1  Effect of E2 and Eq on IGFBP3 mRNA expression           
 PEO-1 cells were treated with 10-8M E2 or Eq in vitro for 48h. IGFBP3 mRNA 



























Figure 6.9:  Effect of E2 and Eq on IGFBP3 mRNA expression in PEO-1 cells. PEO-1 cells were 
treated with E2 (10-8M) or Eq (10-8M) for 48h and expression of IGFBP3 mRNA was measured 
with Taqman qRT-PCR. Bars indicate Mean±SEM. Asterisks indicate significant difference 










6.3.3.2 Dose-related effect of E2 and Eq on IGFBP3 mRNA 
expression                                                               
 PEO-1 cells were treated with increasing doses of E2 (10-12M, 10-10M and 10-8M) in 
vitro for 48h. IGFBP3 mRNA expression was inhibited in a dose-dependent manner 
by E2 and the strongest suppression was with 10-8M E2 (Fig. 6.10, A, P<0.05, 
P<0.001). PEO-1 cells were also treated with increasing doses of Eq (10-12M, 10-10M 
and 10-8M) in vitro for 48h. IGFBP3 mRNA expression was suppressed significantly 
by Eq, although the effect was not dose-dependent and the strongest inhibition was 
with 10-12M Eq (Fig. 6.10, B, P<0.05).                                                  























































Figure 6.10: Dose-related effect of E2 and Eq on IGFBP3 mRNA expression in PEO-1 cells.  
PEO-1 cells were treated with increasing dose of E2 (A) and Eq (B) (10-12M-10-8M) for 48h and 
expression of IGFBP3 mRNA was measured with Taqman qRT-PCR. Bars indicate 




6.3.3.3 Time dependent effect of E2 on FN1 mRNA expression             
As shown above, treatment of PEO-1 cells with increasing doses of E2 for 48h 
significantly inhibited IGFBP3 mRNA. When a fixed dose of E2 (10-10M) was added 
to PEO-1 cells,  a significant 2-fold supression of IGFBP3 mRNA was observed after 
6h, 24h and 48h (Fig. 6.11, P<0.01, P<0.001).                                        






























Figure 6.11: Time-dependent effect of E2 on IGFBP3 mRNA expression in PEO-1 cells. 
Expression of IGFBP3 mRNA was measured 0, 6, 12, 24 and 48h after addition of E2 (10-8M) by 
Taqman qRT-PCR. Bars indicate Mean±SEM. Asterisks indicate significant difference from 










6.3.3.4 Effect of the ER antagonist, ICI 182,780 on E2 and Eq 
inhibition of IGFBP3 mRNA expression   
Treatment of PEO-1 cells with 10-8M E2 and Eq in vitro for 48h resulted in 
significant inhibition of IGFBP3 mRNA expression. ICI 182,780 (10-6M) alone 
suppressed IGFBP3 mRNA expression significantly. Addition of ICI 182,780 did not 
















































Figure 6.12: IGFBP3 mRNA expression in PEO-1 cells treated with E2, Eq and ICI 182,780.  
PEO-1 cells were treated with E2 (10-8M) or Eq (10-8M) or +/- ICI 182,780 (10-6M) for 48h and 
expression of IGFBP3 mRNA was measured with Taqman qRT-PCR. Bars indicate 







6.3.3.5 Dose-related effect of E1S and EqS on IGFBP3 mRNA 
expression 
PEO-1 cells were treated with increasing doses of E1S (10-10M, 10-8M and 10-6M) in 
vitro for 72h. IGFBP3 mRNA expression was inhibited significantly by E1S and the 
strongest suppression was with 10-8M E1S (Fig. 6.13, A, P<0.05, P<0.001). PEO-1 
cells were also treated with increasing doses of NaEqS (10-10M, 10-8M and 10-6M) in 
vitro for 72h. IGFBP3 mRNA expression was suppressed significantly by NaEqS 
and the strongest inhibition was with 10-8M NaEqS (Fig. 6.13, B, P<0.01, P<0.001).  
In both cases the response to treatment with the sulphated steroid resulted in 
suppression that approximated a dose-dependent effect.            
                                                                                                    
   
 
Figure 6.13: Dose response of E1S 
and NaEqS on IGFBP3 mRNA 
expression in PEO-1 cells.  PEO-1 
cells were treated with increasing 
dose of E1S (A) and NaEqS (B) (10-
10M-10-6M) for 72h and expression 
of IGFBP3 mRNA was measured 
with Taqman qRT-PCR. Bars 
indicate Mean±SEM. Asterisks 
indicate significant difference from 
































































6.3.3.6 Effect of the STS inhibitor, STX64, on E1S and NaEqS 
inhibition of IGFBP3 mRNA expression 
Treatment of PEO-1 cells with increasing doses of E1S (10-10M, 10-8M and 10-6M) 
for 72h resulted in suppression of IGFBP3 mRNA expression in a dose-dependent 
manner (compare with Fig. 6.13A) and the inhibitory effect of E1S at 10-8M and 10-
6M was statistically significant. STX64 (10-5M) alone suppressed IGFBP3 mRNA 
expression and addition of STX64 did not reverse the inhibitory effect of E1S (Fig. 
6.14, A, P<0.001). Similarly, NaEqS (10-10M, 10-8M and 10-6M) inhibited IGFBP3 
mRNA expression in a dose-dependent manner (compare with Fig. 6.13B) and 
STX64 (10-5M) alone suppressed IGFBP3 mRNA expression and addition of STX64 



















































































































































































Figure 6.14: IGFBP3 mRNA expression in PEO-1 cells treated with E1S, NaEqS and STX64.  
PEO-1 cells were treated with increasing dose of E1S (A), NaEqS (B) (10-10M-10-6M) or +/- 
STX64 (10-5M) for 72h and expression of IGFBP3 mRNA was measured with Taqman qRT-
PCR. Bars indicate Mean±SEM. (n=3, *=P<0.05, **=P<0.01, ***=P<0.001) 
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6.3.4 Effect of oestrogen on LOX mRNA expression in PEO-1 cells         
PEO-1 cells were treated with 10-8M E2 or Eq in vitro for 48h. There was no effect of 

























Figure 6.15: Lack of effect of E2 and Eq on LOX mRNA expression in PEO-1 cells. PEO-1 cells 
were treated with E2 (10-8M) or Eq (10-8M) for 48h and expression of LOX mRNA was 














6.3.5 Effect of oestrogen on E-cadherin mRNA expression in PEO-
1 cells            
PEO-1 cells were treated with 10-8M E2 or Eq in vitro for 48h. There was no effect of 





























Figure 6.16: Lack of effect of E2 and Eq on E-cadherin mRNA expression in PEO-1 cells. PEO-1 
cells were treated with E2 (10-8M) or Eq (10-8M) for 48h and expression of E-cadherin mRNA 














Despite research on ovarian cancer over many years there have been no significant 
improvements in clinical outcomes. Thus identification of important factors that can 
influence EOC development is often regarded with enthusiasm and expectation. 
Although oestrogens as potential tumour promoting factors for EOC have excited 
international scientific interest, the mechanism of oestrogen action in the process is 
still not clear.  A few epidemiological data have indicated that HRT users have a 
higher risk of ovarian cancer, while there are few studies on the mechanism of this 
effect. The data presented in this chapter are the first to demonstrate possible 
pathways by which oestrogens derived from CEE, a popular oestrogen form of HRT, 
might influence the development of EOC and provide potential methods to prevent 
and treat this disease. 
 
As demonstrated in Chapter 4 there is high ERα mRNA expression in the PEO-1 cell 
line and growth of these cells is stimulated by E2 implying the presence of functional 
ER (O'Donnell, Macleod et al. 2005). Therefore PEO-1 is regarded as a good 
oestrogen-responsive EOC model. In the present chapter, the effect of E2 and Eq on 
the migration of PEO-1 cells was tested first. As expected, the migration of the cells 
was stimulated by both E2 and Eq and the effect could be reversed by ER (ERα and 
ERβ) antagonist ICI 182,780, although this was not statistically significant, 
suggesting that further repeats of this experiment are required to reach statistical 
significance. If proven to be correct, this would indicate that Eq, one of CEE 
metabolites, has the same effect as E2 in promoting the migration of PEO-1 cells. 
Similarly, E1S and EqS stimulated the migration of the cells. In the case of E1S this 
was significant, and the effect could be blocked by STX64, an STS inhibitor. This 
suggests that E1S and EqS, components of CEEs, were converted to active 
oestrogens, E2 and Eq, through the action of STS in the cancer cells, with the active 
oestrogen products acting on the cells to increase their migration. Although there is 
no published data on the effect of STX64 on the migration of cancer cells, there are 
studies about its inhibitory effect on the proliferation of cancer cells and growth of 
tumours. STX64 inhibited the proliferation of MCF-7 cells (breast cancer cell line) 
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overexpressing STS cDNA (MCF-7STS) by 32% and caused about 20% MCF-7STS 
tumour regression (Foster, Chander et al. 2008b). In addition, STX64 inhibited the 
growth of Ishikawa (endometrial cancer cell line) xenograft in ovariectomized mice 
by 48% when1mg/kg STX64 was given to the mice daily (Foster, Chander et al. 
2008a). Measurement of the width of the wounds in the present study was done 
manually, meaning it was relatively subjective, although this should be compensated 
to some extent by measuring 3 points on every scratch and obtaining the average 
width. Further studies should be done to repeat these experiments or include another 
method to measure the migration of the cells to reduce the error. Moreover, another 
functional test, such as a cell proliferation assay to study the effect of oestrogen on 
the proliferation of the cancer cells could be included. 
 
Having demonstrated that both natural and CEE-derived oestrogens have similar 
effects on promoting cell migration, selected E2-responsive cancer-associated genes 
in PEO-1 cells were then measured to test the effect of E2 and Eq. A number of E2- 
regulated genes have been identified in PEO-1 cells by gene microarray. Among 
these genes, IGFBP3 and FN1 have the two largest fold-changes that were confirmed 
by real-time RT-PCR (O'Donnell, Macleod et al. 2005). FN1 and IGFBP3 are 
reported to be involved in the development of cancers. IGFBP3 has been shown to 
act as potent inhibitor of IGF-IR signaling in several non-small cell lung cancer cell 
lines, causing growth arrest and inducing apoptosis (Lee, Chun et al. 2002). 
Recombinant IGFBP3 inhibited basal and E2-stimulated MCF-7 breast cancer cell 
proliferation (Huynh, Yang et al. 1996). In ovarian cancer, IGFBP3 has been 
associated with disease stage and residual tumour volume when measured by ELISA 
or by quantitative RT-PCR (Katsaros, Yu et al. 2001; Lu, Katsaros et al. 2006; Wiley, 
Katsaros et al. 2006). FN1 is an ECM glycoprotein, which is involved in cell 
adhesion, migration, growth and differentiation. Its expression was found to be down 
regulated in ovarian cancer and was related to histological grade (Chang, Zhang et al. 
2009). The reduction in FN1 and IGFBP3 mRNA in response to E2 was consistent 
with the O’Donnell study, although the fold change was smaller in the present study. 
Moreover, time-course studies of E2 on FN1 and IGFBP3 mRNA expression 
confirmed the inhibitory effect of E2 on these two genes in PEO-1 cells. Therefore 
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the reduced expression of FN1 and IGFBP3 by E2 can influence apoptosis, 
proliferation and migration of cancer cells. As expected, similar to the effect of E2, 
Eq treatment dramatically decreased FN1 and IGFBP3 mRNA expression in PEO-1 
cells, and the effect was further confirmed by the observation that FN1 and IGFBP3 
mRNA expression was inhibited by Eq in a dose-dependent manner. Together, the 
above results suggest both E2 and Eq can influence the development of EOC by 
regulating cancer-associated genes. The ER antagonist ICI 182,780 abrogated the E2 
inhibitory effect on FN1 mRNA expression. Surprisingly, ICI 182,780 alone 
decreased IGFBP3 mRNA expression and did not reverse E2 inhibitory effect on 
IGFBP3 mRNA expression. The mechanism behind this effect requires further study 
but it is possible that ICI 182,780 activates other unknown pathways while blocking 
ER. Agonistic effects of ICI 182,780 have also been found in some other cells. 
Robertson found agonistic up-regulation of GAPDH mRNA in superficial 
endometrial cells and antagonistic down-regulation of ER and PR mRNAs in the 
inner layer of the myometrium of the sheep uterus, and concluded that the agonist 
versus antagonist effects of ICI 182,780 relative to those of E2 were a function of the 
gene examined, as well as the specific cell within the uterus (Robertson, Zhang et al. 
2001). Moreover, Pinto concluded that ICI 182,780 has agonistic effects on several 
typical oestrogenic responses in fish, but its actions are tissue-specific. They 
observed ICI 182,780 mimicked some E2 actions on gene expression in sea bream 
liver, up regulating ER alpha, vitellogenin II and choriogenin L, but did not have 
these effects in the testis (Pinto, Singh et al. 2006). The agonistic effect of ICI 
182,780 suggests caution in the use of ICI 182,780 as a pure anti-oestrogen to block 
oestrogen function, and may explain why there are some EOC cases insensitive to 
anti-oestrogen treatments. 
 
As mentioned above, although E2 has an inhibitory effect on FN1 and IGFBP3 
mRNA in the present study, the effect is not as clear cut as described in O’Donnell’s 
study (O'Donnell, Macleod et al. 2005). The difference in fold-change inhibition 
might be explained by the different passage numbers of the PEO-1 cells. The present 
study used the cells with higher passage numbers in which the sensitivity to 




As confirmation of the ability of PEO-1 to metabolize sulphated oestrogens, and 
indicative of the presence of STS and 17βHSD1/5, FN1 and IGFBP3 mRNAs 
expression was significantly suppressed by 10-8M and 10-6M E1S. Similarly NaEqS 
inhibited IGFBP3 mRNA expression significantly and tended to reduce FN1 mRNA 
expression, although there was no statistical significance, suggesting the conversion 
of NaEqS to Eq and subsequent regulation of the cancer-associated genes. STX64 
was used to confirm whether E1S and NaEqS were converted by the STS pathway. 
As predicted, STX64 abrogated the E1S inhibitory effect on FN1 mRNA expression 
significantly and a suggestion of reversion of E1S inhibitory effect on FN1 mRNA, 
although this was not significant. Surprisingly, STX64 alone decreased IGFBP3 
mRNA expression and did not reverse E1S and NaEqS inhibitory effect on IGFBP3 
mRNA expression. Interestingly, this effect of STX64 is similar to ICI 182,780 since 
both decreased IGFBP3 mRNA but not FN1 mRNA. The mechanism behind this 
effect requires further study but it is possible that STX64 actives other unknown 
pathways while blocking the STS pathway. Both the E1S and NaEqS inhibitory 
effects indicate that the components of CEEs can regulate the oestrogen-responsive 
cancer-associated genes, and then influence the development of EOC. 
 
As introduced in Chapter 1, STX64 is a tricylic coumarin-based sulfamate that 
irreversibly inhibits STS activity. It was selected for the first Phase I clinical trial of 
an STS inhibitor in postmenopausal women with breast cancer. As expected it was 
able to almost completely block STS activity in peripheral blood lymphocytes and 
tumour tissues. Serum concentrations of E1, E2, androstenediol and DHEA all 
decreased significantly from pre-treatment levels. Therefore STX64 is shown to be 
an efficient and well-tolerated STS inhibitor for breast cancer treatment (Stanway, 
Purohit et al. 2006). Since the present results show there is active STS converting 
inactive E1S to E1 and then to active E2 in EOC, STX64 was evaluated to test its 
inhibitory effect on STS action in EOC. Its different effects on FN1 and IGFBP3 
mRNA expression suggest different regulatory mechanisms on different genes. 
Although it can inhibit STS function and thus abrogate E2 effects on some cancer-
associated genes it may also activate other pathways to influence other genes. To 
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determine its overall effect on EOC, STX64 effect on the proliferation and migration 
of EOC cells treated with E2 precursors need to be further investigated.   
 
Due to increased female longevity, women now spend nearly half of their adult lives 
in a state of relative oestrogen deficiency. HRT consisting of daily oral 
administration of CEEs either alone or in combination with MPA are effective at 
relieving menopausal symptoms. However there are many absolute contraindications 
to HRT, such as cancer of the breast, cancer of the endometrium, endometrioid 
ovarian cancer, thromboembolic disorders amongst others (Kubba 1995). Ovarian 
cancer other than endometrioid ovarian cancer is not included in the 
contraindications. The finding in this study that CEE-derived oestrogen can influence 
cancer-associated genes in EOC raises caution concerning the clinical use of the 
oestrogen-containing HRT. It is worthwhile evaluating whether ovarian cancer or 
family history of ovarian cancer should be included in the absolute contraindications. 
If individual patients with EOC do require HRT treatment, the physician should think 
about the forms and duration of HRT carefully, since local application of oestrogen 
does not influence the serum concentration of oestrogen and short-term use has less 
opportunity of causing and promoting EOC. 
 
As discussed in Chapter 1, both LOX and E-cadherin are expressed in EOC cells and 
are known to be involved in the development of many cancers (Birchmeier and 
Behrens 1994; Ren, Yang et al. 1998; Erler, Bennewith et al. 2006). Therefore, in 
addition to IGFBP3 and FN1, the effect of E2 and Eq on these two genes was also 
tested. However, there was no effect of E2 or Eq on LOX and E-cadherin. Thus E2 
and Eq only regulate specific cancer-associated genes and it is important to identify 
these specific genes since enhancement or blockade of the relevant pathways may 
provide novel potential treatments for EOC. 
 
In this chapter only one EOC cell line was chosen to test the hypothesis, while 
primary EOC cells would have been the ideal choice. However, each patient has their 
own characteristics, so responses to E2 in different primary cancer cells are likely to 
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be variable. It would take considerable time to identify consistent oestrogen-
responsive primary cells. Given the limited time and resources, an EOC cell line was 
used. The discoveries of stimulatory effect of E2 on the migration of EOC cell and 
inhibitory effect on cancer-associated genes will inform further research on primary 
EOC cells. 
 
In summary, Chapter 6 demonstrated that both E2 and Eq, metabolites of CEEs by 
EOC cells, and E1S and NaEqS, ingredients of CEEs, tend to stimulate the migration 
of PEO-1 cells. Moreover, both E2 and Eq dramatically decrease FN1 and IGFBP3 
mRNA expression in PEO-1 cell line. ICI 182,780, an ER antagonist, abrogates the 
E2 inhibitory effect on FN1 mRNA expression while alone it decreases IGFBP3 
mRNA expression. In addition, both E1S and NaEqS inhibit FN1 and IGFBP3 
mRNA expression. STX64, an STS inhibitor, abrogates the E1S inhibitory effect on 
FN1 mRNA expression while alone it decreases IGFBP3 mRNA expression. These 
results indicate that local metabolism of inactive oestrogen components of HRT can 
influence the development of ovarian cancer by regulating cancer-associated genes. 
Thus we demonstrate a potential mechanism for HRT-associated oestrogen-mediated 






































7.1 General discussion 
This thesis explored oestrogen pre-receptor synthesis and metabolism as well as 
action in human OSE and EOC. This was performed by studying expression patterns 
of oestrogen producing and metabolizing enzymes and ERs using IHC, Taqman 
qRT-PCR and enzyme activity assay. Additionally, inflammatory regulation of the 
enzymes and ERs by different cytokines was investigated in vitro. Furthermore, the 
action of HRT-derived oestrogen on oestrogen-responsive cancer-associated genes 
was examined in an EOC cell line. 
 
The first hypothesis of the thesis is that oestrogen producing and metabolizing 
enzymes exist in EOC, facilitating local E2 production. In Chapters 3 and 4, the 
results established that the proteins required for local oestrogen production and 
metabolism such as STS, EST, 17βHSD2 and 17βHSD5 were localized in pre-
menopausal, post-menopausal and inclusion cystic OSE as well as EOC cells. STS, 
EST, 17βHSD1, 17βHSD2, 17βHSD5, ERα, ERβ, OATP-B, OATP-D and OATP-E 
mRNAs were also differentially expressed in pre-menopausal OSE and EOC. EST 
mRNA expression was significantly higher in OSE compared to EOC cells while 
OATP-B mRNA expression was the reverse. Radiometric enzyme activity assays 
demonstrated different patterns of E1S and E1 metabolism between OSE and EOC 
cells. The balance of overall activities of STS and 17βHSD1 or 17βHSD5 were 
higher than the overall activities of EST and 17βHSD2 in cancer cells favouring E1 
and E2 production from E1S in EOC, but the reverse was true in OSE cells, favouring 
E2 inactivation from E1S. This suggests OSE tends to be protected from the 
formation of active oestrogen while EOC tends to promote the production of active 
oestrogen.  
 
The second hypothesis of the thesis is that inflammatory cytokines regulate the 
development of EOC by promoting the synthesis of oestrogen in EOC. In Chapter 5, 
the data revealed that in OSE cells, EST and 17βHSD2 mRNA was decreased while 
ERα mRNA was increased by IL-1α. Together, these changes in gene expression in 
response to IL-1α would tend to promote active oestrogen synthesis in OSE and 
suggest a mechanism for inflammatory promotion of tumourigenesis in OSE by local 
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up regulation of active oestrogen biosynthesis. In addition, EST mRNA was inhibited 
by IL-4. In SKOV-3 cells, IL-1α stimulated STS mRNA and enzyme activity, 
resulting in increased conversion of E1S to E1, again favouring active oestrogen 
formation. Moreover, IL-4 inhibited while IL-8 and IL-10 enhanced ERα mRNA 
expression. Together, these results suggest oestrogen production via STS/EST 
pathways in OSE and EOC is regulated by a number of inflammatory cytokines, 
although different genes are regulated by different cytokines in OSE compared with 
EOC cells. Moreover, in addition to the regulation at the pre-receptor level, 
oestrogen action is also be regulated at receptor level with different effects of 
cytokines on ERα mRNA expression in OSE and EOC. 
 
The third hypothesis of the thesis is that exogenous CEEs can be converted to active 
oestrogens locally in EOC, playing an important role in the development of EOC by 
regulating oestrogen-responsive genes. In Chapter 6, the results demonstrated mRNA 
expression of two cancer-associated genes, FN1 and IGFBP3, which were inhibited 
by both E2 and Eq as well as E1S and NaEqS. ICI 182,780 (ER antagonist) and 
STX64 (STS enzyme inhibitor) abrogate the E2, Eq, E1S, and NaEqS inhibitory effect 
on FN1 mRNA expression, while alone they decrease IGFBP3 mRNA expression. In 
contrast to FN1 and IGFBP3, another two cancer-associated oestrogen-related genes, 
LOX and E-cadherin, did not respond to E2 and Eq. These results suggest exogenous 
CEEs used in HRT can be converted to active oestrogens locally by EOC, causing 
altered expression of specific cancer-associated genes, which participate in the 
proliferation or migration of the cancer cells, similar to the effect of endogenous E2. 
This finding provides an insight into the cancer-promoting effects of HRT, which 
contain CEEs, and justifies further experimental and clinical research on the 
application of anti-oestrogen and anti-STS compounds in the treatment of EOC. 
 
In conclusion this thesis presents evidence that oestrogen pre-receptor production 
and metabolism occurs in OSE and EOC cells, and E2 formation is inhibited in 
normal OSE but is promoted in EOC. Inflammatory cytokines also influence the 
local production of E2 by regulating oestrogen metabolic genes and receptors. 
Finally, local HRT metabolites can regulate cancer-associated gene expression in 
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EOC. Together, these data suggest a mechanism for local oestrogen production and 
action that can promote tumour development in EOC, and OSE cells from pre-
menopausal women, whilst protected from these effects in the quiescent ovary, are 
likely exposed to higher active oestrogen in an inflammatory environment. 
 
7.2 Future studies and clinical implications 
The studies presented in this thesis have shown the expression of oestrogen pre-
receptor metabolizing enzymes and active E2 produced in EOC based on a small 
number of EOC samples.  In Chapter 3, seven EOC tissues were tested by IHC and 
in chapter 4 mRNA levels in four EOC patients were measured by Taqman qRT-
PCR. These results have provided initial evidence from limited numbers of patients. 
Further experiments with more patients would strengthen this observation. Moreover, 
since there are 4 main subtypes of EOC, it would be of interest to measure STS/EST 
enzyme expression in different subtypes of EOC. The main advantage of the 
classification is to help identify the subtypes that are more sensitive to oestrogen 
stimulation, thus helping select the patients most suitable for anti-oestrogen treatment. 
Furthermore, studying the association of genes such as STS, EST, 17βHSD2, 
17βHSD5, ERα, OATP-B, OATP-D and OATP-E with the risk of EOC recurrence 
and survival time, would be helpful in determining which genes or combination of 
genes can be used as independent factors for prognosis. Based on the above 
discussion an experiment could be designed using a tissue microarray to test the 
expression of above proteins on 50 serous, mucinous, endometrioid and clear cell 
EOC respectively, and compare to EOC recurrence and survival time. 
 
As demonstrated in this thesis, STS and 17βHSD5 play an important role in 
conversion of inactive E1S to active E2 in EOC, and E2 can influence the 
development of EOC by regulating cancer-associated genes. Thus, blocking STS 
pathway in EOC might be a potential treatment for EOC.  In Chapter 6 the STS 
inhibitor, STX64, was shown to significantly reduce E2 stimulatory effect on the 
migration of PEO-1 cells and reverse E2 inhibitory effect on FN1, but not on IGFBP3 
mRNA expression. This is strong evidence to support the use of STX64 as a 
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treatment for EOC, although further experiments need to be performed. In vitro 
experiments such as testing E2 effects on the proliferation or invasion of the cancer 
cells should be included. Moreover, in vivo experiments using a xenograft model 
would provide further supporting evidence.  PEO-1 cells can be injected into the 
flanks of nude mice to produce EOC tumours. Mice could then be given oral STX64 
to test its effect on reducing tumour growth. Once such pre-clinical models have 
demonstrated STX64 effectiveness in suppressing the growth of EOC in vivo, a stage 
І clinical trial could be designed and applied to investigate STX64 efficiency of 
treating EOC. Recently, a 2nd generation of STS inhibitor, STX213, has been 
developed. It has been tested pre-clinically and is shown to be more potent and have 
a longer duration of action in vivo in both rats and mice compared to STX64 (Foster, 
Chander et al. 2008b). It would therefore be interesting to test STX213 effect on 
treating EOC and compare it with STX64. Another approach to blocking STS 
function would be RNA interference (RNAi). It would be interesting to test STS 
expression and activity after RNAi treatment in EOC cells. Since 17βHSD5 is 
responsible for the final step in the biosynthesis of E2 from E1S in EOC, inhibition of 
its function alone or together with STS would be potentially more effective. Further 
work testing the effect of a 17βHSD5 inhibitor or knocking down expression of 
17βHSD5 by RNAi would be of interest.   
            
The results in Chapter 4 showed lower expression of EST mRNA in EOC compared 
with OSE cells, and consequent interconversion between E1 and E1S in opposite 
directions. Since EST opposes the effect of STS, increasing the expression and 
activity of EST combined with inhibition of STS could be an approach to the 
treatment of EOC. Further investigation should include both in vitro and in vivo 
experiments. Firstly, the expression of EST and metabolism of E1S in EOC could be 
retested after EST was transfected to EOC cells. Secondly, the proliferation, 
migration and invasion of EOC cells could also be compared after transfection of 
EST. If the transfection was effective and enhanced expression of EST, thereby 
reducing the biosynthesis and action of E2, in vivo experiments on a xenograft model 




The main focus of this thesis is on the STS pathway of oestrogen synthesis, since the 
mRNA and protein expression of aromatase is much lower than STS. However, this 
does not exclude the possible production of E2 through aromatisation. As introduced 
in Chapter 1, after menopause, the serum concentration of DHEAS is much higher 
than that of E1S. STS and 3βHSD1 in EOC could then convert DHEAS to A, an 
aromatase substrate. If aromatase is expressed in some EOC patients, although the 
expression is low, since the concentration of precursor A is higher, the production of 
E2 might be significant. Allowing for conversion from DHEAS there is potentially a 
high concentration of A in the serum after menopause, which could diffuse into EOC 
and be converted to E2 by aromatase. Therefore it would be worth testing aromatase 
expression in a large number of EOC samples to find out if there is a subgroup of 
EOC with higher expression of aromatase alone or together with STS. In addition, 
dynamic conversion of exogenous A or T to E2 (aromatase enzyme activity) could be 
tested in short term cultures of EOC cells. Aromatase inhibitors (AIs) could be given 
to the patients with higher aromatase expression, or recently-developed dual 
aromatase-sulphatase inhibitors (DASIs) which can block both STS and aromatase 
could be tried on the patients with higher expression of both enzymes.   
 
Studies on STS pathway and STS inhibitors extend the repertoire of possible anti-
oestrogen treatments for EOC. However, this raises the question of how to choose 
the most suitable anti-oestrogen treatment clinically: namely anti-STS, anti-
aromatase or anti-ER. The relative expression of STS, aromatase or ER might be one 
criterion, and subtypes of EOC, age, stage might be other subsidiary criteria. Further 
clinical research is required to find the most effective treatment. 
 
As stated in Chapter 1, although OSE is usually regarded as the cell of origin of EOC, 
other compelling evidence has suggested distal tubal epithelium is another possible 
precursor of some types of EOC. Therefore separation and culture of primary distal 
tubal epithelium cells, investigation of production and action of oestrogen in these 
cells and comparison with OSE and EOC cells would be useful to clarify the effect of 
oestrogen on initiation and promotion of different kinds of EOC. There is increasing 
evidence that ovarian cancers contain cancer stem-like cells which might be 
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responsible for the tumourigenesis and chemo-resistance of ovarian cancer (Bapat, 
Mali et al. 2005). Moreover, oestrogen has been shown to expand breast cancer stem-
like cells through paracrine FGF/Tbx3 signalling (Fillmore, Gupta et al. 2010). The 
role of oestrogen in the development of EOC is studied in the thesis but the influence 
of oestrogen on the stem cell population has not been assessed. It would be of much 
interest to isolate the ovarian cancer stem-like cells, investigate their biosynthesis of 
oestrogen, and test the effect of oestrogen on the differentiation, proliferation and 
apoptosis of these cells.  
 
Oestrogen metabolism pathways in OSE and EOC are studied in detail in this thesis, 
and are shown to play an important role in the development of EOC, while there are 
many other hormones including GnRH, gonadotrophins, androgen and progesterone 
which also have recognized effects on OSE and EOC. Although there are 
experimental studies investigating the effect of these hormones on EOC separately, 
their action together has not been studied. Clinically, GnRH agonist, anti-androgen 
and progesterone have been used in refractory or recurrent ovarian cancer patients 
who have failed one or more chemotherapeutic treatments, and are effective in some 
cases. However, combinations of these hormonal therapies have not been used 
consistently. Therefore, it is potentially promising to explore the effect of different 
hormone combinations in EOC treatment, such as oestrogen together with anti-
androgen, GnRH antagonist or progesterone agonist, which would provide evidence 
to support their combined use in clinical practice in the future.   
 
In the thesis, the expression of target genes was compared between pre-menopausal 
OSE and EOC cells. We imagine that post-menopausal OSE cells would be more 
suitable for the comparison, since most EOC occur after menopause. However a 
shortage of postmenopausal OSE prevented extended exploration. Therefore it would 
be important to establish a proper post-menopausal OSE cell line model. This kind of 
cell line would provide further opportunity to study the biology of postmenopausal 
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